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Abstract 
AMP-activated protein kinase (AMPK) acts as the cell’s master energy regulator, sensing and 
maintaining the concentration of ATP in a narrow range irrespective of energy demand.  
This kinase has received significant attention as a drug-target for type-2 diabetes, obesity 
and cancer. Although historically the AMP:ATP ratio has been considered the signal for 
AMPK activation, we have recently demonstrated that ADP is likely to be an important 
physiological regulator of AMPK in both mammals and yeast.  
 
The binding of adenine nucleotides and staurosporine to the full-length 111 
heterotrimer, both phosphorylated and unphosphorylated, is described. Binding was 
monitored through displacement of fluorescently labelled nucleotides (coumarin-AXP), 
either via direct coumarin excitation or Forster Resonance Energy Transfer (FRET) in which 
tryptophan residues were excited. Mg.ATP was found to bind more weakly than ADP, a 
feature which is likely key to AMPK regulation. 
 
A -Nicotinamide adenine dinucleotide (NADH) coupled 
spectrophotometric assay was used to monitor AMPK kinetics and 
its regulation by nucleotides. NADH binds at Site-1, within the  
-subunit (pictured right), and competes with allosteric activation 
by AMP, but not the protective effect of AMP/ADP against T172 
dephosphorylation. Therefore it seems that AMP binding at Site-1 
mediates allostery whilst AMP/ADP binding at Site-3 affords 
protection against dephosphorylation. In order to explore this idea 
further, AXP binding constants were used to model binding site occupancies over the 
concentration ranges used in vitro. The modelling demonstrates that, in vitro, Site-1 is 
occupied by AMP and Site-3 by AMP/ADP in a manner consistent with their assigned 
regulatory functions. This modelling study was also extended to consider in vivo binding site 
occupancy. 
 
It was important to verify that coumarin-ADP bound in a homologous fashion to ADP, 
specifically in the same exchangeable binding pockets. X-ray crystallography was used to 
determine the structure of a truncated form of AMPK in complex with coumarin-ADP.  
This structure is compared to an ADP-bound form.  
 
SNF1 is the Saccharomyces cerevisiae AMPK ortholog. The binding of nucleotides to SNF1, 
and its regulation by ADP, was also characterised. As with the mammalian enzyme AXP 
bound at two exchangeable sites, and interacted with Mg.ATP more weakly than ADP.  
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 Chapter 1: Introduction 
 1.1 AMPK 
AMP-activated protein kinase (AMPK) has frequently been dubbed ‘the cellular fuel sensor’ 
and has more recently been referred to as a ‘whole-body energy gauge’ (3, 4).  
Broadly speaking, AMPK is responsible for activating catabolic pathways and inhibiting 
anabolic systems during periods of metabolic stress. It is ubiquitously expressed throughout 
the body, activated by phosphorylation and catalytically active as a Ser/Thr kinase (Figure 1).  
It produces immediate effects through targeted phosphorylation of substrates such as 
acetyl-CoA Carboxylase (ACC) (3), and in the longer term downstream effectors of AMPK 
regulate transcription and progression through the cell cycle (5). 
AMPK was first named in 1988, with reference to its most potent activator AMP.  
It previously appeared under various guises, including 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGR) kinase (5). Activation of AMPK via a phosphorylation cascade was 
amongst the first to be described.  
AMPK is conserved throughout the entire eukaryotic kingdom, with homologues found in 
mammals, fungi and plants (5). Of particular note is the Saccharomyces cerevisiae ortholog, 
sucrose-nonfermenting 1 (SNF1). The study of SNF1 was important in isolating the upstream 
AMPK kinases, and in structural characterisation of the heterotrimeric complex. 
Convergence of the yeast and mammalian studies in 1994 marked the creation of the  
AMPK family (6).  
AMPK is a heterotrimeric complex composed of a ~63kDa  catalytic subunit, a ~30kDa  
scaffolding subunit and a regulatory 36-63kDa  subunit (Figure 2). All three subunits, 
present in 1:1:1 ratio are required for stable complex formation. In mammals, there are two 
isoforms of , two of  and three of , each encoded by a single gene, therefore a total of 12 
different complexes are theoretically possible (7).   
17 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: AMPK operates as part of a futile cycle.  
Phosphorylation of the heterotrimeric AMPK by upstream kinases at T172 results in an 
active kinase complex. Dephosphorylation by the relevant phosphatases returns the protein 
to an inactive state. Adenine nucleotides bind to the -subunit. AMP allosterically activates 
AMPK, whilst both AMP and ADP protect T172 from dephosphorylation.  
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Figure 2: Domain schematic of AMPK subunits.  
The mammalian isoforms of 1/2 and 1/2 are very similar and a general example for 
each is shown here. Abbreviations: AID: autoinhibitory domain, GBD: glycogen binding 
domain (also referred to as the carbohydrate binding module), CBS: cystathionine  
-synthase domain. 
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Figure 3: Schematic diagram of AMPK activation and its effects on downstream targets.  
AMPK activation acts to replenish cellular ATP supplies, playing a central role as a regulator 
of both lipid and glucose metabolism and of protein levels, cell growth and turnover.  
Taken from www.cellsignal.com/reference/pathway/AMPK.  
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 1.2 AMPK activity 
Any metabolic stress which inhibits ATP production or which accelerates ATP consumption 
will lead to shifts in the cellular nucleotide ratios, and therefore to AMPK activation.  
AMPK acts to limit ATP consuming pathways and promote ATP producing pathways in order 
to restore ATP concentrations to basal levels during periods of cellular stress. Whole body 
genetic deletion of AMPK activity in mouse models results in embryonic lethality, 
highlighting the importance of this enzyme in mammals (8). 
Numerous AMPK phosphorylation targets have been identified (Figure 3) which have far 
reaching effects throughout the cell. Here, the role of AMPK on carbohydrate metabolism, 
lipid metabolism, protein synthesis, cell growth and apoptosis are considered further. 
 
 1.2.1 Carbohydrate Metabolism 
Glucose is the major cellular energy source in most tissues (although not in cardiac tissue), 
and glucose homeostasis is therefore regulated in a number of ways; the rate of glucose 
uptake from the blood, glycolytic rate, glycogen metabolism and through gluconeogenesis in 
the liver. AMPK regulates all of these processes and examples of each are given. 
 
In addition to the glucose gradient, it is the expression of glucose transporters (GLUTs) and 
their localisation to cellular membranes which regulates the uptake of glucose from the 
blood. AMPK activity regulates glucose uptake in at least four ways:  
 1) In response to insulin signalling or energetic stress GLUT4 is translocated to the plasma 
membrane facilitating rapid glucose uptake (9). AMPK activity stimulates this 
translocation, predominantly in skeletal and cardiac muscle tissue, but perhaps also in 
adipocytes (10-12). AMPK’s role is insulin independent, and it is therefore not involved 
21 
 
with maintaining glucose homeostasis through the classic regulatory pathway (13, 14). 
Although AMPK is activated in response to muscle contraction (see Section 1.5.3.3). 
 2) AMPK also affects glucose transportation via phosphorylation of Rab GTPases AS160 and 
TBC1D1 which associate with 14-3-3 proteins promoting GLUT4 vesicle recycling (15, 16).  
 3) AMPK phosphorylation of insulin receptor substrate-1 (IRS-1) on S789 prevents 
inhibitory phosphorylation of IRS-1 by JNK, IKK and S6 kinase. AMPK phosphorylation of 
IRS-1 also stimulates downstream activation of the Akt/AS160 pathway.  
Overall, this increases the sensitivity of the cell to an insulin stimulus, thereby increasing 
glucose uptake (17, 18). 
 4) AMPK indirectly increases transcription of the GLUT4 gene through phosphorylation of 
proliferator-activated receptor gamma coactivator-1  (PGC-1α) and sequestering of 
histone deacetylase 5 (HDAC5) from the nucleus. This results in increased activity of the 
transcription factor, myocyte enhancer factor (MEF), known to upregulate the  
GLUT4 gene (19, 20).  
 
Glycogen homeostasis is maintained by glycogen synthase (GS) which extends polymer 
chains and glycogen phosphorylase (GP) which breaks them down. AMPK directly 
phosphorylates GS causing inactivation and an acute drop in glycogen synthesis (21). 
Counter intuitively, chronic AMPK activation (via naturally occurring mutations or 
pharmacological treatment – Sections 1.3.4 and 1.5.2.3) actually increases glycogen 
synthesis, through increased glucose uptake and therefore production of  
glucose-6-phosphate, an allosteric activator of GS (22). This suggests that AMPK may have an 
inhibitory/activatory effect on glycogen synthesis dependent on the level of AMPK activation. 
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Glycolysis, a key metabolic step which sees glucose converted to pyruvate, is controlled by 
phosphofructokinase 2 (PFK2). AMPK phosphorylation of PFK2 S466 (cardiac and inducible 
isoforms only) causes increased production of fructose-2,6-diphosphate, an allosteric 
activator of PFK1, and ultimately an increase in the rate of glycolysis in cardiac tissue (23, 24). 
Through activation of PFK and increased glycolytic rate AMPK is key in mounting the cellular 
response to energetic stress, e.g. anaerobic exercise, anoxia and ischemia.  
A recent proteomics screen identified 12 in vitro substrates of AMPK in the brain, many of 
which were related to glycolysis, although further investigation is required to understand 
the significance of this in vivo (25). 
 
Gluconeogenesis is a metabolic pathway present in hepatocytes which produces glucose 
from non-carbohydrate carbon sources such as lactate and glycerol. It has been 
demonstrated in knock-out mouse models that AMPK activation in the liver inhibits 
gluconeogenesis and therefore reduces release of glucose into the blood. This effect is 
mediated through transcriptional regulation of gluconeogenic enzymes, for example;  
 1) Inhibition of the transcription factor hepatic nuclear factor 4(HNF-4) (26-28). 
 2) Phosphorylation of CREB coactivator CRTC2 resulting in export to the cytosol where it 
can no longer bind CREB and regulate transcription of gluconeogenic genes (29-31). 
 
AMPK activation aims to increase glucose availability to stressed cells, thus increasing their 
fuel supplies and ultimately restoring the ATP concentration to basal levels.  
Clearance of glucose from the blood is an important goal of anti-type-2 diabetes drugs, 
suggesting that AMPK is a good candidate for treatment of this disorder.  
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 1.2.2 Lipid Metabolism 
Although carbohydrates are considered the cellular energy source of choice, in times of 
starvation lipid metabolism is important to maintain a consistent fuel supply to cells.  
The balance between carbohydrate and lipid metabolism is carefully controlled.  
AMPK influences the uptake and synthesis of fatty acids and mitochrondrial -oxidation  
(the breakdown of fatty acids to acetyl-CoA).  
The uptake of fatty acids into cells is mediated by fatty acid translocase (FAT/CD36) and 
fatty acid binding protein (FABP). Aminoimidazole-4-carboxamide ribotide (AICAR) is an 
AMPK activator; following its administration AMPK has been shown to stimulate fatty acid 
uptake, although the mechanism behind these effects (be it direct phosphorylation or 
transcriptional regulation) remains unclear (32, 33). 
 
Following entry into the cell, fatty acids are converted to active fatty acyl-CoA which can either 
enter the mitochondrial -oxidation pathway for conversion to acetyl-CoA, or be stored.  
ACC catalyses the conversion of acetyl-CoA to malonyl-CoA and was one of the first AMPK 
substrates to be identified (34). There are two isoforms of ACC, the cytosolic ACC1 and the 
mitochondrial ACC2, which are phosphorylated and therefore inhibited by AMPK at S80 and 
S221, respectively. Malonyl-CoA is a substrate for fatty acid synthesis, it is also an allosteric 
inhibitor of carnitine palmitoyltransferase 1 (CPT1) which regulates fatty acid transport into 
the mitochondria for oxidation. By inhibiting ACC, AMPK decreases malonyl-CoA inhibition 
of CPT1 and thus increases fatty acid breakdown in the mitochondria (35).  
Malonyl-CoA concentrations are also regulated by malonyl-CoA decarboxylase (MCD). 
Increased MCD activity, regulated by AMPK phosphorylation, increases the rate of fatty acid 
oxidation (36). AMPK also negatively regulates the ACC and fatty acid synthase (FAS) genes, 
through down-regulation of the transcription factor SREBP1c (37-40). Additionally AMPK 
may directly phosphorylate and inactivate FAS (41).  
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AMPK stimulates mitochondrial biogenesis through regulation of transcription factors and 
co-activators including PGC-1 and nuclear respiratory factors (NRF). The mitochondria are 
the cellular location of fatty acid breakdown and oxidative respiration and it is therefore 
clear how increased mitochondrial capacity is beneficial in the restoration of cellular energy 
balance (42).  
 
Triglycerides are important molecules in the storage and transportation of energy. AMPK 
activation has been shown to decrease both liver and plasma triglyceride levels in mouse 
models (43). AMPK directly inactivates in vitro: 
 1) Glycerol-3-phosphate acyl-transferase (GPAT), a rate limiting enzyme in the synthesis of 
triglycerides (44). 
 2) Hormone-sensitive lipase (HSL) which hydrolyses triglycerides to free fatty acids (44). 
 
HMGR catalysis is the rate-limiting enzyme in cholesterol synthesis. Its inhibition is 
correlated with decreased ATP concentrations, an effect mediated by phosphorylation of 
HMGR S871 by AMPK (45). Phosphorylation is thought to disrupt the interface between 
HMGR and NADPH (46). HMGR was one of the first AMPK targets to be discovered  
(along with ACC) (34).  
 
 
AMPK increases fatty acid uptake and breakdown, and reduces the activity of triglyceride 
and cholesterol synthesis pathways in response to metabolic stresses. Stimulation of these 
downstream effects is important in reversing the effects of obesity.   
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 1.2.3 Protein Synthesis 
The synthesis of proteins is an energetically costly process. When a cell is placed under 
metabolic stress AMPK acts to inhibit transcription/translation in various ways  
(summarised in Figure 4).  
One central regulator of protein metabolism is the kinase mammalian target of rapamycin 
(mTOR). This enzyme promotes ribosome biogenesis and therefore increases the rate of 
translation through activation of the ribosomal S6 kinases (S6K1 and S6K2). mTOR also 
phosphorylates 4E-binding protein (4E-BP1) allowing formation of translation-initiation 
complexes (47). mTOR and AMPK have antagonistic activities, it is therefore unsurprising 
that AMPK inhibits the activation of mTOR (and therefore protein synthesis): 
 1) AMPK phosphorylates the tuberous sclerosis 1/2 complex (TSC1/TSC2), a guanosine 
triphosphate activating proteins (GAP), enhancing their activity. This inactivates Rheb 
GTPases which function to activate mTOR (48).  
 2) AMPK phosphorylation of the protein raptor causes it to bind 14-3-3 proteins, excluding 
it from the complex and inhibiting the activity of mTOR (49). 
 
Elongation factor 2 (eEF-2) is responsible for the translocation of the peptidyl-tRNA 
complexes through the ribosome. AMPK inhibits protein synthesis through activation of  
eEF-2 kinase which goes on to inhibit eEF-2 activity (50).  
 
Additionally, there are many documented cases of AMPK phosphorylation influencing the 
activity of transcription factors and their binding proteins, leading to decreases in mRNA 
production which will obviously affect the rate of protein synthesis. There are also reports 
of decreased RNA polymerase I activity through AMPK phosphorylation of proteins found in 
the transcription initiation complex (51).   
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Figure 4: AMPK inhibition of protein synthesis. 
1) AMPK activates eEF-2-kinase, resulting in inactivation of eEF-2 and translational 
processes. 2) AMPK phosphorylation of TSC1/2 inhibits Rheb, resulting in decreased 
activation of the mTOR complex, 3) AMPK phosphorylation of Raptor results in binding to 
14-3-3 proteins and excludes it from the mTOR complex. Inhibition of the mTOR complex 
results in reduced peptide translation and ribosome biogenesis through 4e-BP and S6K (46). 
Orange arrows; AMPK phosphorylation   
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 1.2.4 Cell Growth and Apoptosis 
The balance between cell survival and cell death (apoptosis) is tightly controlled. AMPK 
activity is thought to have both pro- and anti-apoptotic effects in various tissues and in 
response to various signals, a number of examples are outlined here. 
 
Pro-apoptotic: 
 1) In addition to its roles in protein metabolism mTOR has downstream anti-apoptotic 
effects through Ulk1. Therefore inhibition of mTOR activation by AMPK is pro-apoptotic.  
 2) Overactivation of AMPK via glutamate signalling in neuronal tissues results in apoptosis 
(52, 53).  
 3) AMPK stabilises p53, a major proapoptotic protein, via Ser15 phosphorylation (54). 
 
Anti-apoptotic 
 1) In endothelial cells AMPK reduces reactive oxygen species (ROS), through increased 
expression of uncoupling protein 2, perhaps through AMPK regulation of PGC1
and through suppression of NADPH oxidase (55).  
 2) Activation of AMPK 1, but not 2 decreased apoptosis through nuclear factor kappa-
light-chain-enhancer of activated B cells (NF) mediated transcription of B-cell 
lymphoma-2 (Bcl-2) and survivin in endothelial cells (55). Bcl-2 and survivin are  
anti-apoptotic factors, which inhibit entry into the caspase cascade. 
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Cell growth and proliferation are energetically costly; therefore AMPK acts to inhibit them 
directly.  
 1) Cells treated with low glucose or transfected with constitutively active AMPK are 
arrested in the G1/S phase through a p53-dependent mechanism (56, 57).  
 2) AMPK may regulate cell growth by reducing the cytoplasmic level of the RNA-binding 
protein HuR which is essential for stabilising mRNA cell cycle regulators, including 
several cyclins (58).  
 3) AMPK activates the TSC1/2 complex (Figure 4) which, via its role in mTOR regulation, 
has a well-documented tumour suppressor function. TSC1/2 is thought to restrict both 
cell growth and proliferation (59). 
 
AMPK regulation of cell division and apoptosis suggest that it has the potential to influence 
the progression of tumour formation, and that it may be a worthy drug-candidate in this 
capacity (discussed further in Section 1.3.3). Since AMPK has both pro- and anti-apoptotic 
effects in some tissues and under certain conditions it is important to understand the 
underlying molecular pathways which are being stimulated.  
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 1.3 AMPK in Health and Disease 
A coherent understanding of how the body maintains its energy balance might facilitate 
new health care strategies. AMPK is involved in sustaining energy balance by responding to 
hormonal and nutrient signals in skeletal muscle, heart, adipose tissue, liver, pancreatic  
β cells and the brain (specifically the hypothalamus) (3).  
In Section 1.2 I described the impact of AMPK activation at a cellular level, on glucose and lipid 
metabolism, protein production, apoptosis and cell growth (Figure 3). Given the central role of 
AMPK signalling in the regulation of cellular energy homeostasis it follows that it can influence 
the balance between healthy and disease states. Now I consider the impact of AMPK on 
different tissues types and at a whole-body level, focusing on; the metabolic syndrome, 
obesity, type-2 diabetes, cancer, Wolf-Parkinson-White Syndrome (WPWS), cardiac function, 
Alzheimer’s disease and ageing. A number of pharmacological agents, described in detail in 
Section 1.5.2.3, are referred to throughout this section on health and disease.  
 
 1.3.1 Obesity 
Obesity, the accumulation of excess body fat, is increasingly prevalent in the western and 
developing world. A person is considered obese if they have a body mass index (BMI) 
greater than 30kg/m2. Obesity is a risk factor in many other chronic physical and mental 
disorders and is central to the metabolic syndrome. This is broadly defined as including 
glucose intolerance, insulin resistance, central obesity, high blood cholesterol and 
hypertension. It is a risk factor for both diabetes and cardiovascular disease. The metabolic 
syndrome varies in prevalence between sexes, countries and age groups; for example a 
survey in Iran showed the prevalence was less than 10% for both men and women in the  
20-29 year age group, rising to 38% and 67% respectively in the 60-69 year age group (60, 61). 
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Various studies have shown AMPK activity contributes to the pathophysiology of obesity,  
in both beneficial and detrimental fashions. AMPK activity in peripheral tissues acts to 
increase glucose uptake/metabolism, fatty acid oxidation etc. as described in Section 1.2.  
It has been suggested that AMPK signalling is suppressed with obesity and therefore that 
therapeutic AMPK activation may be beneficial in its treatment. In heart, skeletal muscle 
and liver tissue AMPK activity is reduced in most genetic models of rodent obesity, but no 
differences in the levels of activation are observed in animals made obese by a high-fat diet 
(described in (46)). In obese humans, muscle AMPK activity appears to be unaltered (62), 
suggesting that down regulation of AMPK is not a signal which precedes the onset of obesity.  
 
In contrast, A-769662 (a direct AMPK activator) treatment of obese (ob/ob) mice increases 
AMPK activity and reduces body-weight (43). This suggests that whilst AMPK signalling in 
obese individuals is not compromised, activation of AMPK might still be exploited as a 
treatment for obesity.  
 
AMPK activity in the brain plays a key role in the regulation of food intake and therefore 
affects weight-gain. AMPK activity in the hypothalamus integrates endocrine, nutrient and 
neuropeptide signals to influence the feeding response of the organism. Fasting and 
refeeding result in activation and inhibition of hypothalamic AMPK respectively (63).  
It is the changes in nutrient and hormone levels associated with the feeding state of an 
organism which produce these fluctuations in AMPK activity; for example the  
anorexigenic (inhibit feeding) adipokine, leptin, inhibits the pathway, whilst the  
orexigenic (promote feeding) adipokines, adiponectin and ghrelin, are stimulatory  
(See Section 1.5.3.4) (63). AMPK activity causes alterations in neuropeptide expression and 
therefore the action of hypothalamic neurones (e.g. agouti-related peptide (AgRP), 
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neuropeptide Y (NPY) and proopiomelanocortin (POMC)). In general, stimulation of 
hypothalamic AMPK results in feeding and weight gain whilst inhibition results in  
weight loss (64). However, deletion of AMPK2 in POMC neurons caused mice to increase in 
body weight and fat content, whilst its deletion in AgRP neurons produced a  
lean phenotype (65). POMC and AgRP neurones produce orexigenic and anorexigenic signals 
respectively. The ultimate role of AMPK in the progression of obesity is therefore cell-type 
dependent and far from fully understood.  
AMPK activity in the hypothalamus is an attractive target for anti-obesity drugs.  
This presents something of a challenge because to be effective, drugs must be designed to 
inhibit AMPK in the brain and thereby act to combat obesity, but be null/activatory in 
peripheral tissues in order to be anti-diabetic.  
 
 1.3.2 Type-2 Diabetes 
Diabetes mellitus is a chronic condition caused by high-levels of circulating blood glucose; 
this occurs when the pancreas fails to produce sufficient insulin or when the body is unable 
to respond to the hormone correctly. Whilst genetic factors and ethnic origin play a role in 
the development of type-2 diabetes, the major risk factors are those of the metabolic 
syndrome (described in Section 1.3.1).  
As discussed in Section 1.2.1 AMPK increases glucose uptake through stimulation of GLUT4 
transcription and translocation to the cell membranes, increasing cellular sensitivity to 
insulin signals, increasing the glycolytic rate, and decreasing hepatic gluconeogenesis. 
Therefore activation of AMPK acts to clear glucose from the blood, which is the ultimate 
goal of anti-diabetic drugs.  
Indirect activators such as exercise and metformin (a prominent type-2 diabetes 
pharmaceutical), are thought to activate AMPK by increasing cellular AMP/ADP 
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concentrations, and reduce the symptoms of the metabolic syndrome (66, 67).  
Metformin is thought to reduce glucose blood plasma concentrations by inhibiting 
gluconeogenesis through AMPK, although this has recently been challenged by a number of 
genetic models (see Section 1.5.3.2) (66). AICAR treatment of rodent and human tissue 
samples, and in diabetic mouse models, increases glucose uptake primarily through 
increased GLUT4 expression and translocation (for example Halseth et al (2002)(68)).  
The magnitude of AICAR stimulated glucose transport is dependent on nutritional status and 
muscle fibre type (reviewed in (69)). AICAR treatment of insulin-resistant mouse models 
results in increased clearance of glucose from the blood plasma, and the effects are 
therefore insulin independent (70).  
AMPK activators combat the symptoms of the metabolic syndrome and type-2 diabetes,  
and for this reason pharmaceutical companies are interested in developing direct activators, 
such as A-769662. The treatment of obese (ob/ob) mice with A-769662, reduced  
plasma glucose, body weight, plasma/liver triglyceride levels and decreased transcription of 
gluconeogenic genes (43). This and other AMPK activators are discussed in greater detail in 
Sections 1.5.2 and 1.5.3. 
 
 1.3.3 Cancer 
The malignant phenotype of cancer cells is characterised by increased lipid production,  
DNA and protein synthesis, and cell proliferation and migration. The role of AMPK in the 
regulation of cell growth and apoptosis is described in Section 1.2.4 and obviously suggests 
a potential link between AMPK and cancer. Additionally, AMPK acts to reduce the activity of 
anabolic pathways which ultimately reduces cell growth. AMPK activation appears to be 
generally anti-proliferative, although it may have varied effects dependent on cell-type and 
stimulus. Some examples are highlighted here.  
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Tumour Suppressor 
Patients treated with metformin, thought to activate AMPK, show a 30% reduction in cancer 
deaths compared to a control group (71). Additionally AMPK activators including AICAR and 
A-769662 confer increased resistance to tumour formation in both cell lines and animal 
models (72-74).  
The role of AMPK in breast cancer is the best studied (75). AMPK expression and signalling is 
significantly reduced in primary breast cancer tissue samples (76). Metformin-treated breast 
cancer patients show reduced levels of the proliferation marker Ki-67. Ki-67 is a nuclear 
protein that is associated with ribosomal RNA transcription; its expression is strictly 
associated with cell proliferation (77). Genome wide studies of metformin treated breast 
cancer cell lines highlight inhibition of both ribosomal proteins, and mitosis-related gene 
family members e.g. kinesins, tubulins, histones, and auroras, consistent with decreased 
proliferation (75).  
Other natural AMPK activators (listed in Table 3) have been shown to suppress growth of 
breast cancers through decreased cyclooxygenase-2 (COX2) expression (75). COX2 is key in 
the conversion of arachidonic acid to the signalling molecule prostaglandin, and is often 
upregulated in cancer tissue.  
 
Tumour Promoter 
Cancerous tissue rapidly proliferates and therefore always exists in a state of metabolic stress. 
During specific stages of tumorigenesis, AMPK activation could confer an advantage to 
tumour cells through its role in increasing glycolytic rate, combating hypoxia,  
nutrient shortage and apoptosis (78, 79). One example of this was recently reported, 
knocking out AMPK or its upstream kinase (LKB1) results in increased cancer cell death in 
response to glucose deprivation. In 1 AMPK knock-out cells, NADPH concentrations are 
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reduced due to glucose deprivation and reduced glycolysis/oxidative respiration, the 
resulting cellular stress leads to apoptosis. AMPK acts to increase fatty acid oxidation and 
provide an alternative route through which NADPH can be produced, thereby increasing 
cancer cell survival (80). 
 
It is probable that the role of AMPK in cancer cell metabolism, growth and proliferation 
operates in a context dependent fashion, perhaps with varied effects over the  
course of tumorigenesis. Therefore, potentially, both AMPK activators and inhibitors could 
be beneficial in cancer treatment. 
 
 1.3.4 Cardiac Function and Wolf-Parkinson-White Syndrome (WPWS) 
AMPK is a key regulator of energy metabolism in the heart; myocardial tissue has high 
energy requirements met through a combination of fatty acid and glucose metabolism, both 
processes are regulated by AMPK (described in Section 1.2). AMPK is activated in response 
to increased cardiac work (e.g. during exercise), a similar effect having been demonstrated 
in skeletal muscle (see Section 1.5.3.3) (81). In the event of ischemia AMPK is rapidly 
activated, increasing fatty acid oxidation, glycolysis and glucose uptake (82). Whilst this 
protects the heart from ischemic shock in the short term, prolonged activation of AMPK and 
its downstream effects (e.g. fatty acid metabolism) may result in inhibition of glucose 
oxidation and therefore decreased cardiac efficiency (82).  
 
WPWS is a form of cardiac hypertrophy categorised as a pre-excitation syndrome.  
A number of point mutations have been identified in the AMPK 2 subunit which cause 
abnormal glycogen accumulation and cardiac conductivity, resulting in WPWS (Table 1)(83).  
Although these mutations may ultimately be fatal, they affect only a few hundred people 
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from a limited number of families (83). Increased glycogen content in animals harbouring 
similar mutations was originally observed in the skeletal muscle of Hampshire pigs,  
and subsequently in the cardiac tissue of transgenic mouse models harbouring human-
disease containing mutations (83, 84). 
No 2 complexes have yet been crystallised, but when the equivalent mutations are mapped 
onto the 1 structure they predominantly reside near AXP binding sites or are key 
phosphate interacting residues (46). These mutants, in general, increase basal AMPK activity 
and decrease sensitivity to AMP activation, although some discrepancies in their activities 
have been reported (83, 85, 86). Altered nucleotide binding to these mutants has also been 
reported (Peter Saiu – PhD Thesis) (86). Additionally AMPK is known to localise to and be 
inhibited by glycogen, therefore increased glycogen concentrations in cardiac tissue may 
lead to misregulation of the enzyme (83). However, all in all, it is not clear how 
dysregulation of AMPK leads to the WPWS cardiac phenotype.  
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Table 1: WPWS point mutations.  
The mutations in human 2 that are associated with WPWS are given along with their 
corresponding residues in rat 1. Their effects on AMP regulation, based on in vitro studies, 
are shown. This table is adapted from Xiao et al (2007) and Faith Mayer (PhD Thesis) (87).  
Mutation in 
human 2 
Equivalent 
residue in 1 
Effect on 
regulation 
R302Q R69 Yes 
L351 Insertion R117-E118 No 
H383R H150 Yes 
R384T R151 Yes 
T400N T167 Yes 
Y487H Y254 nd 
N488I N255 nd 
E506K E273 nd 
R531G/Q R298 Yes 
S548P S315 nd 
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 1.3.5 Alzheimer’s Disease (AD) 
Metabolic stress is associated with the pathogenesis of Alzheimer’s disease (AD) (88).  
In fact, a decline in glucose metabolism is an early diagnostic marker of AD. 
AD is a form of dementia which affects an estimated 24 million people worldwide,  
with the majority of sufferers being over 65 years old. A number of genetic components 
which act as risk factors for the development of AD have been characterised.  
The pathological traits of the disease are amyloid  plaques and neurofibrillary tangles  
in the brain. Tau, a microtubule-associated protein, is the major constituent of 
neurofibrillary tangles; these are hyperphosphorylated, insoluble protein aggregates which 
disrupt the structure and function of the neuron. The extent of tau tangle formation is more 
closely associated with the severity of AD than  plaques (89). 
Proteins related to insulin signalling, including insulin, insulin-like growth factor-1 (IGF-1), 
their receptors and downstream substrates e.g. insulin receptor substrate-1/2,  
are significantly reduced in the neurons of AD sufferers and therefore these cells are  
insulin resistant (90). It is this which results in abnormal glucose uptake.  
The concentrations of GLUT1 and GLUT3 glucose transporters are also reduced on the 
neuronal cell membranes of AD patients (91), thus the glucose supply to these neurones is 
decreased resulting in ‘starvation’. AMPK activation has been shown to excite glutamate 
neurones, stimulating glucose uptake by increasing the translocation of glucose transporters 
(GLUT3) to the membrane and upregulation of their expression (52). AMPK therefore 
provides a secondary way for neurons to regulate glucose uptake, a mechanism that could 
be exploited for AD treatment.  
Whilst AMPK activity stimulates glucose uptake, it remains unclear what role it may play in 
plaque and tangle formation: 
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 1) Immunohistochemical staining has shown AMPK localised to hyperphosphorylated pre-
tangle structures, and mature tangle-like structure, suggesting AMPK may be involved in 
their formation. AMPK phosphorylates tau protein at numerous sites (92, 93). 
 2) Tau is acetylated in tangle structures, reducing trafficking to the proteasome, SIRT1 
reduces this acetylation and AMPK potently activates SIRT1, thus the degradation of tau 
is enhanced. 
 3) AMPK inhibits GSK3 in vitro which is a known tau kinase (94). 
 4) AICAR treatment of rat neurons inhibited tau phosphorylation (95).  
 5) AMPK activation via AICAR, resveratrol and quercetin treatments decreased the 
deposition of amyloid plaques (perhaps through increased autophagy) in both cultured 
cells and mice models (96-98).  
 
The roles of AMPK in the progression of neurodegenerative diseases is closely linked with its 
regulation of cellular metabolism, although unique roles in tangle and plaque progression 
are emerging. AMPK has been implicated as both a neuroprotective and neurodegenerative 
factor in non-AD neuronal cell lines (46). Perhaps the most convincing evidence comes from 
AMPK 2 knock-out mice which have reduced neuronal death in response to stroke, 
suggesting that AMPK activation is pro-apoptotic and neurodegenerative (99).  
This remains an interesting area of study in the AMPK field.  
 
 1.3.6 Ageing 
There are several studies which suggest that AMPK activation via phosphorylation declines 
with age (100-103). This appears to parallel many metabolic changes associated with age 
such as the prevalence of AD, obesity and the metabolic syndrome. The mechanism for this 
decrease in AMPK activity is unknown but might be due to increased dephosphorylation by 
phosphatases; ceremides (sphingosine and fatty acids – mostly found in the cell membrane 
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but known to also be signalling molecules) inhibit AMPK signalling by increasing the activity 
of PP2A. Ceramide concentrations are significantly increased in brain regions susceptible to 
the pathological changes of AD, in obese and diabetic patients and in the elderly (104-106).  
 
Autophagy is important in the regulation of ageing and several age-related degenerative 
diseases (90), it is the process by which cellular components are degraded through the 
lysosomal system. AMPK inhibits mTOR, the main inhibitor of autophagy (see Section 1.2.3). 
AMPK also directly activates unc-51-like kinase (ULK1) the mammalian autophagy initiating 
kinase (107, 108). AMPK also regulates autophagy in response to stress/exercise in order to 
recycle nutrients for metabolic breakdown (46, 109). 
 
Dietary restriction (DR) is known to extend lifespan in a wide range of species.  
DR in Caenorhabditis elegans results in AMPK activation through increased AMP/ADP 
concentrations and subsequent phosphorylation of the FOXO/DAF-16 transcription factor (110). 
FOXO/DAF-16 upregulates genes involved in detoxification of reactive oxygen species (ROS) 
and therefore reduces progression to apoptosis. The authors showed that lifespan is 
increased in transgenic worms in which AMPK is constitutively active, demonstrating that 
AMPK activation is responsible for this ageing effect (110). 
AMPK activation increases the lifespan of C.elegans through inhibition of the cAMP-
regulated transcriptional co-activator-1 (CRTC-1)/CREB signalling pathway (111).  
Chronic activation of this pathway is associated with insulin resistance, hyperglycaemia  
and inflammation (112). Whilst there is a wide range of CREB target genes, only a subset are 
activated by the CRTC-1/CREB pathway, notably a number of genes involved with 
endoplasmic reticulum (ER) stress. ER stress is a known feature of AD pathology, ageing and 
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the metabolic syndrome (90). Increased AMPK activation combats this cellular stress and 
reduces stimulation of apoptosis. 
Both genetic and pharmaceutical inhibition of mTOR and its downstream effector S6K,  
has been shown to increase lifespan in S.cerevisiae, C.elegans and Drosophila melanogaster 
(113, 114). As described in Section 1.2.3 AMPK activity decreases mTOR activity through 
decreased Rheb activation and exclusion of Raptor from the mTOR complex.  
Transgenic S6K knockout mice have both increased lifespan and AMPK activity (114). 
However double S6K and AMPK knockout transgenic mice do not have increased lifespan, 
suggesting that the interplay between AMPK and mTOR/S6K in regulation of ageing is more 
complex than originally thought.  
 
Some studies suggest that AMPK signalling regulates lifespan, perhaps by improving  
general health. Mice treated with metformin have extended lifespans through increased 
AMPK activity (115). With so many factors being implicated in the regulation of lifespan it is 
perhaps unsurprising to find a link between AMPK and these pathways. Further studies on 
higher organisms will elucidate the mechanism through which AMPK activation  
increases life-span. This is certainly an interesting ‘side-effect’ of AMPK activators prescribed 
primarily in the treatment of metabolic disorders. 
 
 1.3.7 Concluding Remark 
A number of downstream targets of AMPK and their implications on human health have 
been described. AMPK has recently been linked to the regulation of, amongst others, cell 
polarity, ion influx, circadian rhythms, inflammation and bile-acid metabolism, and in the 
progression of stroke, atherosclerosis and vascular dysfunction (46, 90, 116). It has been 
said that “…it can seem like AMPK is involved in regulating every biochemical pathway 
conceivable!”(116).   
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 1.4 The  Heterotrimer 
There is evidence that some of the downstream effects of AMPK phosphorylation are 
isoform dependent. I will now consider the two , two  and three  subunits at a molecular 
level, and highlight what is known about their differences and similarities. 
Through alternate initiation and splicing there are additional transcripts to those covered in 
this section. There are also a number of Single Nucleotide Polymorphisms (SNPs) mapped to 
the seven AMPK genes, the physiological effects of which are largely undetermined (46).  
 
 1.4.1 Overall architecture 
Although the complex as a whole has not been crystallised, in 2011 the Gamblin laboratory 
published the structure of an active mammalian 121 complex missing only the -subunit 
Glycogen Binding Domain (GBD) (Figure 5).  
The domain structure of the  subunits is shown in Figure 2. The C-terminal region of the 
-subunit forms a -sheet structure that serves as a binding platform for both the  and  
subunits (Figure 5 - green). The  interface comprises mainly hydrogen bonding  
(Figure 5 - green/pink); whilst the  interface consists mainly of hydrophobic interactions 
(Figure 5 - green/light blue). The -subunit forms a distinctive, pseudosymmetric structure 
which binds nucleotides and is resistant to protease treatment (Figure 5- pink).  
The -subunit interacts with the -subunit through the -hook structure which forms a lid 
over one of the nucleotide binding sites (Figure 5 – dark blue). The N-terminal -kinase 
comprises a classic kinase fold, and interacts with the -subunit with a surface area of 
1100Å2 (Figure 5 - yellow).  
Implications of the various interactions between the regulatory domain and -kinase are 
touched upon in this introduction and are considered in more detail throughout the thesis.   
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Figure 5: Structure of 12(GBD)1 AMPK. 
Ribbon representation of a mammalian complex (11-469,524-5482187-2721): yellow;  kinase 
domain, pink;  regulatory domain, blue;  subunit, green;  subunit missing the GBD.  
The complex is bound to two AMPs, and staurosporine, all shown in stick representation. 
The α-hook and activation (T) loop of the kinase domain are shown in heavier lines and 
coloured dark blue and purple respectively. The phosphorylated T172 residue is indicated. 
PDB ID: 2Y94. (1) 
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 1.4.2 The  subunit 
The -subunit is catalytically active as a Ser/Thr protein kinase and possesses a highly 
conserved N-terminal kinase domain and more divergent C-terminal regulatory region 
(Figure 2). There are two mammalian  isoforms encoded by two separate genes.  
Following identification of the second α isoform that is more ubiquitously expressed,  
the initial isoform identified in liver was termed α2 and the new isoform α1 (117).  
AMPK is activated by phosphorylation of a conserved threonine residue (T172) on the 
kinase T-loop, and inactivated through dephosphorylation (Figure 1). 
 
Although 1 is widely expressed, it is 2 which is predominant in skeletal and cardiac 
muscle, suggesting divergent roles for the two isoforms. For example, following rigorous 
exercise only 2 containing heterotrimers (223) are activated in skeletal muscle (118, 
119), whilst both isoforms contribute equally to activity in the liver (120).  
 
Immunofluorescence and western blotting studies have shown that 1 localises to the 
cytoplasm whilst2 is present in both the cytoplasm and the nucleus, suggesting a potential 
role for it in transcriptional regulation (121). This difference is due to the presence of a 
nuclear localisation signal on the 2 subunit, there is also evidence for a nuclear export 
signal at the C-terminal of the -subunit (122, 123). It has been shown that 2, but not 1, 
regulates gene transcription in response to external glucose in pancreatic cells (124).  
More work is necessary to fully understand the signals which stimulate the cellular 
redistribution of the 2 subunit. 
Both isoforms have similar specific activities and only subtle differences in substrate 
specificity. 2 containing complexes appear to be more sensitive to allosteric activation by 
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AMP and dephosphorylation by phosphatases, thus allowing modulation of the AMPK 
response in an isoform specific way (120).  
The  N-terminal region (1-278) is sufficient for catalytic activity and produces a classic 
kinase fold (125). The active site is positioned in a cleft between two lobes, the smaller of 
which is composed predominantly of -sheet structure. The larger lobe is 63% -helical in 
mammalian AMPK and mediates substrate binding, activation and catalysis (126).  
In the structure of an inactive (unphosphorylated) form of human 2 (Figure 6 - PDB ID: 
2H6D) conserved elements are visible, including the catalytic loop in the large lobe which 
runs from His-133 through to Glu-143 and the invariant Asp residue, D157, required for 
catalysis (126). In the active structure shown in Figure 6 the phosphorylated T172 residue 
is clearly visible and is bound in a pocket created by tandem Arg-Asp residues from the 
kinase as seen in related structures (125). The activation loop is also well-defined and its 
conformation is stabilised through interaction with the subunit (Figure 5 and Figure 6).  
It is hypothesised that promotion of kinase binding to the regulatory fragment upon 
AMP/ADP binding to the  domain mediates protection of the activation loop from 
dephosphorylation by phosphatases (described in Section 4.4.2.1)(1).  
 
Several papers describe an autoinhibitory domain (AID), spanning around 70 residues C-
terminal to the -kinase domain. This is an established mechanism for the regulation of 
other kinases, specifically those to which AMPK is evolutionarily related (127). The inactive 
states of truncated Snf1 kinases have been crystallised (128, 129); however it is not clear if 
the interface between the kinase and regulatory subunits demonstrated in Xiao et al 
(2011)(1) could accommodate the formation of the AID. It could be that this structure 
operates to downregulate kinase activity when the kinase domain is dissociated from the 
regulatory fragment prior to dephosphorylation.   
45 
 
 
 
 
 
Figure 6: Overlay of inactive (orange) and phosphorylated (yellow) AMPK kinase domain 
structures. 
The active form is complexed with staurosporine (white – stick representation). A number of 
conserved structural elements are labelled. PDB ID: 2Y94 (active), 2H6D (inactive). 
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 1.4.3 The  subunit 
There are two  isoforms; which share around 70% amino acid sequence identity and a 
similar domain structure (Figure 2)(130). Heterotrimers containing 1 or 2 subunits have 
been shown to have similar levels of activity but different cellular localisation (131).  
In mouse myoblasts 21 complexes are anchored to the mitochondrial membrane 
whereas 22 complexes translocate to the nucleus (122). In terms of tissue distribution, 1 
is expressed very highly in the liver (rodent models) where it is present in almost all AMPK 
complexes. About 50% of complexes in skeletal muscle contain 2, and have been 
implicated in exercise induced AMPK activity (119, 131).  
 
The -subunit undergoes significant post-translational modification, including 
myristoylation and phosphorylation which are important in regulation (see Sections 
1.5.1.3 and 1.5.1.4) (132, 133).  
In 2003 a Glycogen Binding Domain (GBD) was identified on the  subunit (Figure 7), 
through which allosteric inhibition of AMPK activity by glycogen is mediated  
(see Section 1.5.2.2) (134, 135). Rat 1 GBD comprises a compact -sandwich, formed from 
two anti-parallel -sheets, homologous to carbohydrate branching enzymes and starch 
binding domains (136). In this crystal structure the GBD is complexed to β-cyclodextrin 
(Figure 7), bound through an extensive network of hydrophobic stacking interactions 
between the protein and five glucose units (137). -cyclodextrin is not a natural AMPK 
ligand and it may therefore not accurately mimic physiological sugar-binding.  
A second structure of the S.cerevisiae AMPK homolog identified a potential interface between 
the GBD and -subunit involving a number of residues from the -subunit CBS2 (Figure 8).  
The residues within the hydrophobic core of the interface are conserved in mammalian 
AMPKs, suggesting that they might play an important role in the structure or regulation  
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of the protein. However, the position of the GBD in the yeast structure would sterically clash 
with the kinase domain in the active AMPK structure (these structures are shown in  
Figure 5 and Figure 8). This raises the intriguing possibility that only one domain  
(the kinase or the GBD) can bind to the regulatory fragment at any time.  
The GBD is flexibly linked to the rest of the heterotrimer, at least in certain conditions.  
Two observations support this idea; 1) full-length AMPK protein crystals contain no density 
for the GBD, 2) NMR reveals the independent tumbling of a small domain tethered to the 
rest of the complex, the resonances of which correspond to the GBD  
(Personal Communication – Bing Xiao). Perhaps in vivo this allows tethering of the protein to 
glycogen, without hindering substrate access to the kinase domain. 
The GBD and its autophosphorylation is required for small molecule (e.g. A-769662) activation 
of the complex (discussed further in Section 1.5.2.3). Therefore it is certainly both an 
interesting and open question as to how the GBD interacts with the rest of the heterotrimer.  
 
 1.4.4 The  subunit 
There are 3  isoforms (138), and a fourth variant of 2 termed 2short (139). The -subunit is 
formed of four cystathionine beta synthase (CBS) motifs arranged as two Bateman domains. 
CBS motifs from AMPK and other proteins have been shown to bind adenosine-containing 
ligands such as AMP and ATP (86, 140). Competitive binding of AXPs to the subunit allows 
the protein to respond to changes in cellular energy status (see Section 1.5.2).  
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Figure 7: Complex of 1 68-163 ‘GBD’ bound by -cyclodextrin. 
-cyclodextrin (white – stick representation) binds the GBD, forming an extensive network 
of hydrophobic stacking interactions. PDB ID: 1Z0M. 
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Figure 8: Structure of Snf1398-633 Sip2154-415 Snf4. 
Snf4- (pink), Sip2- (green), Sip2 GBD (grey and labelled), Snf1- (blue). The GBD 
predominantly forms an interface with the -subunit. PDB ID: 2QLV.  
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1 and 2 are expressed in a wide number of tissues, while 3 is only found in skeletal 
muscle (138). In most tissues 80-90% of AMPK heterotrimers contain 1, 10-20% 2 and any 
remaining complexes contain 3. Exceptions include the brain and the testis where the three 
isoforms are present in about equal amounts (139). In the central nervous system 1 
containing heterotrimers have a predominantly nuclear localisation relative to those 
containing 2 (141). Differences in the cellular localisation and tissue distribution suggest 
that the isoforms may have different functional roles. 
 
The -subunit is, structurally, the best investigated of the three subunits. Crystal structures 
are available for full-length Schizosaccharomyces pombe Snf4 (142), S.cerevisiae Snf4  
(2, 143) and mammalian (1, 87, 144). The structures display similar topologies; the four 
CBS motifs generate an elliptical disc of ~60Å across and 30Å deep (145). A pair of adjacent 
CBS motifs produce helix/-hairpin/helix structural elements (Figure 9) which are termed 
Bateman domains (126). The four CBS motifs in the -subunit therefore potentially generate 
four nucleotide binding sites, labelled Sites 1-4 following the numbering of the CBS motifs 
(Figure 10) (see Section 1.5.2). All four sites are located between pairs of adjacent helix-loop 
strands; in three of the four sites, the three which bind AXP, an Asp residue is positioned  
on one helix such that it forms interactions with the 2’, 3’ hydroxyl groups of the  
AXP ribose moiety. The adenine rings are sandwiched between -strands and make various 
hydrophobic interactions. The phosphates are positioned in the solvent accessible core of 
the -subunit and their charge neutralised through electrostatic interactions with the 
protein (146). The four CBS motifs contribute different numbers of basic residues for 
interaction with the phosphates (e.g. CBS2 contributes H151, R152 and K170 whilst  
CBS3 contributes none), for this reason there is a high degree of connectivity between  
the binding sites.  
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Figure 9: The Topology of the CBS domain. 
-strands are numbered β1-3 and α-helices numbered α1 and α2 (145). 
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Figure 10: Structure of the AMPK -subunit. 
Ribbon representation of the mammalian  subunit with three bound AMP molecules.  
Site-4 is non-exchangeably bound, whilst Site-1 and Site-3 are exchangeable with ADP/ATP.  
PDB ID: 2V8Q. (87). 
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Figure 11: The AMPK signalling pathway. 
AMPK is activated in response to increases in cellular AMP and ADP concentrations deriving 
from a variety of physiological stresses, or the presence of pharmacological inducers.  
LKB1 and CaMKK are AMPK’s upstream kinases, and phosphorylate T172.  
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 1.5 Regulation of AMPK 
The primary event in AMPK activation is the phosphorylation of T172 on the T-loop of the 
-kinase domain by its upstream kinases. However, many other factors contribute to the 
complexity of AMPK regulation; dephosphorylation, autophosphorylation, myristoylation, 
ubiquitination, acetylation, nucleotide binding, glycogen binding, pharmacological/small 
molecule activation and endocrinological activation (summarised in Figure 11).  
 
 1.5.1 Post Translational Modifications 
 1.5.1.1 T172 phosphorylation by upstream kinases 
The kinase protein family is one of the largest in existence; phosphorylation-based 
activation cascades allow extracellular signals to be conferred to a broad but specific range 
of cellular targets. Phosphorylation of T172 increases activity by approximately 1000-fold (7). 
For a long time the identity of the upstream AMPK kinase(s) remained elusive,  
but through sequence homology with yeast enzymes two candidates were identified, 
Ca2+/calmodulin-dependent protein kinase kinase (CaMKK and Liver Kinase B1 (LKB1) (147).  
 
Direct AMPK T172 phosphorylation by LKB1 purified from liver extract has been 
demonstrated (148, 149). LKB1 is thought to be the predominant upstream AMPK kinase in 
most tissues. Cell lines lacking LKB1 expression e.g. HeLa cells,  and those expressing 
dominant negative forms are unresponsive to AMPK activation mediated be changes in 
adenine nucleotide concentrations (AMPK still responds to calcium) (148-150).  
A number of LKB1 related mouse models have demonstrated the importance of a functional 
LKB1 complex in the regulation of metabolism and in the prevention of tumour  
formation (151). LKB1 also activates a number of AMPK related protein kinases, many of 
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which are thought to be involved with maintenance of cell polarity and progression through 
the cell cycle (152, 153) (154).  
Deletion of LKB1 in skeletal or cardiac muscle only reduced the activation of 2 containing 
complexes, suggesting that LKB1 may not operate through 1-containing  
complexes (155, 156). Mutations in LKB1 are linked to Peutz-Jeghers syndrome, an inherited 
predisposition to cancer (7). The adverse effects of aberrant LKB1 activity are mediated 
through AMPK and other AMPK related kinases.  
 
CaMKK phosphorylation of T172 in vitro has been demonstrated (157). Overexpression of 
CaMKK and treatment with Ca2+ ionophores increases AMPK activity, whilst treatment with 
CaMKK inhibitors or siRNA decreases AMPK activation (158, 159).  
In pancreatic cells AMPK appears to be regulated in a Ca2+-dependent manner,  
in fact most conditions which activate AMPK also increase intracellular Ca2+ concentrations 
(e.g. muscle contraction, mitochondrial uncoupling and oxidative stress) (160).  
CaMKK is weakly expressed in liver, where LKB1 is the predominant AMPK kinase, however 
it is highly expressed in neuronal tissue. K+-induced depolarisation of rat cerebro-cortical 
slices has been shown to activate AMPK in an AMP independent manner,  
highlighting an important tissue-specific role for CaMKK and an additional  
regulatory point for AMPK (159). 
More recently a third upstream AMPK kinase, Tak1, was proposed. This kinase 
phosphorylates T172 in vitro (161), but subsequent data suggested that Tak1 may simply 
function upstream of LKB1 (162). It remains unclear whether this kinase plays a role in the 
activation of AMPK in vivo.  
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 1.5.1.2 Dephosphorylation by phosphatases 
The ratio of phosphorylated to unphosphorylated AMPK depends upon the relative activity 
of the upstream kinases and phosphatases. LKB1 is constitutively active; therefore it is 
predominantly the rate of the phosphatase which influences this equilibrium.  
The rate of dephosphorylation is decreased by binding of AMP/ADP to the -subunit 
(discussed further in Section 1.5.2) (1).  
Members of the phosphoprotein phosphatases (PP1 and PP2A) and metal-dependent 
protein phosphatases (PP2C, PPM1E and PPMF1) families have been shown to 
dephosphorylate AMPK in vitro but the physiologically relevant phosphatase(s) have not yet 
been demonstrated in humans (163, 164).  
The S.cerevisiae AMPK homolog, SNF1, is dephosphorylated by a PP1 family phosphatase 
Glc7 complexed with a regulatory subunit, Reg1 (discussed further in Appendix 1.1.4).  
In pancreatic -cells, PP1 and the regulatory subunit R6 have been implicated in  
glucose-induced AMPK dephosphorylation (165). A direct interaction between the -subunit 
GBD and R6 was identified, which is homologous to the interaction between SNF1 and Reg1 
in the yeast system (165). It may be the regulatory subunits associated with the various 
phosphatases which dictates their ability to dephosphorylate AMPK. 
Increased expression of PP2A and PP2C, leading to decreased AMPK activity, may be an 
important feature of AMPK regulation. For example, glucose and palmitate appear to 
regulate AMPK activity via increased PP2A activity, and lipoic acid regulates AMPK activity 
through modulation of PP2C levels (see Section 1.5.3.4) (166, 167).  
It remains to be seen if a single major AMPK phosphatase exists in vivo, or if contributions 
from several candidates are responsible for inactivation of AMPK in a stimulus/localisation 
dependent fashion.   
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 1.5.1.3 Other phosphorylation sites 
In addition to phosphorylation on the critical T172 residue, a number of secondary 
phosphorylation sites on the  and  subunits have been identified. These sites are both 
autophosphorylated and phosphorylated by other kinases (132, 150).  
 
A large number of putative phosphorylation sites at the C-terminus of the -subunit have 
been proposed. These sites are within the region which interacts with the other subunits 
suggesting phosphorylation could regulate heterotrimer formation. Additionally, 
phosphorylation at these sites may regulate AMPK activation. For example, 1 S485 and 2 
S491 phosphorylation is correlated with decreased AMPK activity in cardiac tissue in 
response to insulin treatment (168, 169). Akt (PKB) phosphorylates S485 in vitro and PKA 
phosphorylates this residue in cell-based assays in response to elevated cAMP levels (170). 
PKA is also thought to phosphorylate 1 S173 which may inhibit T172 phosphorylation 
through steric hindrance (171). Recently p70S6 kinase was found to phosphorylate 2 S491, 
an effect which is integral to the inhibition of AMPK in the hypothalamus in response to 
leptin (see Section 1.5.3.4) (172). 
 
Four native phosphorylation sites have been identified on the 1 subunit of AMPK,  
located at S24/25, S108 and S182, (164, 173, 174). Complexes with a truncated β subunit or 
with a mutated autophosphorylation site, β1 S108A, are insensitive to A-769662 
stimulation, suggesting some role of this phosphorylation in the action of pharmacological 
agents (discussed in Section 1.5.2.3) (173). A reduction in the AMP regulation of AMPK in 
S108A mutants has also been reported in cells, suggesting a place for -subunit 
phosphorylation in regulation of the heterotrimer (175). 
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 1.5.1.4 Myristoylation  
N-myristoylation of proteins can play a number of different roles in complex stabilisation 
and the targeting and binding of proteins to membranes (176). Both -subunits are co-
translationally N-myristoylated (132). A proportion of cellular AMPK is membrane 
associated, in vitro AMPK appears to become membrane associated in response to AMP and 
nutrient stress (133). Disruption of the myristoylation site, through mutation, results in 
localisation throughout the cytoplasm and increased recovery of AMPK from the soluble cell 
fraction (132, 175).  
 
Myristoylation has also been reported to affect regulation of AMPK by nucleotides and its 
activity. A decrease in basal AMPK activity is observed when the 1 subunit is myristoylated, 
suggesting this modification is important in maintaining an inactive AMPK state (133, 175). 
Recent in vitro studies have suggested a role for myristoylation in up-regulation of T172 
phosphorylation by AMPK kinases in response to AMP and ADP (133, 177).  
The authors suggest that AMPK is regulated through a myristoyl switch, in which the 
myristoyl group interacts with a hydrophobic pocket and reduces the phosphorylation of 
T172 by upstream kinases, activatory signals (AMP/ADP) release the repression and result 
in membrane association of the complex (178).  
However, AMP does not promote T172 phosphorylation of AMPK purified from rat liver 
(and therefore myristoylated) (179). It therefore remains to be seen whether myristoylation 
has a regulatory role in addition to its role in localising AMPK to membranes.   
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 1.5.1.5 Ubiquitination and acetylation 
The addition of ubiquitin chains to proteins has, historically, been thought to mediate 
targeting of the protein to the proteasome for degradation, although more recently it has 
been demonstrated that it plays an important regulatory role akin to protein 
phosphorylation. There is only limited evidence that AMPK is regulated by ubiquitination. 
 The ubiquitin ligase, cell-death inducing DFFA-like effector a (CIDEA), expression levels are 
inversely correlated with basal metabolic rate. This complex is thought to ubiquitinate AMPK 
targeting it for proteasomal degradation. In CIDEA knock-out mice AMPK activity and stability 
is increased, suggesting ubiquitination plays an inhibitory role in AMPK regulation (180). 
The 1 subunit has been found to be ubiquitinated in the presence of deubiquitininating 
enzymes (DUB) inhibitors. The polyubiquitin chains are predominantly Lys29 and Lys33 
linked suggesting that they play a role in direct AMPK regulation rather than in targeting 
AMPK for degradation (181). 
 
Protein acetylation is a further regulatory mechanism employed by cells. There are only 
limited reports of AMPK acetylation; HDAC1 and p300 control the reversible acetylation of 
the -subunit. Deacetylation is thought to increase the affinity of AMPK for LKB1 and 
therefore increase activation through T172 phosphorylation (182). Further studies are 
required to determine whether acetylation affects phosphorylation state and nucleotide 
regulation directly. 
There are multiple ways that AMPK is post-translationally modified. The fact that 
phosphorylation is the most well-established, does not mean that it is the most important;  
it will therefore be interesting to see how the interplay between the many modifications 
mediates AMPK activity.  
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 1.5.2 Direct Regulators 
 1.5.2.1 Nucleotide Regulation  
The characteristics of AXP binding to the -subunit varies between homologues (Table 2). 
The mammalian 1 isoform binds three nucleotides, one of which is a non-exchangeable 
AMP (as described in Section 1.4.4)(Figure 10). In the mammalian structure Site-1 and 3 can 
bind exchangeably, Site-4 is non- exchangeably bound by AMP and Site-2 is empty.  
The lack of binding at Site-2 has been suggested to be due to a natural Asp to Arg mutation 
at a position that might be involved in AXP binding (146).  
S.pombe and S.cerevisiae structures suggest that Site-4 (equivalent to the non-exchangeable 
site in AMPK) binds AXPs exchangeably. In the case of S.pombe it has also been observed 
that ADP can bind Site-2 (equivalent to the empty site in AMPK). Nucleotide occupancy of 
the four potential binding sites, in different species, is summarised in Table 2. 
 
The current consensus is that AMPK responds to the AMP/ADP:ATP ratio of the cell and thus 
acts as an ‘energy gauge’ (3). In the early days of AMPK research, the enzyme was thought 
to respond to ADP activation, but further investigation suggested that AMP was a much 
more potent activator and that the original results were caused by adenylate kinase 
contamination.  
 
AMP allosterically activates the phospho-form of the kinase on average about 2-4 fold (174) 
(7). The 2 isoform is the most sensitive to allosteric activation by AMP, followed by 1 and 
3. Differing sensitivities to regulation may allow for greater variation in the AMPK response.  
It is unclear how nucleotide binding at the exchangeable sites produces allosteric activation 
of the catalytic domain but both exchangeable sites competitively bind AMP/ADP/ATP.  
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In contrast to previous structures, two co-crystallisation experiments of truncated AMPK in 
complex with AXP recently revealed a 5o rotation of the Bateman domains with respect to 
one another in the presence of ATP as opposed to AMP. This may explain the allosteric 
activation of AMPK by AMP. However the complexes contained 1 (ATP) and 2 (AMP), 
suggesting, perhaps, some influence of the -subunit on the structure of the  (144). 
In the ATP-bound structure, the previously termed ‘non-exchangeable’ Site-4 was occupied 
by ATP, as was Site-1, however Site-3 was unoccupied. The displacement of the ‘permanent’ 
AMP by ATP in the crystal, which has not been shown in solution, might well account for the 
rearrangement of the Bateman domains. 
 
Two further regulatory roles of AMP are 1) the protection of T172 from dephosphorylation 
by phosphatases, and 2) promotion of phosphorylation of T172 by upstream kinases  
(an effect which is dependent on myristoylation state)(discussed in Section 1.5.1.4) (177). 
Recently the Gamblin/Carling/Kemp laboratories demonstrated that both regulatory effects 
are additionally mediated by ADP (1, 177). 
 
 1.5.2.2 Glycogen Regulation 
Glycogen is a highly branched glucose polymer, which forms large cytoplasmic particles. 
AMPK plays a key role in the regulation of glycogen metabolism (discussed in Section 1.2.1). 
Indeed aberrant AMPK activity results in glycogen storage disease in skeletal and cardiac 
tissues (discussed in Section 1.3.4).  
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The localisation of AMPK to the periphery of glycogen particles has been observed via 
electron microscopy, in cell-based systems, and in cell-free systems (136, 183, 184). 
Glycogen is thought to bind the GBD at the same interface as -cyclodextrin (Figure 7). 
Conserved residues in this interface include 1 W100, K126, W133, L146 and T148, and they 
appear to be involved in AMPK association with glycogen (134, 136, 185).  
 
High levels of skeletal muscle glycogen have been shown to allosterically inhibit AMPK 
activation in response to either pharmacological treatment or exercise in vivo (186, 187). 
Allosteric inhibition and reduced T172 phosphorylation of AMPK by glycogen granules has 
been observed in vitro and in cell-free assays (134, 135). This effect appears to be 
dependent on the level of glycogen chain branching, and some polysaccharides containing 
branch point structures were found to inhibit AMPK more potently than others (134).  
In this model, AMPK is thought to interact with glycogen in two ways; 1) Glycogen branch 
points (16 linked) are only accessible during times of cellular energy shortage when the 
structures are broken down to release glucose; AMPK is inhibited, acting as a feedback 
mechanism allowing rapid re-synthesis of glycogen when environmental glucose 
concentrations increase. 2) Interactions of AMPK with the reducing ends of linear chains 
(14 linked) localises AMPK to glycogen particles and in close proximity to some of its 
targets (e.g. GS), but does not regulate the protein directly (134, 135).  
 
Of course the real difficulty in identifying the natural ligand which mediates AMPK 
regulation by glycogen is the intrinsic heterogeneity of glycogen preparations. However, it is 
clear that the interaction between AMPK and glycogen is not simply a localisation effect,  
but also involves effects on the enzyme’s regulation.  
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Table 2: Site occupancy by nucleotides. 
The data was compiled from numerous crystal structures of mammalian and yeast  
subunits as referenced in the table. (NE: non-exchangeable). 
  
 Site-1 Site-2 Site-3 Site-4 Ref 
Mammalian 
AMPK 
AMP/ADP/ATP/Mg.ATP/NADH 
ATP/AMP 
- AMP/ADP/ATP/Mg.ATP 
AMP 
AMP (NE) 
ATP/AMP 
(1, 87) 
(144) 
S.pombe - ADP - AMP/ADP/ATP (142, 188) 
S.cerevisiae -  - ADP/AMP/NAD
H 
AMP? 
(2) 
(189) 
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 1.5.2.3 Pharmacological agents 
The activation of AMPK has a number of beneficial effects in the treatment of type-2 
diabetes (discussed in Section 1.3) and for this reason pharmaceutical companies have 
pursued the development of small molecule activators of AMPK.  
 
In an experimental setting, AICAR has been widely used as an AMPK activator. AICAR is a 
nucleoside which, upon cellular uptake, is converted to AICAR 5’-monophosphate (ZMP) by 
adenosine kinase. ZMP mimics the activatory effects of AMP, albeit with lower potency 
(190, 191). Short-term AICAR treatment does not alter the cellular adenine nucleotide 
concentrations; however, over prolonged periods the accumulation of ZTP may inhibit 
AMPK (192, 193). ZMP is not a specific AMPK activator as it interacts with other  
AMP-binding proteins, for example stimulating GP and inhibiting fructose-1,6-bisphosphate 
(194, 195). For this reason it is not practical as a pharmaceutical agent.  
 
In 2003 a specific AMPK activator A-769662 was shown to activate both recombinant and 
partially purified heart and liver AMPK (43). Its administration to obese (ob/ob) mice 
improves several aspects of type-2 diabetes and the metabolic syndrome; reducing plasma 
glucose and triglyceride levels, increasing fatty acid utilisation, decreasing liver fat area and 
triglyceride concentration, and decreasing overall body weight (43). A-769662 was most 
concentrated in the liver and plasma tissues, suggesting that it is possible to target drugs to 
specific tissues dependent on delivery mechanism/concentration administered (43).  
A-769662 both allosterically activates and protects T172 from dephosphorylation via a 
mechanism distinct from that of AMP/ADP (43, 173, 196). The compound more potently 
activates 1-containing complexes, suggesting some isoform specificity.  
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-subunit truncations and  S108A phosphorylation site mutation results in a loss of AMPK 
activation, suggesting that the activity somehow requires this subunit (173, 197). 
Interestingly A-769662 did not compete with sugar binding to the GBD (134).  
For three reasons A-769662 is not an ideal pharmaceutical agent;  
 1) A-769662 was delivered to mice models via intraperitoneal injection (although oral 
administration has been demonstrated), this is not practical in a clinical setting since type-
2 diabetes and obesity are chronic disorders treated regularly over long periods (43).  
 2) Skeletal muscle is an important drug target in the treatment of type-2 diabetes.  
A-769662 did not activate AMPK in this tissue, where the 2 isoform is predominant. 
 3) Recently it has been suggested that A-769662 may have additional targets to AMPK  
(e.g. Na+K+- ATPase). Thus, A-769662 may not be a specific AMPK activator (198, 199).  
Therefore, there is considerable interest in designing a more potent, direct AMPK activator 
for in vivo applications.  
 
Salicylate, the breakdown product of aspirin, has recently been shown to directly activate 
AMPK both allosterically and through protection of T172 against dephosphorylation.  
The regulatory effect of salicylate competes with A-769662 activation in a concentration 
dependent manner; it is both more potent in 1 containing heterotrimers, and absent in 
S108A mutants. Taken together, this suggests that binding to the same AMPK site might be 
responsible for activation by both A-769662 and salicylate (200). In order for AMPK 
activation to be achieved in vivo it is possible that a high-dose would need to be 
administered, however it is an intriguing possibility that the anti-cancer effects of aspirin 
may be mediated through AMPK. 
 
Whilst activation of AMPK in most tissues is beneficial in the treatment of type-2 diabetes, 
its activation in the hypothalamus may increase the feeding response of the organism 
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resulting in obesity. Therefore specific inhibitors of AMPK activity may also be interesting 
drug candidates. Compound C acts as a reversible AMPK inhibitor, competing for binding 
with Mg.ATP in the -kinase domain (66). Although Compound C has some AMPK selectivity, 
it has been shown to inhibit a range of other kinases and biological processes (201). 
Furthermore, the apparent inhibition of AICAR activation is due to disruption of AICAR 
cellular uptake, suggesting that Compound C may not be a direct inhibitor (202).  
 
 1.5.3 Indirect Regulators 
 1.5.3.1 Natural Compounds 
It appears that a number of naturally occurring compounds activate AMPK indirectly 
resulting in anti-obesity and anti-cancer phenotypes consistent with AMPK stimulation 
(Table 3) (described in Section 1.3). Many of these compounds are thought to increase the 
cellular AMP:ATP ratio through inhibition of mitochondrial ATP production (203).  
One exception is quercetin which has been shown to decrease expression levels of the PP2C 
phosphatase thereby increasing the activity of AMPK (204). It will be interesting to ascertain 
which of the downstream effects of these compounds are mediated through AMPK.  
 
 1.5.3.2 Metformin and thiazolidinediones 
Metformin is a prominent type-2 diabetes pharmaceutical agent. The main site of 
metformin action is the liver where it suppresses gluconeogenic and lipogenic  
gene expression (46). 
Metformin inhibits Complex I of the respiratory chain and thereby indirectly activates AMPK 
through increasing cellular AMP/ADP concentrations (66, 67). Studies utilising -subunit 
mutants demonstrate that AMP/ADP binding is necessary for metformin mediated AMPK 
activation (205). 
67 
 
More recently it has been shown that cultured hepatocytes carrying 1 and 2 or LKB1 
knock-out mutations show decreased glucose output in response to metformin treatment, 
suggesting that the effect may in part be AMPK-independent (206). Whilst this suggests that 
control of heptatic gluconeogenesis by metformin may not be AMPK-mediated, it does not 
negate the fact that AMPK is activated in a metformin dependent fashion (207).  
Therefore other beneficial effects of metformin treatment may still act through AMPK. 
 
Thiazolidinediones bind to the nuclear hormone receptor PPAR-, which is predominantly 
expressed in the adipose tissue but also in the skeletal muscle, liver and macrophages (46). 
The thiazolidinediones improve heptatic insulin sensitivity but do not reduce lipid content, 
and they activate AMPK in cardiac and skeletal muscle through increasing AMP/ADP 
concentrations (46, 208, 209). Chronic thiazolidinedione treatment may ultimately increase 
AMPK activity through increased adiponectin production (see Section 1.5.3.4)(210). 
 
 1.5.3.3 Exercise 
During exercise AMPK is activated in an intensity- and time-dependent manner throughout 
skeletal muscle (118, 211-213). Different AMPK isoforms appear to be differentially regulated 
in response to exercise, with the 223 heterotrimer being primarily activated (119).  
Small increases in the cellular AMP:ATP ratio are observed in response to exercise (155);  
it is therefore this and increases in AMP/ADP concentration which activate AMPK. 
Additionally increased Ca2+ concentrations activate CaMKK, and therefore AMPK (160).  
It seems likely that this is the basis of many of the health benefits associated with regular 
exercise, for example through increasing GLUT4 expression and therefore insulin sensitivity 
as well as increased mitochondrial capacity/density (19, 42, 214). Therefore AMPK may 
mediate, at least in part, the beneficial health effects of exercise.   
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Table 3: Naturally occurring AMPK activators. 
A number of compounds have been shown to indirectly activate AMPK through increasing 
cellular AMP/ADP levels. These compounds, their origin and the relevant references are 
shown.  
  
Compound Origin Reference 
Curcumin Principal curcuminoid of the spice turmeric (215) 
5-fluorouricil Chemotherapy drug  (216) 
Epigallocatechin gallate Most abundant catechin in tea (217, 218) 
Genistein Isoflavone found in a number of plants (216) 
Capsaicin Active component of chili peppers (219) 
p-HPEA-EDA A phenolic compound of virgin olive oil (220) 
Catechin Component of green tea extract (217) 
Quercetin Flavonoid found in fruits, vegetables, leaves and grains (221) 
Resveratrol Found in the skins of red grapes (222) 
Berberine Plant extract (223) 
Various Nutmeg extract (224) 
Ginsenosides Ginseng (225) 
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 1.5.3.4 Endocrine regulation of AMPK 
Hormones are secreted into the blood stream from endocrine glands and influence  
whole-body homeostasis. A number of hormones and cytokines play roles in the progression 
of the metabolic syndrome and have been shown to regulate AMPK. 
 
Leptin is secreted by the adipose tissue; it is an anorexigenic hormone which targets the 
hypothalamus. Obese (ob/ob) knock-out mice are severely overweight and diabetic (226, 227). 
Through AMPK stimulation, leptin increases the oxidation of fatty acids, increases glucose 
uptake and prevents the accumulation of lipids in skeletal muscle. Increased T172 
phosphorylation does not appear to correspond to elevated AMP/ADP concentrations 
suggesting that another mechanism activates AMPK and therefore it remains unclear how 
leptin activates AMPK (228, 229). Chronic leptin treatment required an intact sympathetic 
nervous system and appeared to increase expression of 2 and 2 AMPK subunits (63, 229).  
In the hypothalamus leptin signalling reduces AMPK activity and decreases food intake 
through altered neuropeptide expression (63). Recently 2 S491 phosphorylation by p70S6K 
kinase, acting downstream of PI3K-AKT, was found to underlie AMPK inhibition in the 
hypothalamus. Using S491A mutants this phosphorylation site was shown to be integral to 
leptin signalling in both cell-based systems and in mouse models (172). This suggests that 
there may be multiple factors which contribute to AMPK inhibition in addition to T172 
dephosphorylation.  
 
Adiponectin is also secreted from the adipose tissue and has a complementary/additive 
effect to leptin; increasing glucose uptake and fatty acid oxidation whilst decreasing 
gluconeogenesis (18, 230). The levels of this hormone are often decreased in obese and 
type-2 diabetic humans, compounding the deleterious effects of these diseases (231).  
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AMPK is integral to adiponectin signalling in the skeletal muscle where dominant-negative 
expression results in a loss of all downstream effects of adiponectin (232).  
AMPK is also activated in the hypothalamus, stimulating food intake (233). It appears that 
this is due to both an increase in AMP and Ca2+ concentrations, although the exact mechanism 
through which adiponectin stimulates these changes remains unclear (230, 234, 235). 
Consistent with LKB1 and CaMKK dependent activation, LKB1 knock-out blunts but does 
not abolish adiponectin signalling in hepatocytes (236).  
 
Ghrelin is an orexigenic hormone which acts on the hypothalamus to stimulate food intake, 
through binding to its G-coupled receptor, it raises Ca2+ concentrations and activates AMPK 
via CaMKK(237, 238). It is this AMPK activity which, if inhibited pharmacologically, would 
be beneficial in combating the obesity epidemic. 
 
Oestrogen, androgens, IL-6 and resistin have also been linked to AMPK activity (46).  
Several factors including ciliary neurotrophic factor (CNTF) and -lipoic acid, inhibit AMPK 
signalling in the hypothalamus thereby reducing food intake, whilst stimulating AMPK 
activity in peripheral tissues (i.e. increasing fatty acid oxidation and glucose uptake) (239-242). 
TNF downregulates AMPK and reduces fatty acid oxidation through increased activity  
of PP2C (242-244). -lipoic acid stimulates AMPK in the skeletal muscle, and inhibits AMPK 
in the hypothalamus, through regulation of PP2C (46). 
 
A plethora of hormones and cytokines have been shown to regulate AMPK, cementing the 
enzyme as a key regulator of whole-body metabolism, and as a valuable drug-target in the 
treatment of multiple diseases.   
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 1.5.4 Concluding Remark 
AMPK is regulated in multiple ways both directly and indirectly; it is therefore an important 
point of integration in the transduction of signals through the cell and in coordinating 
complex cellular responses to both external and internal stimuli. This thesis focuses on the 
regulation of mammalian AMPK and the S.cerevisiae ortholog, SNF1, by ADP.  
 
 
 1.6 Aims 
This project aims to further the understanding of how AMPK is regulated by nucleotide 
binding to the heterotrimer specifically: 
 1) To determine the affinities of AXP for the AMPK -subunit, and for the equivalent Snf4 
subunit of the S.cerevisiae homolog.  
 2) To confirm the AXP -subunit sites at which fluorescently labelled nucleotides bind (used 
in (1)),via X-ray crystallography. 
 3) To monitor AMPK/SNF1 kinetics and regulation by nucleotide using a coupled 
spectrophotometric assay. 
 4) To model the occupancy of AMPK/SNF1 binding sites by AXP based upon the Kd values 
determined in (1). Firstly, given the conditions of the in vitro assay performed in (3), and 
secondly given intracellular AXP concentrations.  
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 Chapter 2: Methods 
General methods of molecular biology, protein expression and protein purification are 
covered in this Chapter. Specific biophysical and X-ray crystallographic methods are 
described within the relevant Chapters.  
 
 2.1 Molecular Biology 
 2.1.1 DNA constructs 
All vectors were kindly provided by Dr Richard Heath and Dr Matthew Sanders (NIMR).  
AMPK 
A tricistronic vector containing all three AMPK subunits (N-terminal hexahistidine (His)-  
andwith a commercial pET3d backbone was used for expression in E.coli.  
The polycistronic vector was constructed from individual monocistronic vectors by repetitive 
cycles of restriction enzyme digestion and ligation as described in Neumann et al (245).  
Each subunit has an individual ribosome binding site (RBS), transcription was driven through 
a T7 promoter, and the vector carried an ampicillin resistance gene.  
Full length AMPK:   Human 111 
Truncated AMPK:  Rat 1 396-548, human 2187-272, rat 1 
 
SNF1 
A pETDuet-1 vector (Novagen) carrying Snf4 () and the His-Snf1 () subunits and a 
pRSFDuet-1 vector (Novagen) carrying the Gal83 () subunit were co-transformed for the 
expression of SNF1 in E.coli. The vectors carried ampicillin and kanamycin resistance genes 
respectively; transcription was driven through a T7 promoter.  
Full length SNF1:   Snf1, Gal83, Snf4 
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Site Directed mutagenesis 
Site-directed mutants were generated using the QuikChange site-directed mutagenesis kit 
(Strategene) according to the manufacturer’s protocol.  
 
CaMKK 
CaMKK was expressed from a pET DUET-1 vector (Novagen) from which N-terminally  
His-tagged CaMKK was expressed in E.coli cells (158). 
 
 2.1.2 Bacterial strains 
JM109 Competent Cells (Sigma); F(traD36, proAB+ lacIq, (lacZ)M15) endA1 
recA1hsdR17(rk
-, mk
+) mcrA supE44 - gyrA96 relA1 (lacproAB) thi-1. This competent cell 
line is a general purpose cloning strain used to generate high quality plasmid DNA.  
Vectors were transformed (as described in Section 2.1.5), single colonies picked into 10ml LB 
containing the relevant antibiotic, grown overnight at 37oC 200rpm (revolutions per 
minute), and purified using a QIAprep Spin Miniprep Kit (Qiagen) as per the  
manufacturer’s instructions.  
 
XL10-Gold® Ultracompetent Cells (Stratagene); Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lacHte [F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr]. 
This competent cell line was used to produce plasmids generated during mutagenesis.  
The Hte phenotype increases transformation efficiency.  
 
One Shot® BL21 Star™ (DE3) Chemically Competent E. coli (Invitrogen); F- ompT hsdSB F- 
ompT hsdSB (rB-mB-) gal dcm rne131 (DE3). Competent cells were used for the expression of 
recombinant proteins. The DE3 designation means the strain contains the DE3 lysogen 
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which carries the gene for the T7 RNA polymerase under the control of the lacUV5 
promoter. Isopropyl -D-1-thiogalactopyranoside (IPTG) is a lactose analogue which relieves 
repression of the lacUV5 promoter through clearence of the Lac repressor.  
This allows expression of T7 RNA polymerase, and therefore transcription of the gene of 
interest, controlled by a T7 promoter.  
 
Ampicillin (100mg/ml stock) and kanamycin (50mg/ml) were prepared as stock solutions in 
ddH2O and stored at -20
oC. Ampicillin and kanamycin were used at a final concentration of 
100g/ml and 50g/ml respectively.  
 
 2.1.3 Agarose gel electrophoresis 
DNA preperations were analysed by electrophoresis on a 1% agarose gel made with tris-
acetate-EDTA (TAE) buffer containing 0.2g/ml ethidium bromide for 40minutes at 140V. 
DNA loading buffer was added to DNA at a ratio of 1:5. DNA was visualised by exposure to 
UV radiation and the size of DNA fragments was determined through comparison with 
standard markers (Bioline Hyperladder I). 
 
 2.1.4 DNA sequencing 
DNA was sequenced by GATC biotech following the company guidelines. 
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 2.1.5 Transformation 
Bacterial transformation is the process whereby competent cells take up DNA molecules 
from the external environment. In vitro this technique is used to introduce plasmids carrying 
a gene of interest to a chemically competent cell-line. 50-1000ng of plasmid DNA  
(see Section 2.1.1) was added to a single aliquot of E.coli competent cells (see Section 2.1.2) 
and incubated on ice for 10minutes. The DNA:cell solution was heat shocked at 42oC for  
45 seconds and immediately returned to ice for 2 minutes. Cells recovered in 250l SOC 
media (2%(w/v) tryptone, 0.5% yeast extract, 0.05% NaCl, 20mM glucose) at 37oC,  
and subsequently 30l was plated on agar plates of the appropriate antibiotic resistance. 
Plates were incubated overnight at 37oC. 
 
 2.2 Protein biochemistry 
 2.2.1 Protein expression 
A single bacterial colony from an agar plate (see Section 2.1.5) was picked into 10ml of Luria 
Bertani medium (LB - 1% (w/v) tryptone, 0.5% yeast extract, 0.5% (w/v) NaCl) containing the 
appropriate antibiotic. The starter culture was incubated at 37oC, 200rpm for around 
5hours. For each subsequent 750ml ‘large-scale’ culture 250l of the starter culture was 
plated onto an agar plate of the appropriate antibiotic and incubated overnight at 37oC. 
Cells were suspended by washing each plate with 10ml of LB-antibiotic and pooling the 
resulting cultures. 7.5ml of this ‘small scale’ culture was used to inoculate 750ml of LB 
containing the appropriate antibiotic, and ‘large-scale’ cultures were incubated at 37oC, 
200rpm until the optical density at 600nm (OD600) was 1.2. The cells were induced with 
1mM IPTG and incubated overnight at 25oC, 200rpm. Cells were pelleted by centrifugation 
at 4000rpm, 4oC for 30minutes and the supernatant discarded, the pellet was washed with 
0.9% NaCl and repelleted as before. Cells were stored at -20oC until cell lysis  
(see Section 2.2.2). 
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 2.2.2 Cell Lysis 
Cells were prepared as described in 2.2.1, thawed on ice and resuspended in an appropriate 
volume of lysis buffer (>5ml per gram of cells)(50mM Tris.HCl pH 8.0, 300mM NaCl, 20mM 
Imidazole, 0.5mM tris(2-carboxyethyl)phosphine (TCEP), 1mM MgCl2, 25 units Benzonase 
nuclease (Merck) and 1 cOmplete, EDTA-free Protease Inhibitor Cocktail Tablet (Roche) per 
50ml of lysis buffer). Cells were lysed on ice by sonication (Branson Sonifier 450) at 50% 
power 90second pulses with 30sec rest for a total of 14minutes. The lysate was centrifuged 
at 25,000rpm, 4oC, for 45minutes, the supernatant was kept on ice, pooled and passed 
through a 0.45micron filter.  
 
 2.2.3 Protein Purification  
 2.2.3.1 Nickel affinity purification 
Immobilised metal ion affinity chromatography (IMAC) is based on the principle that certain 
divalent metal ions (such as Ni2+) strongly coordinate amino acids, particularly histidine.  
The introduction of a poly-histidine tag to the protein of interest (see Section 2.1.1) allows 
these overexpressed proteins to selectively bind the column whilst un-tagged proteins are 
washed away.  
Nickel affinity purification was performed using a 5ml HisTrap HP column (GE healthcare). 
The column was equilibrated with binding buffer (50mM Tris.HCl pH 8.0, 300mM NaCl, 
20mM imidazole, 0.5mM TCEP), the filtered lysis applied and then washed with binding 
buffer using a P1 pump at a flow rate of 2ml/min. Bound protein was eluted using an 
AKTAprime, flow rate 2ml/min, with a gradient of 0-100% elution buffer (50mM Tris.HCl  
pH 8.0, 300mM NaCl, 300mM Imidazole, 0.5mM TCEP) over a volume of 100ml;  
5ml fractions were collected throughout. Samples of the lysis, flow through, wash and 
fractions were taken for analysis on an SDS-PAGE gel (see Section 2.2.6). The best fractions 
were pooled for further purification.   
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 2.2.3.2 Ion exchange chromatography 
Ion exchange chromatography separates proteins based on differences in charge. The pI of a 
protein is the pH at which the protein carries no net electrical charge, at a pH above its pI 
the protein carries a net negative charge and vice versa. Full length 111 has a pI of 6.7, 
(crystallography construct: Rat 1 396-548, human 2187-272, rat 1 pI 7.9) (SNF1: Snf1 Gal83 
Snf4 pI 5.6). In all cases a HiTrap mono-Q HP column (anionic exchange)(GE healthcare) was 
used since the buffer pH was higher than the protein’s pI. The column was equilibrated and 
the sample diluted with a low-salt buffer (50mM Tris, 100mM NaCl). The sample was then 
loaded using a P1 pump at a flow rate of 2ml/min, and the column washed. Bound protein 
was eluted using an AKTAprime, flow rate 2ml/min, with a gradient of 0-100% high-salt 
elution buffer (50mM Tris.HCl pH 8.0, 1M NaCl, 0.5mM TCEP) over a volume of 100ml;  
5ml fractions were collected throughout. Samples of the fractions were taken for analysis on 
an SDS-PAGE gel (see Section 2.2.6). The best fractions were pooled for further purification. 
 
 2.2.3.3 Size exclusion chromatography 
Size exclusion chromatography separates molecules based on their size, larger molecules 
pass through the column quicker than smaller molecules which are retarded by passing 
through the porous beads which make up the column. A Superdex 200 gel filtration column 
(GE healthcare), volume 120ml, was equilibrated with gel filtration buffer (50mM Tris.HCl 
pH 8.0, 300mM NaCl, 1mM TCEP) on a AKTAprime at a flow rate of 1ml/min.  
The 5ml sample was injected onto the column and eluted into 2ml fractions. Samples were 
collected for analysis by SDS-PAGE. The best fractions were pooled for further purification or 
phosphorylation (Section 2.2.4). 
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 2.2.4 In vitro phosphorylation 
After gel filtration the best fractions were pooled and the concentration measured  
(see Section 2.2.7). The samples were phosphorylated through incubation with  
(final concentrations); 2.5mM MgCl2, 0.5mM AMP and 0.5mM ATP. 1mg of 
CaMKK(purified in house) was added for every 100mg protein. The sample was left 
overnight (16-17hours) at 25oC and repurified as in Section 2.2.3.3. A sample of 
unphosphorylated protein was retained for SDS-PAGE (see Section 2.2.6) and mass 
spectrometry analysis.  
 
 2.2.5 His-tag cleavage 
After gel filtration the best fractions were pooled and the concentration measured  
(see Section 2.2.7). 1mg of His-3C (kindly provided by Dr Vangelis Christodoulou, NIMR) was 
added for every 100mg AMPK/SNF1, and the sample incubated at 20oC for 2hours.  
The sample was repurified as in Section 2.2.3.3. A sample of uncleaved protein was retained 
for SDS-PAGE analysis (see Section 2.2.6).  
 
 2.2.6 Sodium Dodecyl sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
5l of NuPAGE LDS Sample Buffer (Invitrogen) was added to 15l aliquots of protein sample, 
and heated at 90oC for 3minutes. Protein samples and Mark 12 protein standards 
(Invitrogen) were loaded onto a NuPAGE 4-12% Bis-Tris Gels (Invitrogen). Gels were run at 
180V for 35minutes in NuPAGE MES SDS Running buffer (Invitrogen). Protein bands were 
visualised by staining with InstantBlue (Novexin), a Coomassie based staining solution.  
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 2.2.7 Determination of protein concentration 
The pooled protein fractions were concentrated using a Vivaspin 20 (Sartorius), 100K, 
centrifuged at 4000prm until the desired concentration was achieved. The concentration 
was measured using UV-vis spectrophotometry. The samples absorbance was measured at a 
wavelength of 280nm using a Nanodrop Spectrometer (ND-1000) or Jasco V-550 UV-Vis 
spectrophotometer. The protein concentration was calculated as described by the Beer 
Lambert equation: 
𝐴 =  𝜀 × 𝐶 × 𝐿 
 
Where: A = absorbance;  = extinction coefficient (M-1cm-1); C = concentration (M); L = 
pathlength (cm). Protein extinction coefficients were determined using the ExPASy 
ProtParam tool available online or using published extinction coefficients. 
 
 2.2.8 Dynamic Light Scattering (DLS) 
DLS measures the size distribution of molecules in an aqueous solution; it is a measure of 
the heterogeneity of a protein sample. 30l of 0.6mg/ml sample was centrifuged at 
10,000xg, 20oC, for 30minutes. A Viscotek-802 DLS with Omnisize 3.0 Software was used to 
perform 10 scans per sample and subsequently taking an average. Protein samples for 
which the calculated molecular weight did not exceed 20% of the expected size, and the 
polydispersity was less than 20% were considered optimum samples for crystallisation trials.  
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 Chapter 3: Nucleotide binding to AMPK 
 
 3.1 Abstract  
AMP, ADP and Mg.ATP binding to the -subunit of AMPK regulates the catalytic activity of 
the -kinase.  Binding constants for the interactions between nucleotides and full-length 
active (phosphorylated on T172) AMPK have not previously been defined.  
In this Chapter the binding of AXP to the full-length 111 heterotrimer,  
both phosphorylated and unphosphorylated, is described. Binding was monitored through 
displacement of fluorescently labelled nucleotides, either through direct coumarin 
excitation or Forster Resonance Energy Transfer (FRET) from excitation of intrinsic 
tryptophan residues. 
AMPK binds nucleotides exchangeably at two sites, one (Site-1) with significantly higher 
affinity than the other (Site-3). Mg.ATP binds competitively but with weaker affinity than the 
regulatory nucleotides, AMP and ADP. Binding of nucleotides to a number of -subunit 
mutants and the interaction between the -kinase active site and staurosporine  
(an inhibitor) was also characterised. 
Various biophysical techniques (CD, MALLS) were utilised to ensure the protein samples 
were of a high quality, and highlighted some interesting differences between the 
phosphorylated and unphosphorylated AMPK species. 
  
81 
 
 3.2 Introduction   
 3.2.1   Previous reports of nucleotide binding to AMPK 
The -subunit of AMPK comprises four CBS motifs, arranged in two Bateman domains  
(as described in Chapter 1). The role of CBS motifs as adenosine-nucleotide binding modules 
was first demonstrated in 2004 (86). Scott et al cloned and purified GST fusions of a number 
of CBS motifs both in isolation and as tandem repeats from AMPK 2, 1 and 3, IMPDH2, 
CLC2 and CBS itself. Ligand binding assays were performed by incubation of various 
concentrations of [14C]AMP or [-32P]ATP with CBS constructs and measurement of bound 
radioactivity by scintillation counting. This study showed that AMPK proteins bound both 
AMP and ATP competitively. The 1 CBS 1-4 construct bound AMP and ATP at two sites with 
Kd values of 20M (AMP) and 119M (ATP). The binding curves were analysed assuming two 
identical AXP binding sites were present, and that binding of AXP at the sites was 
cooperative. The constructs containing 2 CBS Sites-1-4 bound 2 molecules of AXP with 
strong positive cooperativity (Hill coefficient = 2), whilst this was also observed for the 1 
construct the extent of cooperativity was less. These authors observed no effect of MgCl2 on 
ATP binding (86).  Two nucleotide molecules were still found to bind to a number of WPWS 
point mutants introduced into the 2 construct, but with reduced affinity. 
 
Scott et al (2004) established that the -subunit of AMPK is the key to -kinase regulation by 
nucleotides. However the Kd values were determined based on interactions between the 
isolated Bateman domains and AXPs and not the intact heterotrimeric AMPK. In 2007, the 
Gamblin laboratory published the crystal structure of an AMPK truncate which included the 
complete 1 subunit (as described in Section 1.4.4) (87). This structure confirmed 
adenosine-nucleotides exchangeably bound the AMPK-subunit with a stoichiometry of 2:1 
(the third observed AMP being non-exchangeable). At the same time Kd values for 
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nucleotide interactions with the truncate were reported. Fluorescently-labelled reporters, 
mant-ATP and mant-AMP, bound with a stoichiometry of 2:1 and with affinities of 4M and 
10M respectively.  Competition assays provided Kd values of 12.5M and 24.5M for ATP 
and AMP respectively. The binding data were analysed assuming the AXP binding sites were 
independent and identical. No effect of MgCl2 on ATP binding was reported (87).   
Using the same fluorescent reporters, equilibrium dissociation constants for AMP/ADP/ATP 
binding to a number of WPWS mutations (R69Q, H150R, R298G) in the truncated AMPK 
construct were determined and suggested weaker binding at both sites (Peter Saiu –  
PhD Thesis). 
 
A similar but more powerful approach, in which fluorescently-labelled nucleotides were 
used to probe the interactions between AXP and AMPK is described in this Chapter.  
The remainder of the introduction focuses on fluorescence, the development of 
fluorescence AXP reporters, and FRET.  
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 3.2.2   Fluorescence  
The absorption of a photon by a fluorophore causes an electronic transition from a ground 
state to a higher energy excited state. The excess energy in the electronically excited states 
will eventually be lost by vibrational relaxation and internal conversion until the lowest 
vibrational level of the first excited state is reached. As the species returns to the ground 
state a photon is emitted, and it is this which we term fluorescence. The transitions 
between energy states are often represented in Jablonski diagrams (Figure 12). 
Loss of energy via a radiative pathway (of which fluorescence is an example) is competitive 
with other non-radiative pathways such as release of heat, interactions with solvent 
molecules, collisions with other molecules or resonance transfer to other chromophores.  
These non-radiative processes are sensitive to solvent properties, temperature and pH,  
and for this reason fluorescence intensity is also affected by these parameters.  
 
Upon binding a protein, a fluorescent ligand will often experience a change in environment 
from an aqueous solvent to a partially hydrophobic binding pocket. In many cases this will 
result in changes in fluorescence emission intensity and emission maximum. Monitoring this 
change offers one way to characterise the interactions between small molecule ligands  
and proteins. The small amounts of sample required and the short data collection times 
involved make optical methods particularly useful in this area.   
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Figure 12: Jablonski diagram. 
A photon is absorbed upon excitation causing an electronic transition from the ground state 
(S0) to an excited state (S1-2). Excess energy is lost via internal conversion, when the lowest 
vibrational state of the excited state is reached (S1) a photon is emitted to return the species 
to S0. The species may return to one of multiple vibrational states of S0.  
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 3.2.3   Fluorescent nucleotide derivatives  
Nucleotides bind to a wide range of proteins. Such interactions are fundamental to many 
cellular processes, and many techniques have been developed to study the kinetic and 
equilibrium constants which describe them. The use of fluorescent nucleotide derivatives to 
monitor AXP binding to proteins is widespread owing to its high sensitivity (246). 
 
Adenine nucleotides consist of an adenine ring, ribose sugar, and the relevant number of 
phosphates (Figure 13a). Fluorescent nucleotide analogues with high extinction coefficients, 
good quantum yields (greater than 0.1) and absorption bands at longer wavelengths than 
endogenous backgrounds (i.e. mid-UV and longer) have been synthesised and date from the 
1970’s (247). Many such compounds are commercially available. When designing a 
nucleotide derivative it is important to consider the choice of fluorophore, the linker which 
connects it to the nucleotide and the likelihood of non-specific binding (247). 
 
There are many nucleotide derivatives, a few of which are described here. The purine ring 
system can be modified, producing so-called ‘etheno’ nucleotides (Figure 13a).  
These derivatives are not strongly sensitive to changes in environment and therefore 
measurements are often made using fluorescence anisotropy. They are often found to alter 
the rate and equilibrium constants for nucleotide-protein interactions. 
 
Modifications which do not alter the purine ring system but instead conjugate a fluorophore 
to the ribose moiety, at the 2’- and/or 3’-hydroxyl positions, often mimic more closely their 
parent nucleotides. In the case of myosin, other nucleoside triphosphatases and AMPK 
these hydroxyl groups project from the nucleotide binding site away from the protein so 
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that the fluorophore lies on or near the surface of the protein (Section 5.4)(246).  
In this position it often acts as a good reporter of binding. 
2'(3')-O-methylanthraniloyl (mant) derivatives of adenine nucleotides (Figure 13c) have 
been used to study many nucleotide-binding proteins, including AMPK.  
The mant fluorophore was chosen for its small size, and sensitivity to changes in 
environment (typically 2-3 fold enhancement in fluorescence upon binding to proteins) (87).  
 
Webb et al (2003) synthesised nine coumarin-labelled nucleotides with various lengths and 
types of linkers and described their properties. One particular analogue (Figure 13d) shows a 
17-fold enhancement of fluorescence upon binding actomyosin. They conclude that 
‘coumarin fluorophores provide a compromise between the wavelength and good 
environmental sensitivity of their fluorescence’. Such coumarin-labelled nucleotides have 
been used previously to measure ADP release from actomyosin (248). The large 
fluorescence enhancement upon protein binding make these coumarin-AXP’s (C-AXP) much 
more sensitive than mant-AXP’s in the study of nucleotide interaction with AMPK. 
 
In addition to chemically synthesised fluorescent reporters other naturally occurring 
molecules can be used to the same end. NADH contains an ADP moiety in which the  
-phosphate is linked to a second ribose and nicotinamide group (Figure 13e).   
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Figure 13: Examples of fluorescently-labelled nucleotides.  
A) 1,N6-ethenoadenosine 5'-triphosphate (ε-ATP);  
B) 2'-(or-3')-O-(trinitrophenyl)adenosine 5'-diphosphate;  
C) 2'-(or-3')-O-(N-methylanthraniloyl)adenosine 5'-diphosphate;  
D) 3’-(7-diethylaminocoumarin-3-carbonylamino)-3’-deoxy-AXP;  
E) Nicotinamide adenine dinucleotide   
B
 
 A 
A 
C D 
E 
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 3.2.4   Förster Resonance Energy Transfer (FRET) 
Tyrosine, phenylalanine and tryptophan residues are intrinsically fluorescent; all three are 
excited at wavelengths in the near-UV region (250-300nm). Phenylalanine fluorescence is 
only observed in proteins lacking both tryptophan and tyrosine. The fluorescence of 
proteins containing tryptophan and tyrosine is generally dominated by contributions from 
tryptophan residues, even though the two residues have similar quantum yields.  
Although this is partly due to the fact that tryptophan has the larger extinction coefficient 
(fluorescence intensity is proportional to the product of extinction coefficient and quantum 
yield) the major effect is the loss of tyrosine excited state energy through energy transfer to 
tryptophan.  
It is possible to measure equilibrium dissociation constants for the interaction between a 
fluorophore and a protein by monitoring FRET between ‘donor’ tryptophan residues, excited 
at 290nm, and the ‘acceptor’ fluorophores from which emission is observed.  
Electronic excitation energy is transferred through nonradiative dipole-dipole coupling from 
one fluorophore to another over distances that may extend to 30Å or more. The efficiency 
of energy transfer depends upon the sixth power of the distance between the fluorophores 
and upon their relative orientation (249). The overlap between the emission of the donor 
and the absorption of the acceptor must also be considered (247). The use of a FRET-based 
approach to study protein-ligand interactions is an established technique. 
 
In the case of C-AXP binding to AMPK there are 11 potential ‘donor’ tryptophan residues in 
full-length human 111, two of which are in the subunit. There are also two ‘acceptor’ 
C-AXP’s binding in the two exchangeable sites of the -subunit as determined by direct 
excitation experiments (Section 3.4.3.1) and observed in the crystal structure of a truncate 
bound to C-ADP (Chapter 5).   
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 3.3   Methods 
 3.3.1   Binding experiments 
In the analysis of each set of binding data, efforts to confirm stoichiometry of the interaction 
were initially undertaken, data were then fitted to the models described in the  
following sections. 
In the case of 2:1 interactions data were analysed assuming two independent  
(non-cooperative), non-identical nucleotide binding sites, to which binding of fluorescent 
ligand is not necessarily optically equivalent.  
 
 3.3.1.1   1:1 interactions  
The interaction of a protein (P) with a ligand (L) to form a simple 1:1 complex (PL) is 
represented by the following scheme: 
 
]PL[
]L][P[
Kd with the dissociation constant, Kd, defined as     
For any mixture of P and L the observed fluorescence signal (FOBS) is given by: 
 
]PL[F]L[F]P[FF PLLPOBS   
Equation 1 
where [X0], [X], and FX represent the total concentration, the equilibrium concentration, and 
the molar fluorescence coefficient of species X. A non-linear least-squares fit to equation (1) 
with [PL] calculated using equation (2) yields the Kd for the interaction and the FX values. 
P L PL+
Kd
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   
2
]L][P[4]L[]P[K][L  ]P[K
]PL[ 00
2
00d00d 
        
Equation 2 
 
 3.3.1.2  2:1 interactions 
In the case of 2:1 interactions, when the ligand (L) binds to two sites on a protein (P) the 
following completely general scheme is appropriate: 
 
The dissociation constants for the two sites are defined as: 
]PL[
]L][P[
K
I
I,d 
]PL[
]L][P[
K
II
II,d           
where  is a ‘cooperativity factor’ which is used to account for the fact that binding at one 
site may increase ( < 1) or decrease ( > 1) the affinity of the ligand for the other site.  
For any mixture of P and L the observed fluorescence signal (FOBS) is given by: 
]LPL[F]PL[F]PL[F]L[F]P[FF IIILPLIIPLIPLLPOBS IIIIII   
Equation 3  
P L PLI+
L
PLII
+
L PLILII+
L
+
Kd,II
Kd,I
Kd,I
Kd,II
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A non-linear least squares fit to equation (3) yields the Kd values for the interaction and the 
FX values. In this case the concentrations are calculated in the following way. The free ligand 
concentration is given by the root of the following equation:  
0C]L[C]L[C]L[C 01
2
2
3
3          
where the coefficients are: 
II,dI,d00
II,d0I,d0II,dI,dII,d0I,d01
0II,dI,d02
3
KK]L[C
K]P[K]P[KKK]L[K]L[C
]P[2KK]L[C
C




   
[P] can then be obtained from equation (4) 
2
II,dI,d
0II,dI,d
]L[2]L[K]L[K
])L[]L([KK
]P[


  
Equation 4 
When [P] and [L] are known [PLI] and [PLII] can be obtained from the expressions for the Kds 
and [PLILII] from equation (5) 
II,dI,d
2
III
KK
]P[]L[
]LPL[

  
Equation 5 
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 3.3.1.3  Competition/displacement  
When two ligands (L and N) compete for binding to a single site on a protein (P) the 
following scheme is appropriate: 
 
The dissociation constants for the two ligands are defined as: 
]PL[
]L][P[
K L,d 
]PN[
]N][P[
K N,d    
For any mixture of P, L and N the observed fluorescence signal (FOBS) is given by:
]PN[F]PL[F]N[F]L[F]P[FF PNPLNLPOBS   
Equation 6 
 
A non-linear least squares fit to equation (6) yields the Kd values for the interaction and the 
FX values. If the protein and the displacing ligand (N) are non-fluorescent, as is usually the 
case, then FN = FPN = FP = 0. For this system the concentrations are calculated in the following 
way. The free protein concentration is given by the root of the following equation:  
0C]P[C]P[C]P[C 01
2
2
3
3   
where the coefficients are: 
 
N,dL,d00
L,d0N,d0N,dL,dN,d0L,d01
00N,dL,d02
3
KK]P[C
K]N[K]L[KKK]P[K]P[C
]N[]L[KK]P[C
1C




   
P L PL+
Kd,L
P N PN+
Kd,N
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[PL] and [PN] can then be calculated from equations (7) and (8) and the remaining 
concentrations from the expressions for the Kds or from conservation of mass  
(e.g., [L] = [L0] - [PL]). 
 PL =  
 L0  P 
Kd,L +  P 
 
Equation 7 
 
 PN =  
 N0  P 
Kd,N +  P 
 
  Equation 8 
 
 3.3.1.4 General Materials  
Unless otherwise noted all binding measurements were performed at 20oC in 25mM Tris, 
1mM TCEP, 100mM NaCl (pH 8) (standard buffer). All fluorescence measurements were 
made using a Jasco FP-6300 spectrofluorimeter equipped with a ETC-273T Peltier 
temperature controller. Quartz cuvettes with 3mm and 5mm path lengths were  
from Hellma. C-AXP’s were kind gifts from Dr Martin Webb. ATP, ADP, AMP and NADH were 
purchased from Sigma and staurosporine from LC laboratories. The concentrations of all 
stock solutions were determined using published extinction coefficients. 
 
 3.3.1.5  Staurosporine binding titrations 
Uncorrected fluorescence emission spectra of staurosporine and its complexes with AMPK 
were recorded at 20oC (unless otherwise specified) in 20% isopropanol (standard buffer).  
An excitation wavelength of 335nm (bandwidth 2.5nm) was used and emission scanned 
from 360-500nm (bandwidth 10nm; sensitivity high). Staurosporine has a characteristic 
emission spectrum with maxima at 378nm and 396nm, the intensity ratio of these peaks is 
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shifted upon AMPK binding. Binding of staurosporine was monitored through titration of 
AMPK into a staurosporine solution (0.06M) mixed by gentle pipetting. The stoichiometry 
of the interaction was 1:1 (as described in results section) and the binding data were 
therefore analysed using non-linear least-squares fits to equation (1). In a titration of 
staurosporine (L) with AMPK (P) FP = 0 and FL can be estimated from the fluorescence signal 
observed from the staurosporine solution prior to the addition of AMPK.  
 
 3.3.1.6  NADH binding titrations 
Uncorrected fluorescence emission spectra of NADH and its complexes with AMPK were 
recorded at 20oC (unless otherwise specified) in standard buffer. An excitation wavelength of 
340nm (bandwidth 2.5nm) was used and emission scanned from 400-550nm (bandwidth 10nm). 
Free (uncomplexed) NADH has an emission maximum at 462nm. In the presence of 
saturating AMPK the fluorescence intensity is increased by 3-6 fold depending on the AMPK 
construct and is blue shifted to 438nm. Binding of NADH was monitored through titration of 
AMPK into a NADH solution (8M), mixed by gentle pipetting. The stoichiometry was 1:1 
therefore the binding data were analysed using non-linear least-squares fits to equation (1). 
In a titration of NADH (L) with AMPK (P) FP = 0 and FL can be estimated from the 
fluorescence signal observed from the NADH solution prior to the addition of AMPK.  
 
 3.3.1.7   Coumarin labelled AXP binding titrations 
Uncorrected fluorescence emission spectra of the coumarin analogues of AXP (C-ATP, C-ADP:  
3’-(7-diethylaminocoumarin-3-carbonylamino)-3’-deoxyadenosine 5’ di- and triphosphate)  
and its complexes with AMPK were recorded at 20oC (unless otherwise specified) in 
standard buffer. C-ATP and C-ADP have emission maxima at 479nm (with excitation at 
430nm). In the presence of excess AMPK the emission maxima are blue shifted to ~ 470nm 
and the fluorescence intensity is increased. The stoichiometry of the interactions (2:1) was 
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confirmed using ‘close to stoichiometric’ titrations in no salt, 7oC conditions. C-AXP binding 
data were therefore analysed using non-linear least-squares fits to equation (3).  
When C-AXP (L) is titrated with AMPK (P) there are six parameters to be determined since  
FP = 0 and FL can be determined from the fluorescence signal observed from C-AXP alone.  
IIIIII PLPLLPL
FFF In order to simplify the analysis we assumed that and that  =1  
LPL F/F I LPL F/F II(i.e., that the binding is non-cooperative). Kd,I, Kd,II and and  were estimated. 
 
 3.3.1.8   AXP binding titrations 
Displacement assays of 1) NADH and 2) C-AXP with AMP, ADP and ATP (with and  
without Mg2+) were used to determine Kd values for adenine nucleotides. Contamination of 
stock ATP/ADP solutions by breakdown products (ADP/AMP) was assessed by HPLC,  
the levels were too low to interfere with the binding assays described here  
(Matthew Sanders –Personal Communication). 
 
NADH displacement data were analysed using non-linear least-squares fits to equation (6) 
with the Kd for NADH binding fixed at the value determined in the direct titration (65M). 
Although this approach ignores any contribution from the binding of AXPs to the weaker of 
the two sites the dissociation constant determined for binding of AXP to the stronger of the 
two sites is in good agreement with that determined using competition with the C-AXPs. 
 
Analysis of the displacement of C-ATPs by AXPs is a more complicated because of the 
multiplicity of species formed. The displacement of C-ATP by ATP clearly occurs in two 
phases and experiments performed at different starting ratios of C-ATP to AMPK indicated 
that the C-ATP displaced by low concentrations of added AXP was from the stronger of the 
two sites (i.e. the strong C-AXP site is also the strong AXP site). Approximate values for the 
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AXP binding constants were estimated by treating the two parts of the curve separately and 
using equation (6). We then developed a method which permitted analysis of the whole 
curve. For any mixture of P (AMPK), L (C-AXP) and X (AXP) the observed fluorescence signal 
(FOBS) is given by: 
 
FOBS = FL L + FPLI  PLI + FPLII PLII + FPLILII PLILII + FPLI  PLIXII + FPLII PXILII   
Equation 9 
 
 Note: Because the AMPK and AXP have no fluorescence contribution we were able to set  
FP = FPXI = FPXII = FPXIXII =  0 IIII PLXPL FF and we also included the assumptions that  
IIIII PLLPX
FF and . The displacement data were then analysed using non-linear least-squares 
fits to equation (9) with the Kds for C-ATP binding fixed at the values determined in the 
direct titrations (see Section 3.4.3.1). Although it would in principle be possible to calculate 
equilibrium concentrations though the approaches described above it was simpler in this 
case to calculate them using the method developed by Storer and Cornish-Bowden 
(described in Section 4.2.5)(250).  
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 3.3.2  Circular Dichroism 
CD measurements were performed using a Jasco J-715 spectropolarimeter. Far-UV spectra 
were recorded at 20oC, over a range of  195-260nm, using 1mm fused silica cuvettes 
(Hellma) with a protein concentration of 0.15mg/ml diluted in dH20. Near-UV spectra were 
recorded using 10mm fused silica cuvettes (Hellma) with a protein concentration which 
produced an absorbance in the range of 1-1.5 (~1mg/ml). The CD signal:noise ratio is 
proportional to the square root of the number of scans and to the square root of the time 
constant; therefore 30-40scans were recorded with a time constant of 0.25sec, scanning 
speed 200nm/min and a spectral bandwidth of 1nm, averaged and the baseline subtracted.  
 
CD intensities were converted from millidegrees and presented as molar CD extinction 
coefficient (M) for near-UV data or the mean residue CD extinction coefficient (MRW) for 
far-UV data. Calculated as either: 
 
∆𝜀𝑀   =
𝑆
32980 × 𝐶𝑀 × 𝐿
 
Equation 10 
∆𝜀𝑀𝑅𝑊 = 
𝑆 ×𝑀𝑅𝑊
32980 × 𝐶𝑚𝑔/𝑚𝑙 × 𝐿
 
Equation 11 
Where: 
L= pathlength (cm); CM = concentration (M); Cmg/ml = concentration (mg/ml); S = CD signal 
(millidegrees); MRW = Mean Residue Weight (Da). 
 
MRW is calculated as MW/N, where MW is the molecular weight and N is the appropriate 
number of peptide bonds.   
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Secondary structure content was determined from far-UV spectra using in-house software 
written by Dr Stephen Martin (NIMR). These programs use a database of reference spectra 
of proteins with known secondary structure content to iteratively solve a series of 
simultaneous equations (one for each ) by a least squares method. This allows the 
determination of the fraction of -helix, sheet, random coil and -turn described by the 
experimental sample.  
Thermal denaturation experiments were performed at a fixed  = 222nm in a 2mm fused 
silica cuvette (Hellma) with a protein sample of 0.3mg/ml. The temperature ranged from  
5-95oC and was controlled by a Jasco PTC-348WI Peltier system. Data were converted to 
MRW as before. Tm values were calculated from the first derivative of the unfolding curve. 
 
 3.3.3  Multi-Angle Laser Light Scattering (MALLS) 
A Superdex S200 size-exclusion column (volume 24ml) was equilibrated with 50mM Tris.HCl 
pH 8.0, 300mM NaCl, 3mM Sodium Azide, 1mM TCEP at a flow rate of 0.5ml/min.  
100l protein samples, concentration 2mg/ml, were injected onto the column using a 
syringe at ambient temperature. The scattered light intensity and protein concentration of 
the column eluate were recorded using a DAWN-HELEOS laser photometer and an OPTILAB-
rEX differential refractometer (dRI) (dn/dc = 0.186), respectively. The weight-averaged 
molecular mass of material contained in chromatographic peaks was determined from the 
combined data from both detectors using the ASTRA software version 5.1 (Wyatt Technology). 
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 3.4  Results and Discussion 
 3.4.1  Expression of recombinant AMPK complexes 
A 111 construct was used throughout these studies. Expression of recombinant AMPK is 
well characterised. The subunits were co-expressed on a tricistronic vector and transformed 
into a competent E.coli cell line. Protein was affinity purified via the N-Terminal 1  
polyhis-tag and further purified by size-exclusion chromatography (see Chapter 2).  
The complex was phosphorylated in vitro with CaMKKas described in Section 2.2.4  
 
Figure 14 shows the purified product of AMPK expression and purification resolved by  
SDS-PAGE. The -subunit has an anomalous electrophoretic mobility, as commented on in 
Neumann et al (2003) (245). This makes resolution of the  and the -subunit difficult 
despite their different molecular weights (30kDa and 37kDa respectively).  
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Figure 14: Expression and purification of recombinant 111. 
Lane 1; phosphorylated AMPK, Lane 2; unphosphorylated AMPK. The purified protein was 
resolved on a 10% SDS-PAGE Novex gel and stained with InstantBlue stain. The molecular 
weight markers are indicated on the left (kDa) and the identity of the bands is indicated on 
the right.  
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 3.4.2  Binding of Staurosporine to AMPK  
Staurosporine (Figure 15b) is a potent inhibitor of both tyrosine and serine/threonine 
protein kinases. Staurosporine acts by blocking ATP binding to the -kinase domain,  
as confirmed in the crystal structure of AMPK and other kinases (1, 251). The ATP binding 
site is conserved between kinases; one of the challenges in developing specific inhibitors as 
drug candidates is being able to achieve acceptable selectivity (252). Mg.ATP binds in a 
conserved pocket between the two kinase lobes of the -subunit; staurosporine is a  
non-selective kinase inhibitor which binds competitively at this site. The binding of the 
inhibitor staurosporine to full-length AMPK was monitored with a view to studying the 
binding of ADP/ATP via competition experiments.  
 
Excitation of staurosporine at 296nm results in emission bands at 378nm and 396nm, upon 
binding to many protein kinases the fluorescence signal is enhanced. A competitive 
displacement assay for evaluating the binding affinity of small molecules to protein kinases 
using staurosporine has previously been described (253).  
 
Although the binding of staurosporine to AMPK does not produce a large change in 
fluorescence intensity it was possible to determine equilibrium dissociation constants by 
monitoring changes in the intensity ratio for the two major emission peaks at 378 and 
396nm (Figure 15a). As expected, staurosporine was found to bind to full length AMPK with 
high affinity and 1:1 stoichiometry (Figure 16). Although analysis of such high affinity 
interactions can be difficult it was possible to determine equilibrium dissociation constants of 
1.68 ± 0.47nM for phosphorylated AMPK and 5.63 ± 2.88nM for the unphosphorylated form.  
102 
 
There are six hydrogen-bonds formed between staurosporine and AMPK (PDB ID: 2Y94). 
There are also substantial Van der Waal and hydrophobic interactions which contribute to 
the high affinity binding.  
 
Previously Engh et al correlated the buried surface area of a kinase inhibitor to its inhibition 
i.e. the larger the interaction surface the more potent the inhibitor (254). The buried surface 
area of the staurosporine: AMPK interaction is  around 320Å (as calculated from PDB: 2Y94), 
and this is amongst the largest of the reported interfaces (254). AMPK is inhibited by 
staurosporine with commercially reported IC50 values of between 14.2nM and 67nM  
(255, 256). These IC50 values and the low nanomolar Kd values reported here fit the model 
proposed by Engh et al (2002) (254).   
 
Binding of staurosporine was also monitored in the presence of 0.5mM ADP, ATP and 
Mg.ATP (Figure 16). No significant competition with nucleotides was observed,  
suggesting that binding of nucleotide at the -kinase ATP binding pocket is relatively weak. 
It is not surprising that Mg.ATP binding to kinases is relatively weak, especially for the 
inactive kinase (discussed further in Chapter 5) (257). The Mg.ATP binding site buries all but 
the terminal -phosphate which is transferred to the substrate during catalysis.  The lack of 
accessibility to the site contributes to the low binding affinities of Mg.ATP and slow 
dissociation of ADP (257).   
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A 
B 
 
Figure 15: A) Emission spectra of staurosporine in the presence and absence of 
phosphorylated AMPK.  
Yellow) On excitation at 335nm, the emission spectrum of 0.06μM staurosporine shows two 
bands centred at 378 and 396nm. Orange) Addition of 0.37μM phosphorylated AMPK 
produces a change in the intensity ratio for these two peaks.  
B) Staurosporine.  
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 A
B 
Figure 16: Determination of the equilibrium dissociation constant for the binding of 
staurosporine to A) phosphorylated and B) unphosphorylated AMPK. 
Titration of staurosporine with AMPK in the presence of no nucleotide (red), 0.5mM ATP 
(green), 0.5mM ADP (yellow) and 0.5mM ATP/1.9mM MgCl2 (>95% Mg.ATP) (blue). The 
change in the ratio of emission peak intensities (where R and R0 are the intensity ratios  
 396:378nm in the presence/absence of AMPK) is plotted as a function of 
[AMPK]/[Staurosporine]. No significant differences in curve shape or signal intensity were 
observed in the different nucleotide conditions, and 1:1 stoichiometry was observed 
throughout.  
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 3.4.3  Binding of nucleotides to AMPK  
 3.4.3.1  Direct coumarin excitation experiments 
Coumarin labelled analogues of ADP and ATP were used as probes to monitor nucleotide 
binding to AMPK (Figure 13D; Section 3.2.3). Initial experiments suggested C-AXP’s bound 
AMPK tighter than the mant-AXP’s previously used by the Gamblin group (87).  
The higher affinity interaction facilitates analysis of subsequent competition experiments.  
 
Only binding of AXP to 1 containing heterotrimers was considered; upon expression 
bacterial, recombinant AMPK complexes which contain 2 or 3 isoforms are found to 
degrade from the N-terminus to produce a stable ‘1-like’ truncate (Personal 
Communication – Matthew Sanders). The significance of this instability in vivo is unknown.  
 
A stoichiometry of 2:1 for C-ADP and C-ATP binding to phosphorylated and 
unphosphorylated full length AMPK and to the truncated crystallisation construct  
(Chapter 5), was demonstrated by performing titrations at low temperature in the absence 
of salt (Figure 17). Equilibrium dissociation constants at 20oC in the presence of 100mM salt 
were then determined as described in the Section 3.3 (Figure 18 inset).  
 
Reducing temperature decreases the kinetic energy of the system and therefore tends to 
increases the affinity of protein:ligand interactions. Decreasing the temperature also 
reduces the energy lost via non-radiative relaxation from the excited to ground state, 
increasing the fluorescence signal. Many binding interfaces are reliant on electrostatic 
interactions, therefore decreasing the buffer salt concentration reduces ‘masking’ of the  
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charged residues and increases the binding affinity.  Experimental conditions of 7oC and 
0mM NaCl are far from physiological. 20oC, 100mM NaCl offers a compromise on sensitivity 
versus relevant biological conditions. 
 
To confirm that C-AXP’s do not bind the -kinase domain a number of control titrations with 
full length and truncated crystallisation constructs were performed in an isopropanol 
containing buffer with and without staurosporine (Table 4). The isopropanol is necessary to 
ensure staurosporine remains soluble throughout the experiments.  The addition of 
isopropanol to the buffer weakened binding of C-AXPS to AMPK slightly, but no significant 
differences were observed in the presence/absence of the inhibitor, or between the 
truncated and full-length protein samples. It is therefore concluded that C-AXP’s do not bind 
to the -kinase domain and that staurosporine is not needed in subsequent titrations  
(Table 4, Table 5 and Table 6). C-AXP’s have previously been demonstrated to be better 
substrates for ATPases than for kinases. This is because the kinase ATP binding pocket has a 
high specificity with respect to ribose modifications, and in this case the coumarin 
fluorophore is conjugated to a hydroxyl of the ribose (Figure 13D) (248). Therefore it is 
unlikely that C-AXP’s are capable of binding to the -kinase domain. 
 
Equilibrium dissociation constants for AXP binding to phosphorylated, unphosphorylated 
and truncated AMPK were determined through displacement of C-ATP from the  
AMPK:(C-ATP)2 complex (Figure 18). Fluorescence emission was monitored at 470nm, 
experiments were performed at 20oC in the presence of 100mM salt. AXP’s bound with a 
stoichiometry of 2:1 and Kd values were determined as described in Section 3.3  
(Table 7 and Table 8).  
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The presence of MgCl2 in the buffers reduced the fluorescence signal upon C-AXP binding to 
AMPK to about 1/5 of that in its absence (Figure 19). Mg.C-AXP binding to AMPK was 
weakened at both exchangeable AXP sites by between five- and fifteen-fold compared  
to free C-AXP. The effect appeared to saturate at [Mg2+] > 0.5mM for C-ATP and at [Mg2+] 
between 2 and 5mM for C-ADP, consistent with the fact that Mg2+ binds significantly more 
strongly to ATP than ADP (Table 4 and Table 5).  
Through displacement of C-ATP it was determined that phosphorylated AMPK binds Mg.ATP 
32-fold weaker at the tighter AXP binding site, and 3.5-fold weaker at the second site 
compared to free ATP (Table 7). This highlights the sensitivity of the AMPK AXP binding sites 
for the Mg2+ bound state of nucleotides. 
Previous studies indicated that Mg2+
 
has no effect on the binding of ATP to AMPK;  
in both cases truncated protein constructs were used suggesting that perhaps the effect is 
only apparent in the complete heterotrimer (described in Section 3.2.1) (86, 87).  
Sensitivity to Mg2+
 
bound versus free ATP contrasts AMPK with other proteins, such as 
kinases and GTPases whose affinity for nucleotide is strongly and positively dependent on 
the presence of Mg2+ (258). 
 
My studies show that Mg.ATP binds 3-30 fold weaker than ADP to AMPK. Physiologically the 
majority of ATP exists as Mg.ATP (3-8mM) whilst most ADP is free (50-200M),  
therefore the weaker affinity of Mg.ATP for AMPK should facilitate ADP to compete for 
binding to the heterotrimer in vivo and to regulate activity, despite its significantly lower 
cellular concentration. This idea is explored in much greater detail in Chapter 4.  
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Figure 17: (A) Determination of stoichiometry for C-ATP binding to AMPK. 
Titration of 24.6μM C-ATP with phosphorylated AMPK.  
(B) Determination of stoichiometry for C-ADP binding to AMPK; Titration of 25.2μM C-ADP 
with phosphorylated AMPK. In each case the change in emission intensity at 470nm,  
on excitation at 430nm, is plotted as a function of the [AMPK]. Hashed lines indicate the 
stoichiometric point; the intensity plateaus when the protein concentration is half that of 
the coumarin ligand, indicating 2:1 binding. Measurements were performed at 7oC in  
25mM Tris, 1mM TCEP (pH 8). 
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Figure 18: Measurement of equilibrium dissociation constants for the binding of AXPs to 
phosphorylated AMPK. 
Displacement of C-ATP from the AMPK:(C-ATP)2 complex by ATP (square), ADP (circle) and 
AMP (diamond) monitored using the change in fluorescence at 470nm  
(Excitation at 430nm). The solid lines are the computed best fits with Kd,I and Kd,II for C-ATP 
binding to AMPK fixed at 1.1 and 4.2 μM respectively in the analysis. Inset: Fluorescence 
titration of C-ATP with AMPK. All measurements were performed at 20oC in 25mM Tris, 
1mM TCEP, 100mM NaCl (pH 8).   
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Table 4: Equilibrium dissociation constants for the binding of C-AXPs to phosphorylated AMPK. 
Dissociation constants were determined at 20oC by fluorescence titrations of C-ATP with 
AMPK in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8) with and without 1mM/5mM MgCl2,  
20% isopropanol and 17M staurosporine (as indicated in the table). The Kd values are 
reported as the mean (± SD) determined from at least three independent measurements.  
nd: Not determined. 
  
Phosphorylated-AMPK C-ADP C-ATP 
Buffer condition KdI (M) KdII (M) KdI (M) KdII (M) 
 0.85 (0.11) 4.89 (1.27) 1.25 (0.14) 5.9 (2.03) 
1mM MgCl2 1.83 (0.35) 13.51 (5.39) 8.5 (3.2) 18.6 (6.2) 
5mM MgCl2 6.22 (1.58) 18.8 (1.1) nd nd 
20% isopropanol 3.62 (1.29) 20.95 (7.05) 1.89 (0.68) 18.57 (6.42) 
20% isopropanol & 
17M Staurosporine 
2.31 (1.08) 14.76 (6.76) 2.13 (0.54) 13.79 (2.61) 
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Table 5: Equilibrium dissociation constants for the binding of C-AXPs to unphosphorylated AMPK. 
Dissociation constants were determined at 20oC by fluorescence titrations of C-ATP with 
AMPK in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8) with and without 1mM/5mM MgCl2,  
20% isopropanol and 17M staurosporine (as indicated in the table). The Kd values are 
reported as the mean (± SD) determined from at least three independent measurements. 
nd: Not determined. 
  
Unphosphorylated-AMPK C-ADP C-ATP 
Buffer condition KdI (M) KdII (M) KdI (M) KdII (M) 
 0.45 (0.03) 3.14 (0.75) 0.24 (0.07) 5.37 (2.00) 
1mM MgCl2 1.47 (0.39) 9.24 (3.45) 4.33 (1.04) 25.5 (1.53) 
5mM MgCl2 6.54 ( 1.47) 26.5 (2.3) nd nd 
20% isopropanol 1.93 (1.27) 11.0 (3.33) 0.72 (0.4) 10.12 (4.02) 
20% isopropanol & 17M 
Staurosporine 
1.64 (1.09) 18.5 (4.08) 1.46 (0.65) 7.45 (3.05) 
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Table 6: Equilibrium dissociation constants for the binding of C-AXPs to truncated AMPK. 
Truncated AMPK refers to the crystallisation construct, (rat α1396-548 human β2187-272 rat 11-330). 
Dissociation constants were determined at 20oC by fluorescence titrations of C-ATP with 
AMPK in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8), 20% isopropanol and  
17M staurosporine (as indicated in the table). The Kd values are reported as the  
mean (± SD) determined from at least three independent measurements.   
Truncated-AMPK C-ADP C-ATP 
Buffer condition KdI (M) KdII (M) KdI (M) KdII (M) 
 1.07 (0.23) 5.94 (1.40) 0.81 (0.08) 9.59 (2.16) 
20% isopropanol 3.61 (1.02) 14.6 (6.72) 1.87 (0.58) 16.71 (4.78) 
20% isopropanol & 
17M Staurosporine 
4.98 (1.46) 15.12 (7.04) 2.55 (1.05) 18.8 (5.83) 
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Phosphorylated KdI (M) KdI (M) KdII (M) 
Ligand vs NADH vs C-ATP 
AMP 1.6 (0.5) 2.5 (0.6) 80 (25) 
ADP 1.3 (0.5) 1.5 (0.4) 50 (15) 
ATP 0.9 (0.3) 1.7 (0.5) 65 (15) 
Mg.ATP 32 (12) 55 (8) 230 (80)  
Mg.ADP nd 21 (9) 85 (35) 
 
 
Table 7: Equilibrium dissociation constants for the binding of AXPs to phosphorylated AMPK. 
Dissociation constants were determined at 20oC by competition against NADH or C-ATP in 
25mM Tris, 1mM TCEP, 100mM NaCl (pH 8) with and without 5mM MgCl2 (as indicated in 
the table). The Kd values are reported as the mean (± SD) determined from at least three 
independent measurements. nd: Not determined. 
 
 
 
 
 
 
 
Table 8: Equilibrium dissociation constants for the binding of AXPs to unphosphorylated AMPK. 
Dissociation constants were determined by displacement of C-ATP. Experimental conditions 
as described in Table 7. 
  
Unphosphorylated KdI (M) KdII (M) 
Ligand vs C-ATP 
AMP 2.13 (0.75) 78 (24) 
ADP 0.86 (0.31) 63 (19) 
ATP 0.51 (0.13) 61 (18) 
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Figure 19: Measurement of equilibrium dissociation constants for the binding of C-ATP to 
phosphorylated AMPK in the presence of Mg2+. 
The change in fluorescence at 470nm (Excitation at 430nm) was monitored in the presence 
(blue) and absence (green) of 1mM MgCl2. The solid lines are the computed best fits.  
All measurements were performed at 20oC in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8). 
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 3.4.3.2  Cooperativity 
Systems involving multiple binding sites can show co-operative binding behaviour, that is, the 
affinity of ligand binding at one site may depend on whether or not another site is occupied.  
In general, it is easiest to assume that a binding event is non-cooperative,  
both energetically (i.e.  = 1) and spectroscopically (the optical properties of the ligand in 
one site are not affected by occupancy of the other). The classic example of positive 
cooperativity is oxygen binding to the ()2 globin chains of haemoglobin. 
There are two common ways to represent cooperativity in a system;  
1) Through use of the Hill equation, which assumes that only the unbound and fully bound 
complexes exist, therefore in systems where a single site may be bound and another 
remain empty, i.e. those which are not strongly positively cooperative,  
these approximations are problematic (259).   
2) Via a co-cooperativity factor, . If < 1 binding is positively cooperative, if  > 1 then 
binding is negatively cooperative, and  = 1 there is no cooperativity (where we are 
dealing with dissociation constants).  can only be properly determined if the binding 
sites are identical. In the case of multiple ligands binding to a single protein the reaction 
scheme is often defined as; 
 
 
 
P L PLI+
L
PLII
+
L PLILII+
L
+
Kd,II
Kd,I
Kd,I
Kd,II
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Cooperativity can only be properly determined in a binding assay where the degree of 
saturation ([bound ligand]/[total protein]) can be determined as a function of  
free ligand concentration. This can be done with techniques such as equilibrium dialysis 
(which requires high [protein]) and through the use of radioactive-labelled nucleotides in a 
filter based binding assay (access to which was not available). It is not generally possible 
using optical methods as the free ligand concentration is not measured directly. 
 
In their 2004 study, Scott et al, studied isolated AMPK -subunit CBS domains.  
They fitted their binding data to the Hill equation and determined a Hill coefficient of ~2, 
suggesting binding is positively co-operative (86). The 2007 Xiao et al study, and subsequent 
work of Peter Saiu (PhD Thesis) assumed binding was independent at the two sites,  
both spectroscopically and energetically (87).  
In the work presented here the sites were assumed to be energetically and spectroscopically 
non-cooperative ( = 1), although the contributions to the fluorescence signal from the  
C-AXP binding at the two sites was thought to be different. A number of fits were performed 
with positive and negative cooperativity factors included in the fitting equations used in the 
analysis of the C-AXP binding curves. The effect of  > 1,  < 1 on the resultant Kd and 
statistical values was recorded (Table 9). If there is negative cooperativity (>1) then the Kd 
for the weaker site would be lower when the strong site was unoccupied (and vice versa). 
Although the intrinsic Kd for the weaker site could therefore be lower than I report the only 
experimental observable is binding to this site when the other site is occupied. 
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 KdI (M) KdII (M) 
2 
1 0.30 8.40 1.15 
0.2 0.29 43.00 1.15 
2 0.31 4.00 1.15 
 
 
Table 9: Effect of  on Kd. 
Fitting of a single titration of phosphorylated AMPK with C-ADP, the parameter was varied 
as indicated and the outputted Kd and 
2 values recorded. Equivalent to the data  
displayed in Table 4. 
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Figure 20: Measurement of equilibrium dissociation constants for the binding of AXPs to 
phosphorylated AMPK. 
Displacement of NADH from the AMPK:NADH complex by AXPs monitored using the change 
in fluorescence at 435nm (Excitation at 340nm). The solid lines are the computed best fits 
with the Kd for NADH fixed at 65 μM in the analysis. Inset: Fluorescence titration of NADH 
with AMPK. All measurements were performed at 20oC in 25mM Tris, 1mM TCEP,  
100mM NaCl (pH 8). 
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 3.4.3.3  NADH experiments 
In order to complement the coumarin titrations, the binding of NADH to AMPK was 
quantified. Previously Kd values of 18.3M and 156M were reported for NADH and NAD
+ 
binding to the truncated crystallisation construct (Peter Saiu – PhD Thesis).  
 
NADH binds weakly to full-length AMPK even at low temperature in the absence of added 
salt but analysis of these binding curves using a 1:1 model was significantly better than  
a 2:1 model. Two additional pieces of evidence suggest a 1:1 model for the binding of NADH 
is appropriate. Firstly the experiments in which NADH is displaced by AXP’s show that when 
a mixture of AMPK (32M) and NADH (15M) is titrated with AXPs almost complete 
displacement of NADH is observed when just over one equivalent of AXP is added.  
Secondly, the C-AXPs which bind to two sites on AMPK cannot be completely  
displaced by NADH.  
 
In the absence of salt and at 7oC a Kd of around 22M is estimated for NADH binding AMPK 
and at 20oC, 100mM salt the binding is significantly weaker, around 65M.  
Equilibrium dissociation constants for AXP binding to phosphorylated, unphosphorylated 
and truncated AMPK were determined through displacement of NADH from the 
AMPK:NADH complex (Table 7, Table 8 and Figure 20). Emission was monitored at 435nm, 
experiments were performed at 20oC in the presence of 100mM NaCl, Kd values were 
determined as described in the Section 3.3. NADH binding was not affected by the presence 
of Mg2+, as NADH binds magnesium very weakly. Importantly, the AXP Kd values determined 
through displacement of NADH corresponded well to the ‘tight’ C-AXP binding site. 
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The cellular concentrations of NAD+/NADH are estimated at 0.1-0.4mM with the oxidised 
form greatly in excess (260, 261). With such weak binding affinities, it is unlikely that much, 
if any, AMPK is bound by these co-factors in a cellular environment. 
Whilst the binding of NADH does not directly regulate AMPK, it can compete in vitro for 
binding at one of the regulatory sites. Importantly NADH competes with allosteric activation 
by AMP, but not the protection against dephosphorylation by AMP/ADP. This suggests that 
the two exchangeable sites have different regulatory roles and is considered in Chapter 4. 
 
 3.4.3.4 FRET-based binding experiments  
A complementary FRET-based approach was also used to study the binding of nucleotides to 
AMPK (see Section 3.2.4).  Usefully, this methodology requires significantly less protein than 
the direct coumarin excitation experiments previously described. 
 
C-ADP and C-ATP bound AMPK complexes have different intensity emission spectra in both 
direct excitation (430nm) and FRET (290nm) experiments. The C-ADP bound complex has a 
consistently lower fluorescence signal when compared to the C-ATP bound complex.  
The signal intensity also varies between unphosphorylated and phosphorylated samples  
(Figure 21). This is not surprising since the fluorescence signal can be strongly affected by 
small changes in the environment of the fluorophore.  
 
Titrations of both unphosphorylated and phosphorylated AMPK with C-AXP were 
performed. Tryptophan residues were excited at 290nm and C-AXP emission monitored at 
450-550nm. Emission and excitation spectra of the relevant fluorophores are shown in 
Figure 22, the overlap between AMPK emission and C-ATP excitation is highlighted. 
Experiments were performed at 20oC in the presence of 100mM NaCl (Figure 23, Figure 24).  
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These titrations did not permit the stoichiometry of the AMPK:C-AXP complex to be 
ambiguously determined, although the 2 values were generally improved (on average,  
1.6-fold) when fitting to a two-site rather than a one-site model.   
Analysis of the FRET-binding curves gave equilibrium dissociation constants for C-AXP 
binding in reasonable agreement with those determined for the tighter AXP binding site 
using direct excitation (Table 10). The second dissociation constant was generally poorly 
defined and, in some cases, there was little evidence for any contribution from binding at 
the second site. This suggests that a large proportion of the observed FRET signal derives 
from binding at the tighter site only.  
There are several potential reasons for this; the binding of a second C-AXP may not be 
accompanied by a significant fluorescence change or that the efficiency of transfer to the 
second site is lower. It is also conceivable that binding at the second site has some 
unexpected effect on the fluorescence properties of the system, for example if a tryptophan 
is able to transfer energy to both coumarins then binding of the second will reduce transfer 
to the first. There is the further possibility of fluorescence homotransfer between the two 
coumarin molecules when the second binds.  
In hindsight, the presence of multiple donor tryptophan residues and two acceptor 
coumarin fluorophores makes analysis of these experiments challenging. 
 
Owing to the uncertainty with the C-AXP:AMPK Kd values and stoichiometries determined by 
the FRET method only single repeats of AXP dissociation titrations were performed  
(Figure 23 and Figure 24). This binding data was not analysed further and therefore no Kd 
values for AXP:AMPK binding were determined by this method. Nevertheless, the form of 
these curves is consistent with the results obtained in the direct coumarin titrations  
(Section 3.4.3.1).  
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B  
 
 
Figure 21: A) Emission spectra C-AXP complexed to phosphorylated AMPK. 
5.6M C-ADP (red) and C-ATP (blue) in complex with 2.1M AMPK.  
B) Emission spectra C-AXP complexed to unphosphorylated AMPK; 5M C-ATP (red) and  
C-ADP (blue) complex with 2.1M AMPK. All spectra were recorded at 20oC in 25mM Tris, 
1mM TCEP, 100mM NaCl (pH 8). Excitation at 290nm. Nb. the C-AXP sites are not 
completely saturated under these conditions.   
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Figure 22: Emission and excitation spectra or AMPK and C-ATP.  
Purple) Excitation spectrum of 6.2M phosphorylated AMPK, em 335nm. Blue) Emission 
spectrum of 6.2M phosphorylated AMPK, ex 290nm. Green) Excitation spectrum of  
5M C-ATP, em 480nm. Red) Emission spectrum of 5M C-ATP, ex 430nm.  
Arrow indicates the overlap between AMPK intrinsic fluorescence and C-ATP excitation 
which is required for FRET. All spectra measured at 20oC, medium sensitivity, in 25mM Tris, 
1mM TCEP, 100mM NaCl (pH 8). 
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Figure 23 : Measurement of equilibrium dissociation constants for the binding of AXPs to 
unphosphorylated AMPK. 
Displacement of C-ATP from the AMPK:(C-ATP)2 complex by ATP (square), ADP (circle)  
and AMP (diamond) monitored using the change in fluorescence at 470nm  
(Excitation at 290nm). Inset: Fluorescence titration of C-ATP with 2M AMPK.  
All measurements were performed at 20oC in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8). 
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Figure 24: Measurement of equilibrium dissociation constants for the binding of AXPs to 
phosphorylated AMPK. 
Displacement of C-ATP from the AMPK:(C-ATP)2 complex by ATP (square), ADP (circle)  
and AMP (diamond) monitored using the change in fluorescence at 470nm  
(Excitation at 290nm). Inset: Fluorescence titration of C-ATP with 2M AMPK.  
All measurements were performed at 20oC in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8). 
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Table 10: Equilibrium dissociation constants for the binding of C-AXPs to AMPK. 
Dissociation constants were determined at 20oC by fluorescence titrations of C-ATP with 
AMPK in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8). The Kd values are reported as the 
mean (± SD) determined from at least three independent measurements. 
  
Protein KdI (M) C-ADP KdI (M) C-ATP 
Phosphorylated AMPK 0.75 (0.24) 0.78 (0.21) 
Unphosphorylated AMPK 0.53 (0.16) 0.14 (0.05) 
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 3.4.3.5  AMPK mutants 
It was observed that NADH competed with only the allosteric regulation by AMP and not 
protection against dephosphorylation conferred by both AMP and ADP suggesting that the 
two exchangeable AXP binding sites mediate different regulatory effects (discussed further 
in Chapter 4). In order to further explore this, a series of point mutants were designed, 
cloned and purified with the intention of specifically eliminating nucleotide binding at each 
of the exchangeable binding sites (Site-1 or Site-3). 
 
In 2007 Xiao et al highlighted that in mammalian AMPK each AXP binding pocket has an 
aspartate residue which forms a bi-dentate interaction with the 2’ and 3’ hydroxyl groups of 
the ribose (D244 in Site-3, D89 in Site-1 and D316 in Site-4). In the fourth potential binding 
site (Site-2) this aspartate is replaced with an arginine. They suggested that this might be the 
reason AXP does not bind to Site-2 in mammalian AMPK.  
DA point mutants were generated in Site-1, Site-4 and Site-3 with the aim of eliminating 
AXP binding (177).  Interestingly, the -kinase regulation of these three mutants by AXP was 
impaired, with the D244A (Site-3) mutant having the most severe effect on allosteric 
activation and protection against dephosphorylation by AMP (Faith Mayer – PhD Thesis). 
However none of the DA mutants ablated C-ADP binding. For the three DA mutants a 
two-site binding model improved 2 values between 2 and 10-fold compared to a one-site 
model, suggesting a stoichiometry of 2:1 was maintained (C-ADP:AMPK). The equilibrium 
dissociation constants are given in Table 11.  
The binding of NADH/AXP to full-length, phosphorylated D89A (Site-1) AMPK was also not 
disrupted (Table 12). It is perhaps superficially surprising that the nucleotide regulation of 
AMPK activity was perturbed in these mutants whereas the binding of AXP remained  
largely unaffected. Presumably, it is not the binding itself which is disrupted in these 
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mutants but instead the transduction of the AMP/ADP binding event to the -kinase, or the 
stability/conformation of the complex. I can conclude that mutation of these conserved 
asparate residues does not abolish binding at each site, and therefore these mutants should 
not be employed in this role as has been previously reported (177). 
 
A further mutagenesis strategy to delineate the separate effects of the two AXP binding 
sites was to introduce residues with large side chains, such as tryptophan, at positions which 
might be expected to block the nucleotide binding pocket, or to introduce negatively 
charged residues in positions which might make unfavourable interactions with the 
nucleotide phosphate groups.  In conjunction with Matthew Sanders (NIMR) the binding of 
NADH and AMP (through competition with NADH) to full-length AMPK K169E, K242E, T86D, 
T86W, and T88D was characterised (Table 13). None of the -subunit mutants abolished 
AMP binding. Two-site binding models are consistent with the data and improve 2 values 
by at least 2-fold, in some cases modest increases in equilibrium dissociation constants were 
determined compared to wild-type but all the mutants maintained regulation by AMP/ADP 
(Faith Mayer – PhD Thesis).  
Modelling of these mutations onto the -subunit crystal structure demonstrates that the 
relevant residues can adopt alternate rotamers which do not disrupt the AXP binding 
pockets in the anticipated manner, perhaps explaining the regulatory/binding phenotypes.  
 
Recently, Chen et al (144) described a number of point mutants which reduced allosteric 
activation of AMPK. Only mutants directed at Site-3 and Site-4 produced this phenotype. 
However, no measurement of the binding affinity or stoichiometry of nucleotide 
interactions was described. It is feasible that mutation of Site-3 and Site-4 resulted in a 
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change of nucleotide binding affinity at Site-1, or that the mutations affected the stability or 
conformation of the complex.  
Further mutational analysis was conducted on the CBS domains of SNF1 and is described in 
Appendix 1.2.2.1. Similarly, these mutants showed no distinctive effects on nucleotide 
binding. 
 
The -subunit is described as a ‘flattened disc’, of ~60Å across and 30Å deep. CBS 1 + 2 and 
CBS 3 + 4 form two Bateman domains; the AXP binding sites are located between pairs of 
adjacent helix-loop strands from the tandem CBS motifs. The four CBS motifs contribute 
varying numbers of basic residues for interaction with the nucleotide phosphates  
(e.g. CBS2 contributes H151, R152 and K170 whilst CBS3 contributes none);  
there is therefore a high degree of connectivity between the sites. Such interdependence 
means that introducing a mutation directed at a single site has implications for the structure 
of the other sites which make up the -subunit. It therefore proved problematic to design 
further mutants with which to ‘knock out’ binding at a single site without affecting the 
properties of a second.   
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 C-ADP 
Protein KdI (M) KdII (M) 
Wild-type 1.1 (0.02) 2 (0.5) 
D89A (Site-1) 0.7 (0.1) 1.5 (0.3) 
D244A (Site-3) 3.5 (1.2) 4 (1.0) 
D316A (Site-4) 1.0 (0.1) 1.8 (0.4) 
 
 
Table 11: Equilibrium dissociation constants for the binding of C-ADP to AMPK DA mutants. 
Wild-type and mutant proteins (as indicated in the table) were IMAC purified and 
unphosphorylated. Dissociation constants were determined at 20oC by fluorescence 
titrations of C-ADP with AMPK in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8). The Kd values 
are reported as the mean (± SD) determined from at least two independent measurements. 
 
 
 
 
 
 
 
 
Table 12: Equilibrium dissociation constants for the binding of AXP to AMPK D89A. 
Wild-type and D89A mutant proteins (as indicated in the table) were fully-purified and 
phosphorylated. Dissociation constants were determined at 20oC by fluorescence 
displacement titrations of NADH with AXP in 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8). 
The Kd values are reported as the mean (± SD) determined from at least two independent 
measurements. 
  
Ligand KdI (M) KdI (M) 
 Wild type D89A 
 vs NADH 
AMP 1.6 (0.5) 0.95 (0.25) 
ADP 1.3 (0.5) 1.25 (0.25) 
ATP 0.9 (0.3) 1.40 (0.40) 
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Table 13: Equilibrium dissociation constants for the binding of NADH and AMP to  
AMPK  mutants. 
Wild-type and mutant proteins (as indicated in the table) were phosphorylated. NADH: 
Dissociation constants were determined by fluorescence titrations of NADH with AMPK. 
AMP: Dissociation constants were determined by displacement of NADH by AMP. 
Experiments were performed in 25mM Tris, 1mM TCEP, (pH 8) at 7oC. The Kd values are 
reported as the mean (± SD) determined from at least two independent measurements. 
  
 NADH AMP (vs NADH) 
Protein KdI (M) KdI (M) 
Wild-type 11.0 (4.5) 2.5 (0.5) 
K169E (Site-3) 9.5 (2.7) 1.6 (0.1) 
K242E (Site-1) 5.7 (0.1) 2.8 (1.2) 
T86D (Site-1) 7.5 (1.5) 1.2 (0.2) 
T86W (Site-1) 9.6 (0.8) 13.2 (1.4) 
T88D (Site-1) 7.1 (0.4) 1.5 (0.3) 
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 3.4.4  Biophysical sample characterisation  
A number of techniques were employed to try and identify characteristic differences 
between phosphorylated and unphosphorylated protein samples, and also to establish that 
the samples were of a high quality. 
 
 3.4.4.1  Circular Dichroism (CD) 
CD is a method used to study the conformation of proteins in solution.  CD is the differential 
absorption of left- and right- handed circularly polarised light. In order to be visible in a CD 
spectrum a chromophore must be inherently chiral or located in an asymmetric 
environment. In the near-UV spectral region (310-255nm) relevant chromophores are the 
side chains of tryptophan, tyrosine, phenylalanine and the disulphide bond. In the far-UV 
region (below 250nm) it is the peptide bond which dominates the signal producing bands at 
~220nm and ~190nm. Tyrosine, tryptophan, and phenylalanine can also make significant 
contributions in this region. 
 
Although it provides only low resolution structural information CD does have major 
advantages over other techniques; it can be sensitive to changes in protein conformation,  
a wide range of solvent conditions can be used with relatively little sample required and the 
spectra are reasonably quick to acquire. 
 
Analysis of far-UV spectra provides information about the secondary structure content of a 
protein sample and can be used to monitor protein unfolding. Near-UV CD offers 
information about the tertiary structure of a protein. Both can be used to detect 
conformational changes in proteins in response to a pH, temperature, etc.  
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Far-UV CD spectra of both phosphorylated and unphosphorylated AMPK were collected 
(Figure 25). All the spectra collected are dominated by the -helical signals at 222, 208 and 
190-195nm, as is often the case for / containing proteins.  Estimation of their secondary 
structure content highlighted no significant differences between the two AMPK species 
(Table 14). At 70oC no dramatic loss of phosphorylated AMPK secondary structure was 
observed, although some -helical content was lost and -sheet gained (Table 14).  
Addition of 20% isopropanol to the buffers, as described in Section 3.4.2 for staurosporine 
titrations (Table 4, Table 5 and Table 6), results in an increase of helical content by around 
10% and reduction of -sheet, turn and unordered content for both phosphorylated and 
unphosphorylated AMPK (Table 14). The secondary structure of both species can be stable 
in buffer conditions and at temperatures well-above those used in the fluorescence assays 
performed as part of this work. 
 
Near-UV spectra of phosphorylated and unphosphorylated AMPK were collected (Figure 26).  
The spectra of both AMPK species are dominated by the tyrosine signal (band maxima  
at 275-282nm), although contributions from phenylalanine are also observed in the region 
255-270nm. No significant signal from tryptophan residues is observed (fine structure above 
280nm); the observed bands are the sum of all contributions, both positive and negative,  
for this reason no tryptophan signal is observed despite AMPK containing many such residues. 
The most striking feature of the near-UV spectra is the differences between the 
phosphorylated and unphosphorylated samples. This difference reflects local changes in the 
tertiary structure surrounding one or more tyrosine residues, because AMPK  
(human 111) contains 43 tyrosine residues it is difficult to interpret the spatial focus of 
this change in structure. 
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Thermal unfolding of phosphorylated and unphosphorylated AMPK was monitored  
(Figure 27). Tris.HCl, present in the standard buffer, has a high thermal coefficient,  
therefore protein samples were diluted in water to minimise change in pH as the 
temperature was increased. The unphosphorylated sample unfolds with a Tm = 75
oC. 
Phosphorylated AMPK failed to unfold, instead a drop in signal at around 60oC was 
observed, this is indicative of fibril formation/increased -content. It is unclear what the 
relevance, if any, this has in a cellular context. 
 
Differences in the secondary structure and stability of phosphorylated and 
unphosphorylated AMPK samples are to be expected. Obviously the two species represent 
different functional states (active/inactive) and bind nucleotide/staurosporine with different 
affinities. That the differences appear quite pronounced, particularly in the case of the 
thermal unfolding data, may suggest significant changes in the overall architecture of the 
two AMPK states.   
In the 1(GBD)1 phosphorylated structure (shown in Figure 5) the -kinase adopts a 
conformation in which the T-loop forms an interface with the -subunit thus protecting 
T172 from dephosphorylation by phosphatases.  It is unlikely that this state is adopted in 
the unphosphorylated protein, as the T-loop only adopts a conformation compatible with 
this interface when it is phosphorylated. It is suggested that the preceding linker region is 
increasingly mobile in the inactive state, causing the -kinase to be flexibly tethered to the 
rest of the heterotrimer. Therefore significant differences between the overall architecture, 
and biophysical properties of the phosphorylated and unphosphorylated protein samples 
are at least consistent with the available crystal structures. 
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Figure 25:  Far-UV CD spectra (AMPK). 
Green) Phosphorylated AMPK (aq); Red) Unphosphorylated AMPK (aq); pale Green) 
Phosphorylated AMPK (20% iso); Pink) Unphosphorylated AMPK (20% iso);  
Purple) Truncated AMPK (aq). Where (aq) refers to 25mM Tris, 1mM TCEP, 100mM NaCl  
(pH 8), and (20% iso) refers to (aq) with 20% isopropanol. All spectra were collected at 20oC. 
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Protein  
% 
α-helix β-sheet Turns Unordered 
Unphosphorylated AMPK (aq) 23.4 21.4 19.7 35.5 
Unphosphorylated AMPK (20% iso) 34.4 17.5 18.8 29.4 
Phosphorylated AMPK (aq) 23.7 20.9 19.5 35.9 
Phosphorylated AMPK (20% iso) 32.9 17.2 19.4 30.5 
Phosphorylated AMPK (aq) 70°C 20.1 24.8 21.0 34.1 
Truncated AMPK (aq) 22.6 21.0 20.0 36.5 
 
Table 14: Secondary structure content predictions. 
Where (aq) refers to 25mM Tris, 1mM TCEP, 100mM NaCl (pH 8), and (20% iso) refers to 
(aq) with 20% isopropanol, all spectra were collected at 20oC unless otherwise specified. 
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Figure 26:  Near-UV CD spectra (AMPK). 
Green) Phosphorylated AMPK; Red) Unphosphorylated AMPK. Spectra recorded in 25mM 
Tris, 1mM TCEP, 100mM NaCl (pH 8) at 20oC.  
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Figure 27: Thermal denaturation (AMPK).  
Phosphorylated (green) and unphosphorylated (red) AMPK. Protein samples were diluted in 
water. 
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 3.4.4.2  Multi-Angle Laser Light Scattering (MALLS) 
A protein sample in solution will scatter light dependent on the number and molecular 
weight of the macromolecular particles in contains. SEC-MALLS uses chromatography to 
initially separate particles based on their size, then measures the light scattering at multiple 
angles together with the protein concentration of the eluent using a differential 
refractometer. These data when combined are used to independently determine absolute 
molecular weight of the protein, assess the degree of aggregation and heterogeneity of a 
sample, and determine the oligomer state. For large proteins (>200kDa) information about 
the shape of the molecule can also be inferred. 
 
SEC-MALLS was employed to determine the absolute molar mass of full-length 
phosphorylated and unphosphorylated AMPK. Both samples elute as single peaks from the 
size exclusion column with no indication of higher molecular weight or aggregated species 
(Figure 28). Absolute molecular weight values of between 136-141kDa were determined, 
comparing well to the calculated molecular weight of 132kDa. These data show that protein 
samples used for in vitro binding experiments described in this Thesis are homogenous and 
of a high-quality. However, examination of the elution profile of phosphorylated AMPK 
compared to unphosphorylated reveals a shift to an earlier retention time suggesting that 
upon phosphorylation AMPK becomes less compact or interacts differently with the column. 
Although these differences might be expected as the two protein species represent 
different functional states, in order to understand the differences at a molecular level,  
it may be of interest in the future to conduct further sedimentation velocity experiments. 
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Figure 28: SEC-MALLS spectra (AMPK). 
Continuous lines represent; molar mass distribution of phosphorylated (green) and 
unphosphorylated (red) full-length AMPK samples, 2) Squares represent the UV absorption 
at 280nm of the samples. Spectra recorded in, 50mM Tris (pH 8), 100mM NaCl, 3mM 
Sodium Azide, 1mM TCEP at ambient temperature. 
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 3.5  Conclusion 
Using a combination of direct C-AXP excitation, FRET and NADH fluorescence experiments 
this Chapter demonstrated that regulatory nucleotides bind exchangeably at two sites to 
full-length phosphorylated and unphosphorylated AMPK. One site bound free AXP with 
significantly higher affinity (~2M) than the other (~65M). Only small differences in 
binding between the active and inactive AMPK species were observed. Mg.ATP similarly 
binds competitively but with a weaker affinity than regulatory nucleotides (55M at the 
tighter site, 230M at the weaker site).  
It is suggested that the weaker binding of Mg.ATP is critical in the competition for binding by 
regulatory nucleotides, given cellular conditions, in which Mg.ATP concentrations are 
significantly higher than those of AMP/ADP. This idea is explored in greater detail in the 
following Chapter.  
In an attempt to specifically ablate AXP binding at the two exchangeable sites a number of 
point mutants in the -subunit were generated but failed to knock-out binding of AXP to 
AMPK in the manner intended.  
 The nanomolar affinity interaction between the -kinase ATP binding pocket and 
staurosporine, a kinase inhibitor, was also characterised.  
The CD and MALLS spectra of phosphorylated and unphosphorylated AMPK were compared 
confirming that the samples were homogenous and well-folded. These studies did highlight 
some differences in the biophysical characteristics of the two species, particularly in terms 
of their thermostability and overall architecture. It is interesting that structural differences 
between the active and inactive AMPK samples are detectable in this way.  
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 Chapter 4: AMPK Kinetics and Modelling 
 
 4.1 Abstract 
A spectrophotometric coupled assay was used to monitor AMPK kinetics and its regulation 
by nucleotides. NADH binds at Site-1, the tighter of the two AXP sites, and competes with 
allosteric activation of AMPK by AMP but not with the protective effect of AMP/ADP against 
dephosphorylation. Therefore AMP binding at Site-1 mediates allostery, and AMP/ADP 
binding at Site-3 mediates protection against dephosphorylation. 
In order to expand upon this conclusion, the AXP binding constants determined in Chapter 3 
were used to model binding site occupancies over the concentration ranges used in the  
in vitro assays. The modelling demonstrates that Site-1 and Site-3 become occupied by AMP 
in a manner consistent with the dose response of their proposed regulatory properties 
(allostery and protection against dephosphorylation, respectively).  
Estimations of in vivo intracellular AXP concentrations were used to model Site-1/Site-3 AXP 
occupation in a cellular context, in which Mg.ATP concentrations are significantly higher 
than those of AMP/ADP.  The model utilises the Kd values determined in the previous 
chapter (AXP binding to AMPK) to demonstrate that; 
1) Allosteric activation by AMP is, perhaps, unlikely to be an important regulatory factor  
in vivo under normal conditions. 
2) ADP can effectively compete with Mg.ATP for binding at the regulatory binding site  
(Site-3) despite the high concentrations of antagonistic Mg.ATP.  
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 4.2 Introduction 
 4.2.1 Kinase cascades 
The reversible phosphorylation of proteins features prominently in cellular  
signal transduction. Serine, threonine, tyrosine and histidine residues are phosphorylated by 
kinases and dephosphorylated by phosphatases. The human genome encodes roughly 500 
protein kinases and about a third as many protein phosphatases. Because aberrant 
phosphorylation is the cause of many human diseases these enzymes receive significant 
attention as potential drug targets (262). 
 
Phosphorylation of a target can bring about a range of effects; targeting for degradation or 
relocalisation, activation or inactivation, and enabling interactions with binding partners (262).  
For example, in the MAPK kinase pathway, multiple kinases are phosphorylated in sequence  
and this has the result of amplifying a small external signal to produce a large downstream 
response (263). Cascade systems also allow for feedback networks which can modify the 
activity of upstream kinases.  
 
AMPK is phosphorylated on T172 by upstream kinases and exerts its effects through 
phosphorylation of many downstream targets. It is therefore at the heart of an enzymatic 
cascade which senses intracellular signals (Ca2+, AMP/ADP, glycogen) and extracellular 
signals (adiponectin, leptin etc.) and transduces them through the cell resulting in 
transcriptional changes and altered cellular metabolism.  
Although it is convenient to think of discrete cascades, in reality signal transduction 
comprises wide networks of interacting proteins, which when stimulated, produce broad, 
far reaching effects.  
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 4.2.2 AMPK Kinetics 
AMPK is a group transfer enzyme, catalysing the covalent attachment of a phosphate  
(from ATP) to an acceptor serine or threonine present on a substrate.  
Group transfer reactions can be either compulsory-order (one substrate must bind first)  
or random-order. Kinases require an essential divalent metal ion, usually Mg2+ to facilitate 
the phosphoryl transfer reaction and assist in ATP binding (264). Although the kinetics of 
group transfer enzymes generally obey the simple Michaelis-Menten equation the 
expressions for the substrate Km values and the catalytic rate are invariably complex, 
mechanism-dependent, combinations of rate constants (see Section 4.4.1.5). 
AMPK is itself a substrate for phosphatases and upstream kinases (see Section 1.5.1).  
LKB1 has been shown to have a Km for AMPK of 5.4 ± 1.4nM, and PP2C a Km of 160 ± 20nM  
(265). Given a cellular AMPK concentration of around 150nM, these data suggest that LKB1 
operates under zero-order conditions ([AMPK] >> Km of LKB1 for AMPK), a fact that may be 
integral in explaining AMPK activation (see Section 4.4.2.5) (265).  
 
 4.2.3 SAMS peptide 
Experimentally, AMPK activity is often measured by monitoring the phosphorylation of a 
small peptide known as SAMS (HMRSAMSGLHLVKRR). This sequence is based on the target 
motif of the AMPK substrate, ACC (266). In general, the amino acids four residues or less from 
the phosphorylation site are the most significant for directing phosphoryl transfer (264).  
A consensus motif was defined requiring a hydrophobic side chain at P-5 and P+4,  
and basic residues at P-4 or P-3, additional basic residues at P-6 or P+3 increase substrate 
specificity (126, 267). The presence of a amphipathic helix extending from P-5 to P-16 may 
also contribute to substrate affinity (268). These basic residues are positioned to interact 
with an acidic patch present on the  catalytic domain, and the P-5 residue anchors itself in 
a hydrophobic pocket on the surface of the kinase structure (126).   
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Figure 29: A) NADH coupled assay. 
AMPK kinetics were monitored using a continuous spectrophotometric assay. The decrease 
in absorbance at 340nm is monitored as NADH is converted into NAD+, this is related with a 
1:1 stoichiometry to phosphorylation of a small substrate peptide by AMPK.  
PK; Pyruvate kinase, PEP; Phosphoenol Pyruvate, LDH; Lactate Dehydrogenase. 
B) [P32]-ATP peptide assay. AMPK phosphorylation activity is monitored through 
incorporation of radioactive [32P] into the SAMS peptide substrate (266). 
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 4.2.4 Coupled Assays 
It is not possible to follow AMPK phosphorylation reactions directly using a 
spectrophotometer because the phospho-peptide product has no suitable optical signal and 
ADP has the same extinction coefficient as ATP. There are numerous applications in which a 
reaction may be monitored by linking it to a second process that provides the appropriate 
spectroscopic signal. The essential requirement is, of course, that the linked process is very 
much faster than the one being studied, so that it does not affect the rate of the process 
being investigated. The release of ADP when SAMS is phosphorylated can be monitored by 
linking it to the PK and LDH system in which the conversion of NADH to NAD+ provides the 
optical signal (either fluorescence or absorbance). All kinase activity measurements with the 
SAMS peptide were therefore made using the continuous spectrophotometric coupled 
enzyme assay based on one initially described by Cook et al (Figure 29a) (269). The classic 
radioactivity assay that is also often used to monitor AMPK kinetics is shown in Figure 29b. 
 
 4.2.5 The Cornish-Bowden method 
In order to simulate the regulation of AMPK by AXPs one needs to be able to calculate 
binding site occupancy under different starting conditions.  The complexity of the AMPK 
system means that it is not possible to derive an analytical solution for calculating the 
concentrations of the different species present at equilibrium.  There are, however,  
several simple iterative methods for calculating equilibrium concentrations in complex 
systems and one of these, the Cornish-Bowden method, is described here and is the basis 
for the work described in Section 4.4.2 (250). The method will be illustrated for the 
following reaction scheme: 
         Ka,L                                                 Ka,N   
P + L ↔ PL                                 P + N ↔ PN  
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The association constants (units: M-1) are defined as: 
Ka,L = 
 PL 
 P  L 
                               Ka,N = 
 PN 
 P  N 
 
 
The total concentrations of the protein and the ligands (P0, L0, and N0) are given by: 
P0 =  P +  PL +  PN  
L0 =  L +  PL  
N0 =  N +  PN  
The concentrations of the species present in complex systems can always be expressed in terms 
of the concentrations of the individual components and the association constants characterising 
the system. In this case, the concentrations of the two complexes (PL and PN) can be expressed 
in terms of the concentrations of the individual components (P, L, and N) as follows: 
 
P0 =  P + Ka,L P  L + Ka,N P  N             Equation 12 
L0 =  L + Ka,L P  L                 Equation 13 
N0 =  N + Ka,N P  N                Equation 14 
 
Rearranging these equations gives: 
 
 P =
P0
1+Ka,L L +Ka,N N 
                Equation 15 
 L =  
L0
1+Ka,L P 
                  Equation 16 
 N =  
N0
1+Ka,N P 
                 Equation 17 
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The procedure for obtaining the equilibrium concentrations is then as follow. Each free 
concentration is initially set to the corresponding total concentration (i.e., [P] = P0 etc.) and 
an improved estimate of [P] (called [P1]) is obtained from Equation 15 as: 
 P1 =
P0
1 + Ka,LL0 + Ka,NN0
 
 
This improved estimate of [P] is then used along with the remaining original estimates 
(L0 and N0) to calculate improved estimates of [L] and [N] (called [L1] and [N1]) as follows: 
 L1 =
L0
1 + Ka,L P1 
 
  
 N1 =
N0
1 + Ka,N P1 
 
 
This procedure is then repeated to get a new estimate of [P] (called [P2]) calculated as: 
 P2 =  
P0
1 + Ka,L L1 + Ka,N N1 
 
and further estimates of [L] and [N] are obtained in a similar way.  
 L2 =
L0
1 + Ka,L P2 
 
  N2 =
N0
1+Ka,N P2 
 
 
The iterations are continued until the new estimates no longer change. Provided that the 
procedure converges to a solution that satisfies Equations 12 to 14 simultaneously,  
the solution must describe the equilibrium state of the system, because a given set of 
equilibrium constants defines a unique state. Once [P], [L], and [N] are known the 
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concentrations of the complexes may be calculated from the expressions for the association 
constants. Note: The order in which the new estimates are calculated is unimportant.  
The following table shows how quickly the procedure converges. The calculation was 
performed with the following association constants and total concentrations. 
Ka,L = 1 x 10
5 M-1  Ka,N = 2 x 10
5 M-1  
P0 = 10 M L0 = 50 M N0 = 20 M 
 
Iteration [P] (M) [L] (M) [N] (M) 
Start 10 50 20 
1 1 45.455 16.667 
2 1.1263 44.939 16.323 
3 1.1417 44.876 16.282 
4 1.1436 44.869 16.277 
5 1.1439 44.868 16.276 
6 1.1439 44.868 16.276 
 
 
 
 4.2.6 Measurement of intracellular nucleotide concentrations 
In order to simulate the occupancy of AMPK binding sites by AXP it is necessary to have 
estimates of the intracellular nucleotide concentrations. Many of the techniques used to 
determine intracellular AXP concentrations have low temporal resolution; the primary 
methods being;  
1) High Performance Liquid Chromatography (HPLC) – nucleotides are extracted, often via 
perchloric acid treatment, and their relative concentrations determined through HPLC 
separation and comparison to known standards (270).  
2) NMR – 31P-NMR can be used to determine the concentration of ATP, phosphocreatine 
(PCr) and phosphate (271).  
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3) Biosensors - For example, protein or RNA based ADP/ATP intracellular biosensors  
(272, 273). 
 
Free AMP/ADP concentrations are often estimated from measurements of the PCr, creatine 
(Cr), ATP and AXP (AMP0 + ADP0 + AMP0) concentrations, based on the near-equilibrium 
nature of the adenylate kinase (discussed in more detail in Section 4.2.7) and creatine kinase 
reactions (274). It is important to consider the short-term impact of PCr on ATP 
concentrations; for example in the skeletal muscle PCr acts as an energy (ATP) reserve 
during periods of intense exercise. 
 
Depending on the species, cell-type, extraction protocol, and measurement technique 
concentrations ranging from 2-20mM ATP (270, 275), 0.009-3mM ADP(271, 275) and  
1-350M AMP (276, 277) have been reported. With such variation present in the literature, 
averages are often quoted as 3-8mM ATP, 50-200M ADP and 1-5M AMP (1). 
 
 4.2.7 Adenylate Kinase 
Adenylate kinase catalyses the conversion of two molecules of ADP into one of ATP and one 
of AMP. It operates at near-equilibrium, responding rapidly to changes in cellular nucleotide 
concentrations. The AMP:ATP ratio in cells varies with the square of the ADP:ATP ratio 
making AMP a sensitive indicator of the energy status of the cell. For many years AMP was 
therefore assumed to be the major regulator of AMPK activity. 
The concentrations of AMP and ADP can be calculated as follows, given total AXP and ATP 
concentrations: 
              k 
2ADP ↔ ATP + AMP 
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Where the equilibrium constant is given by Equation 18: 
K = 
 ATP  AMP 
 ADP 2
                Equation 18 
 
The total concentration of adenine nucleotides, N0 is given by: 
N0 =  ATP +  ADP +  AMP  
 
Substituting in Equation 18 gives 
K = 
 ATP (N0 −  ATP −  ADP )
ADP2
 
 
K ADP 2 =  ATP (N0 −  ATP −  ADP ) =  ATP N0 −  ATP 
2 −  ATP  ADP  
 
K ADP 2 +  ATP  ADP +  ATP 2 −  ATP N0 = 0 
 
For any given ATP concentration and total adenine nucleotide concentration the 
concentration of ADP is given as the solution of the quadratic equation: 
 
 ADP =  
−b +  b2 − 4ac
2a
 
Where:  a= K; b = [ATP]; c = [ATP]2-[ATP]N0 
 
The concentration of AMP is then given by: 
 AMP = N0 −  ATP −  ADP  
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 4.3 Methods 
 4.3.1 Kinetics 
 4.3.1.1 General 
Assays contained the following components in a total volume of 0.5ml: 50mM Hepes  
(pH 7.5), 10mM MgCl2, 0.2mM TCEP, 100mM NaCl, 12 units of pig heart LDH, 8 units of 
rabbit muscle PK, 1mM PEP, 150μM NADH, plus ATP and SAMS peptide at  
appropriate concentrations. Reactions were initiated by the addition of phosphorylated 
AMPK to a final concentration of ~3nM (unless otherwise specified), and initial rates  
(at 25oC) were obtained by recording absorbance changes at 340nm. The assays were 
performed in a temperature controlled Jasco V-550 UV/Vis spectrophotometer, using quartz 
micro-cuvettes with 10mm pathlength (Hellma). 
 
Doubling the concentrations of the coupling enzymes had no effect on the recorded 
velocities; therefore these enzymes are operating fast enough for the measured rates to be 
a true reflection of AMPK kinetics. The measured rates were also shown to be directly 
proportional to the concentration of phosphorylated AMPK.  
 
 4.3.1.2 Km
 
determination  
The Km
 
for the SAMS peptide was determined by measuring initial rates at different SAMS 
concentrations with a fixed ATP concentration of 200μM. The Km
 
for ATP was determined by 
measuring initial rates at different ATP concentrations with a fixed SAMS peptide 
concentration of 90μM. Km and Vmax
 
values were determined by non-linear least-squares 
regression to the Michaelis-Menten equation: 
V0 =
Vmax S 
Km +  S 
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 4.3.1.3 ATPase activity 
The ATPase activity was monitored as described in Section 4.3.1.1, excluding SAMS peptide 
from the reaction mix, and using a higher AMPK concentration (1M). 
 
 4.3.1.4 Staurosporine Inhibition 
Staurosporine inhibition was monitored using the assay described in Section 4.3.1.1.  
All reaction components, excluding SAMS peptide, were preincubated with 10nM AMPK and 
8nM staurosporine for 3 minutes. The reaction was initiated through addition of the 
substrate.  
 
 4.3.1.5 Allosteric activation  
Allosteric activation of AMPK by AMP was studied by measuring the initial rate at increasing 
AMP concentrations using the assay described in Section 4.3.1.1. Effects of NADH on the 
allosteric activation by AMP were investigated at two concentrations of AMP (18 and 88μM) 
by measuring the initial rate at different concentrations of NADH. The SAMS peptide and 
ATP concentrations were 90μM and 200μM respectively.  
 
 4.3.1.6 Dephosphorylation assays  
Phosphorylated AMPK was incubated with 0.5mM AMP or ADP (‘incubation mix’).  
An aliquot of AMPK was diluted to approximately 0.5M in kinase assay buffer at each 
timepoint (50mM Hepes (pH 7.5), 2mM MgCl2, 0.2mM TCEP, 100mM NaCl).  
5μl of this diluted solution was added to 500μl of standard assay mixture (with [SAMS 
peptide] = 100μM and [ATP] = 250μM). PP2Cα was then added to the remaining solution, 
which was incubated at 25oC, and further initial rate measurements were taken at defined 
time intervals. The concentration dependence of AMP/ADP protection were examined by 
including the relevant nucleotide at different concentrations in the starting incubation mix,  
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and monitoring the reduction in active (phosphorylated) AMPK at  a fixed time point 
compared to 0min.  
 
The coupled assay monitors ADP release as SAMS is phosphorylated. It was important to 
ensure that carryover of ADP from the incubation mix was kept to a minimum, and did not 
interfere with recording of the initial rate. This was achieved through dilution of the 
incubation mix by greater than 100-fold into kinase assay buffer, before addition of an 
aliquot to the assay mix. 
 
Small differences in the concentrations and activities of the phosphatase and kinase, and 
contamination of nucleotides by their breakdown products may affect the observed rates. 
Every effort was taken to keep concentrations constant, use the same batches of enzyme 
within similar time frames, and to use fresh AXP preparations. Temperature control was also 
very important to maintain consistency. 
 
 4.3.1.7 Materials 
LDH/PK, ATP, ADP, AMP, NADH and PEP were purchased from Sigma. The peptide was 
synthesised by Dr Graham Bloomberg at The University of Bristol and dissolved in water.  
Recombinant human PP2C was a kind gift from Prof David Carling (CSC Hammersmith).   
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 4.4 Results and Discussion 
 4.4.1 AMPK Kinetics 
AMPK kinetics are generally assayed by monitoring the phosphorylation of the SAMS 
peptide in the presence of -32P ATP (Figure 29b) (1, 266). The complementary use of the 
NADH coupled assay (Figure 29a) to monitor AMPK activity is beneficial because it is much 
quicker than the established method, allowing mutant or truncated protein preparations to 
be rapidly tested for activity without the use of radioactivity.  
 
 4.4.1.1 ATPase 
It is not uncommon for kinases to have an intrinsic ATPase activity. Phosphate and 
phosphorylated peptide are unique products of the ATPase and kinase reactions 
respectively. ADP on the other hand is a common product of both reactions.  
Therefore although continuous spectrophotometric assays based on the detection of ADP 
production have been successfully employed in the study of kinases they are not generally 
used if the kinase has significant ATPase activity.  
It was found that AMPK does indeed have an intrinsic ATPase activity (Figure 30),  
the reaction has a Km of 24.2M, similar to that of the phosphorylation reaction.  
However the Vmax is very low, 4.87nM.S
-1. This corresponds to a catalytic rate of 0.005S-1, 
which is very much lower (2000-fold) than the catalytic rate of the phosphorylation reaction 
(calculated in Section 4.4.1.2).   
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Figure 30: AMPK’s intrinsic ATPase activity. 
The production of ADP was monitored as a function of [Mg.ATP]. Results are an average of 
at least 3 repeats. The solid line is the computed best fit.  
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 4.4.1.2 Km determination 
Since the continuous spectrophotometric assay has not previously been used with AMPK it 
was first necessary to demonstrate its validity and robustness. The Km
 
values determined for 
the SAMS peptide (53.6 ± 1.9μM - Figure 31) and Mg.ATP (24.4 ± 0.93μM - Figure 31)  
were in good agreement with previously published values (53, 54). The apparent Vmax
 
values 
calculated as 34.7 and 24nM.S-1 at these SAMS and Mg.ATP concentrations respectively are 
also in good agreement. The catalytic rate is therefore greater than 12S-1. 
 
 4.4.1.3 Allosteric activation by AMP 
The assay was then used to study allosteric activation by AMP. Figure 32 shows that 
concentrations of AMP greater than 20μM can produce approximately two-fold activation of 
the enzyme in the presence of 200μM ATP. Allosteric activation by AMP was demonstrated 
to be around 2.7 fold at concentrations between 50-120μM AMP. This compares with 
previously published results where AMPK (1) was activated 3.5-fold by 50μM AMP (34). 
 
AMP allosteric activation was inhibited by high concentrations of NADH (Figure 33), 
demonstrating the competitive nature of their binding. There was, however, no effect of 
NADH on AMP/ADP protection against dephosphorylation by phosphatases (1).  
Since NADH is thought to bind at Site-1 it is hypothesised that AMP binding at this site is 
responsible for allosteric activation (discussed further in Section 4.4.2.1). A structure of 
AMPK complexed with NADH would greatly support this assignment of function. 
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A 
B 
Figure 31: Determination of Km values (AMPK). 
Km with respect to (A) ATP (SAMS = 90M) and (B) SAMS peptide (Mg.ATP = 200M); 
Recombinant AMPK complex () was phosphorylated with CaMKK and its activity 
measured at a range of substrate concentrations. Activity of AMPK is plotted as a function of 
substrate concentration. The solid lines are the computed best fits.   
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Figure 32: Allosteric activation (AMPK). 
 AMPK activity was measured in the presence or absence of varying concentrations of AMP 
with constant level of NADH (150M), ATP (200M) and Mg2+ (10mM). Results are displayed 
as fold-increase compared to no AMP condition. 
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Figure 33: NADH competition with allosteric activation (AMPK). 
Allosteric activation of AMPK by 18M (yellow) and 88M (blue) AMP in the presence of 
increasing NADH concentrations. Results are displayed as fold-increase compared to no 
AMP condition, the mean ± SEM (n>3). 
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 4.4.1.4 Protection against dephosphorylation 
In vivo, the rate of T172 dephosphorylation by phosphatases is critical in determining the 
equilibrium between active and inactive AMPK. Therefore, the protective effect of 
AMP/ADP against dephosphorylation of T172 by PP2C was studied. Figure 34 shows time 
courses for dephosphorylation reactions carried out in the presence and absence of 500μM 
AMP and ADP confirming that both provide protection. Over the time course there appears 
to be a greater protective effect of ADP than AMP. This was not observed in the original 
report of ADP protection, however in that case only protection at a fixed time point (20min) 
was determined (1). As shown in Figure 34, at the 20 minute time point the difference 
between the AMP and ADP effects is not yet particularly apparent and this is probably why 
this effect was previously overlooked. Interestingly, greater protection by ADP was also 
described by Oakhill et al (2011) (177). Taken together this suggests that ADP may be a 
more potent activator than was initially thought.  
 
The concentration dependence of the protecting effect of AMP was studied by incubating 
phosphorylated AMPK with PP2C in the presence of different concentrations of AMP and 
determining the percentage of phosphorylated T172 remaining after 25 minutes (Figure 35). 
The concentration dependence of ADP protection was also monitored, because it appeared to 
protect more effectively than AMP, a 45minute time point was used in this case (Figure 36). 
Both AMP and ADP protection against T172 dephosphorylation appear to saturate at around 
0.2mM AXP, consistent with the values reported here and by Xiao et al (2011)(1). 
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Figure 34: Protection against dephosphorylation by AMP (AMPK). 
Phosphorylated AMPK was incubated in the presence of PP2C (green) and 500M AMP/ADP 
(Blue/Yellow). At a number of time points AMPK activity was measured.  Results are 
displayed as percentage of phosphorylated T172 remaining compared to 0min (100%).  
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Figure 35: Protection against dephosphorylation by AMP (AMPK). 
Phosphorylated AMPK was incubated in the presence or absence of PP2C, and in the 
presence of increasing AMP concentrations. After 25minutes AMPK activity was measured. 
Results are displayed as percentage of phosphorylated T172 remaining. All phosphatase 
assays were performed at 25oC. The concentration of AMP carried over to the activity assay 
from 220M AMP was 4.3M. This was kept constant in all other assays. The SAMS and ATP 
concentrations were 100 and 250M respectively.  
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Figure 36: Protection against dephosphorylation by ADP (AMPK). 
Phosphorylated AMPK was incubated in the presence or absence of PP2C, and in the presence 
of increasing AMP concentrations. After 45minutes AMPK activity was measured. Results are 
displayed as percentage of phosphorylated T172 remaining. All phosphatase assays were 
performed at 25oC. The SAMS and ATP concentrations were 100 and 250M respectively.   
0
30
60
90
0 200 400 600
A
ct
iv
e
 A
M
P
K
  (
%
) 
[ADP] (M) 
165 
 
 4.4.1.5 Mg.ATP affinity for the -kinase 
In Chapter 3, the binding constants for AXPs to the -subunit were determined,  
it was demonstrated that C-AXP’s do not bind measurably to the catalytic nucleotide binding 
pocket in the -subunit. Mg.ATP is the preferred ligand for this site and is assumed that it 
binds with higher affinity than free ATP. Following the observations in Section 3.4.2  
(Figure 16), in which Mg.ATP did not compete with staurosporine binding, it was assumed 
that Mg.ATP bound the -kinase domain significantly weaker than the very tight binding of 
the inhibitor.  
Further evidence of a weak interaction was obtained through competition of increasing 
Mg.ATP with staurosporine inhibition of AMPK activity (Figure 37a). Only an estimation of 
the Kd (>0.5mM) was determined. Using the methods described in Section 3.3.1 it is possible 
to calculate that the percentage inhibition of AMPK by staurosporine (compared to the 
absence of inhibitor), given 5mM Mg.ATP (physiological), would be 93%, 75% and 58% given 
Mg.ATP Kd values of 25M, 150M or 0.5mM. Given the experimentally determined value is 
around 60%, it is clear that the Mg.ATP:kinase interaction is weak.  
Given that cellular Mg.ATP is in the millimolar range, a low affinity (0.5mM for example) 
would mean that -kinase ATP-binding site would still be occupied in the majority of AMPK 
heterotrimers (Figure 37b). 
 
The question then is why is the apparent Kd for Mg.ATP significantly higher than the Km for 
Mg.ATP (~ 0.5mM and 24.4μM respectively).   
In the simplest case the Km is equal to or greater than the Kd: 
 
            k1        k2 
E + S ↔ ES → E + P 
            k−1 
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Where the expressions for Km and Kd are: 
 
Kd =
k−1
k1
                         Km =
k−1 + k2
k1
 
 
In this case if k2 is significantly smaller than k-1 then the Km is approximately equal to the Kd. 
However as the complexity of the reaction schemes increases so do the number of terms 
which define the Km, therefore the relationship between Km and Kd is more complicated.  
 
For example, in the case of a bi-substrate, compulsory order reaction: 
           k1                k2          k3          k4 
E + A ↔ EA + S ↔ EAS → EDP → E + D + P 
            k−1            k−2  
  
 
The expressions for Km and Kd are: 
 
Kd(EA) =
k−1
k1
                 Km(S) =
k4
k2
 
k−2 + k3
k3 + k4
                Km(A) =
k3k4
k1(k3 + k4)
 
 
Although the mechanism of AMPK catalysis is unknown (be it compulsory or random order), 
this demonstrates how a Kd value is not restrained to be equal to or greater than the Km in a 
complex catalytic reaction such as that of AMPK phosphorylation (257). 
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A  
 
B   
Figure 37: A) Mg.ATP competition with Staurosporine inhibition. 
Samples taken from a preincubated solution containing 10nM AMPK, 8nM staurosporine 
and a range of Mg.ATP concentration were assayed. Data is plotted as % inhibition 
compared to no staurosporine rates. In addition to the standard buffer conditions,  
20% isopropanol was used throughout.  
B) Simulation of the % occupancy of the -kinase ATP-binding site. 
Experimental data defined a Kd of greater than 0.5mM. Over this range, the occupancy of 
the ATP-binding site ranges from 70-90% as a function of the Mg.ATP Kd. Given a fixed ATP 
concentration of 5mM and free Mg2+ concentration of 0.5mM.  
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 4.4.2 Modelling of AMPK kinetics  
 4.4.2.1 The regulatory roles of Site-1 and Site-3 
Two regulatory sites on the -subunit bind nucleotides exchangeably. Binding of AMP at Site-1 is 
thought to be responsible for allosteric activation and binding of AMP/ADP at Site-3 is thought 
to be responsible for protection of T172 against dephosphorylation by phosphatases (1).   
NADH binds AMPK with a 1:1 stoichiometry (Section 3.4.3.3). Site-1 is thought to be the 
tighter, NADH, binding site because this site is fully occupied in electron density maps of 
crystals soaked with a 1:1 molar ratio of AXP (Personal Communication - Bing Xiao). 
Increasing concentrations of NADH compete with the allosteric activation of AMPK by AMP, 
suggesting that Site-1 mediates this regulatory effect.  
Site-3 is the second, weaker, nucleotide binding site. The observation that NADH does not 
compete with the protective effect of AMP/ADP against T172 dephosphorylation,  
suggests that it is Site-3 which mediates this regulatory effect.  
 
Interestingly, in the structure of active AMPK determined within the Gamblin laboratory,  
a loop (the hook) extends from the -subunit and forms a lid over Site-3 (Figure 5).  
It is suggested that the -hook binds in this way in the presence of AMP/ADP and acts to 
restrict the flexibility of the preceding -linker region and in doing so promotes the 
interaction of the -kinase with the regulatory subunit and thus stabilisation of the 
activation loop (Figure 38). This interaction in turn protects T172 from dephosphorylation. 
Mutation of the -hook (R375Q/T377A/D379A/E380A) results in a loss of AMP/ADP 
protection but not of allosteric activation (1). Modelling of Mg.ATP into this site in the active 
complex suggests that the -phosphate prevents binding of the -hook and thus the 
stabilisation. In this way AMPK is able to differentiate between AMP/ADP and Mg.ATP 
binding at Site-3.  
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Figure 38: The interface between the activation loop and the regulatory fragment. 
The interface is shown in more detail in a similar orientation as in Figure 5.  
Potential electrostatic interactions are indicated by dashed lines. Taken from (1). 
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 4.4.2.2 The program 
Using the Kd values determined in Section 3.4.3.1 the occupancy of Site-1 and Site-3 by 
regulatory nucleotides under the in vitro assay conditions, used to monitor allostery and 
protection against dephosphorylation was modelled.  
 
The program was written in Visual Basic Version 6.0 and based on the Cornish-Bowden 
method (previously discussed in Section 4.2.5). 
A number of parameters, for example nucleotide and cation concentrations, must be 
supplied by the user (Figure 39a). The program calculates the concentrations of all 
nucleotide species, based on published binding constants for the interactions between AXP 
and cations/protons etc. and the Kd values of the AXP:AMPK interactions (Figure 39b  
and Figure 40)(278). Of course the in vitro assays were all carried out using phosphorylated 
(active) AMPK, therefore equilibrium binding constants for AXP binding to AMPK were  
taken from Table 7. 
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A  
B  
 
Figure 39: Screenshot of the user interface.  
A) Inputs. B) Calculation of the concentrations of AXP species: Displayed as percentages of 
the total concentration. 
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Figure 40: Screenshot of the user interface.  
Occupancy of Site-1 and Site-3 by nucleotides: Displayed as percentages of the total 
concentration.  
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 4.4.2.3 In vitro occupancy results 
Figure 41 shows the percentage occupancy of Sites-1 and 3 calculated under the conditions 
of the ‘allosteric activation experiment’ shown in Figure 32 (10mM Mg2+, 0mM Ca2+,  
10nM AMPK, 200M ATP, 0mM ADP, 150M NADH, pH 8.0 and variable AMP) compared 
with the measured fold-activation (scaled with the assumption that fold-activation is 
proportional to percentage occupancy). At maximal fold-activation (AMP ~100M) Site-1 is 
80-90% occupied by AMP, whilst Site-3 is only ~50% occupied. Although the agreement is 
only approximate it is clear that occupancy of Site-1 correlates better with the observed 
effect. Given that the dissociation constants measured in Chapter 4 are, in some cases, 
relatively poorly defined the agreement is not unreasonable. 
 
Figure 42 shows the percentage occupancy of Sites-1 and 3 calculated under the conditions 
of the ‘protection against T172 dephosphorylation’ experiment shown in Figure 35  
(10mM Mg2+, 0mM Ca2+, 0.01mM AMPK, 0mM NADH, 0mM ATP, 0mM ADP and variable 
AMP) compared with the amount of phosphorylated AMPK remaining after 25 minutes.  
In this case it is clear that protection against dephosphorylation correlates much better with 
occupancy of Site-3. Under these conditions Site-1 is almost completely saturated at 25M 
AMP, whilst the regulatory effect saturates at concentrations greater than 200M (at which 
point Site-3 is >70% occupied). 
 
Taken together, this work provides further evidence for the assignment of AMP binding at 
the tighter site (Site-1) being the mediator of allosteric activation and binding of AMP/ADP 
at the weaker site (Site-3) being responsible for protection against dephosphorylation of 
T172.  
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Figure 41: Modelling of allostery (AMPK). 
Blue: Allosteric fold activation shown as % site occupancy, corresponds to Figure 32 
(assuming that at full activation, the relevant binding site is 100% occupied).  
Red: % occupancy of Site-1. Yellow: % occupancy of Site-3 by AMP. 
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Figure 42: Modelling of protection against dephosphorylation by AMP (AMPK). 
Blue active AMPK after 25min (corresponds to Figure 35). Red: occupancy of Site-1 by AMP. 
Yellow: occupancy of Site-3 by AMP. Displayed as AMPK concentration plotted against AMP 
concentration. The total AMPK concentration used in the in vitro assays was 0.01mM. 
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 4.4.2.4 Modelling of ‘in vivo’ AMPK occupancy 
Whilst the modelling of in vitro assay conditions ties the work from Chapter 4 to that in 
Section 3.4.3, and is a useful test of the model, the ultimate aim is to comment on how 
nucleotides are responsible for AMPK activation in an ‘in vivo’ situation.  
 
For this purpose it is assumed that ‘a signal’ results in increased AMP/ADP and decreased 
Mg.ATP concentrations, altering the binding site occupancy of AMPK, and translating to 
increased activity. I aimed to test three important points:  
 1) That occupation of Site-1 by AMP when ‘in vivo’ nucleotide concentrations are used in 
the program is negligible, and therefore that allosteric activation is unlikely to be an 
important factor under ‘normal’ in vivo conditions.  
 2) That occupancy of Site-3 by ADP can be significant compared to that of Mg.ATP and 
therefore that ADP can successfully compete for binding and protect T172 from 
dephosphorylation by phosphatases in an ‘in vivo’ setting.  
 3) That there is a significant increase of regulatory nucleotide occupancy of Site-3 when 
‘stressed’ nucleotide concentrations are used in the calculation.  
 
First it was necessary to define the AXP and ion concentrations which represent ‘basal’ and 
‘stressed’ cellular states. The ranges of cellular nucleotides which are often quoted are [ATP] 
= ~5mM, [ADP] 50-200M and [AMP] 1-5M, and a free Mg2+ concentration of 0.5mM  
(1, 275, 279-281). The low end of these AMP/ADP estimates corresponds to a basal situation 
and the top end to a stressed situation. The ATP concentration is decreased by the increases 
in the AMP and ADP concentrations.  
Despite the relative increase in AMP concentration (from 1 to 5M) being a little greater 
than that of ADP (50 to 200M) it is the absolute concentrations that determines the 
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occupancy of the binding sites. As such the potential occupancy of ADP is much greater than 
that of AMP. 
The calculations show that the occupation of Site-1 by AMP, i.e. the increase in AMPK which 
is allosterically activated, is from 0.09% to 0.39% (at 1M and 5M AMP respectively).  
A drop in ATP/Mg.ATP occupancy of Site-1 is observed (from 94.9% to 82.3%), but it is ADP 
which increases significantly in occupancy (and, of course, ADP does not allosterically 
activate AMPK). Given the very low basal level and small increase in occupancy it is unlikely 
that AMP binding at Site-1, and therefore allostery itself, is an important regulatory effect in 
vivo. Perhaps this regulation only comes into play as a 'last ditch' attempt to rescue the cell 
from death when AMP concentrations become very high.  
 
The cellular concentrations of ATP are significantly higher than those of the regulatory 
nucleotides (AMP and ADP) so it has always been a challenge to envisage how AMP/ADP 
could regulate the enzyme. In Chapter 3 it was suggested that the weaker binding of Mg.ATP 
(the predominant cellular species - Figure 43), relative to free AXP, was sufficient to allow 
ADP to compete effectively for binding to the -subunit. The concentrations of AMP appear 
too low for it to significantly occupy either Site-1 or Site-3, as demonstrated above in 
relation to allosteric activation. However, the change in occupancy of Site-3 by ADP,  
which protects against dephosphorylation of T172, could be 4-fold, increasing from 2.68% 
to 10.14% (50M and 200M ADP respectively).  
It is encouraging that the model can predict an increase in occupancy of the regulatory site 
by ADP given basal and elevated cellular AXP concentrations. This effectively demonstrates 
that ADP can compete with the high ATP/Mg.ATP concentrations for binding and therefore 
be capable of regulating AMPK. 
 
178 
 
The mitochrondrial uncoupler, 2,4-dinitrophenol (DNP) in conjunction with sorbitol, rapidly 
alters the cellular ADP:ATP ratio and thus potently activate AMPK. Together these 
compounds activated AMPK 12-fold relative to untreated cultured muscle cells (282).  
It seems reasonable to assume that this represents maximal activation of AMPK (i.e. 100%), 
and therefore that up to 8% of AMPK is active under basal conditions. This value is perhaps 
a little higher than the 2.5 to 10% ADP-bound fraction under basal and ‘activated’ conditions 
predicted by the model, but is certainly within an acceptable range. 
 
The phosphatase reaction is thought to be important in determining the proportions of 
phosphorylated and unphosphorylated AMPK (since LKB1 is constitutively active).  
It is therefore likely that ADP is the universal activator of AMPK, operating in all cell types 
and in response to a multitude of stress/signals through modulation of the susceptibility of 
AMPK to phosphatase activity.  
 
 4.4.2.4.1 Adenylate Kinase 
Adenylate kinase catalyses the conversion of two molecules of ADP into one of ATP and 
AMP. It has often been suggested that because the AMP:ATP ratio increases as the square of 
the ADP:ATP ratio,  that AMP is a more sensitive indicator of the cellular energy status. 
Simulations show that over the cellular AXP concentrations used in the in vivo modelling 
(Section 4.4.2.4) AMP concentrations do change by a slightly larger proportion that ADP but 
that the highest concentration reached is insufficient for AMPK regulatory sites to be 
significantly occupied (Figure 44). Under these conditions, the absolute increase in ADP 
concentration is larger than that of AMP, and therefore is the more effective monitor of 
cellular energy status. 
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Figure 43: % Mg.ATP over the physiological range of free Mg2+ concentration (AMPK). 
Given starting nucleotide concentrations of 5mM ATP, 50M ADP and 1M AMP, 150nM 
AMPK, pH 8.0. 
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Figure 44: Changes in nucleotide concentration. 
ATP (blue), ADP (red) and AMP (green) plotted against [ADP]/[ATP]. Fluctuations in the 
cellular nucleotide concentrations rarely decrease the ATP concentration this dramatically; 
in fact increases in AMP/ADP of only fractions of a millimolar are to be expected.  
If the ATP concentration decreases by less than 10% then there is a significant increase in 
the ADP concentration but a very small increase in the AMP concentration. 
Calculated based on the adenylate kinase reaction, with a fixed total AXP concentration of 
5.5mM and K= 1, (method described in Section 4.2.7). 
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 4.4.2.4.2 Limitations of the model 
Whilst modelling of AMPK binding site occupancies by AXP can be considered a success 
there are a number of additional factors which should be considered: 
 1) The standard deviations associated with the AMPK:AXP Kd values are unavoidably large 
and these errors can have a significant effect on calculations of the % occupancy.  
 2) The in vivo nucleotide and cation concentrations used in modelling occupancy are not 
well determined. Often the techniques used place the cells under some stress so 
concentrations may not be accurate. Additionally, nucleotide and cation concentrations 
vary with tissue-type and with cellular localisation/compartment.  
 3) Different AMPK  isoforms may be bound by AXP with different affinities (this work 
described only AXP binding to 1), different heterotrimeric complexes may also be 
regulated to differing extents by ADP (this work described only regulation of 1). 
 4) It is unknown what proportion of AMPK must be bound by ADP in order for sufficient 
activation of the kinase to occur. Perhaps there is a large AMPK pool, of which only a 
small percentage must be ADP-bound/activated in order to achieve the relevant 
downstream effects.  
 
 4.4.2.4.3 Linking Site-3 occupancy to AMPK activation 
Having calculated the proportions of AMPK regulatory sites bound by nucleotide, it is 
important to link this to changes in T172 phosphorylation and therefore activation  
(Figure 45). 
In terms of the allosteric effect this is straightforward; we know that AMPK bound at Site-1 
by AMP is ~2-fold more active than unbound AMPK. However as was already established, 
this may not be an important point of regulation in vivo.  
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Figure 45: AMPK species.  
There are at least four major AMPK states, unphosphorylated and therefore inactive, or 
phosphorylated and therefore active. Either of these states may be bound by AMP/ADP and 
therefore protected against dephosphorylation. The concentrations of the two AMPK 
species are defined by the rates of the kinases and phosphatases, and the nucleotide 
concentrations and their binding affinities.  
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It is more challenging to define the effect of AMP/ADP binding at Site-3 on protection 
against dephosphorylation. This depends upon the relative rates of the phosphatase when 
AMPK is bound by regulatory nucleotide and by non-regulatory nucleotide. The identity of 
the in vivo AMPK phosphatase(s), and therefore detailed information about its activity is 
unavailable. 
 
We have proposed that T172 is protected from dephosphorylation when the  
T-loop/-kinase interacts with the regulatory subunit (Figure 38) such that two species exist, 
kinase-regulatory fragment bound and kinase flexibly linked. ADP/AMP binding to the
-subunit shifts the equilibrium from the free to the bound form. In terms of regulation the 
important, but unanswerable, question is to what extent does AMP/ADP binding alter the 
kon and koff of this equilibrium.  
It is clear that ADP binding does not cause a complete shift to a bound-kinase form as one 
would then expect to see little or no dephosphorylation at saturating [ADP], even at long 
time points. A partial shift in the equilibrium towards a completely protected bound form 
could explain the results in terms of a reduction in the effective substrate concentration. 
Ultimately the question is what are the changes in kon/koff rates of the kinase interaction 
with the regulatory subunit, given occupancy of Site-3 by ADP rather than to Mg.ATP? 
 
Even when we have kinetically defined the effect of ADP binding on phosphatase activity, 
there are a number of factors in addition to those listed in Section 4.4.2.4.2,  
which may result in an underestimation of cellular AMPK activation;  
 1) It is unknown what the basal level of AMPK activity is, although a low (<8%) basal level 
of AMPK activity can be inferred from the mitochondrial uncoupling.  It is also necessary 
to define what fold-increase in activity is required for activation of downstream targets, 
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again work with mitochondrial uncouplers provides information about maximal levels  
of AMPK activation (282).   
 2) ADP binding may also increase the rates of the upstream kinases. 
 3) The role of the proposed AID on activation and nucleotide binding is unknown. 
 4) Myristoylation, acetylation, ubiquitination, glycogen and endocrinological signals also 
modulate the equilibrium between phosphorylated and unphosphorylated AMPK in a cell-
type, localisation and signal dependent manner. These factors are hard to introduce to the 
model of AMPK activation since their roles are varied and not completely understood. 
 
I do conclude that it is ADP binding to the -subunit which acts as a universal activator of 
AMPK. It is simplistic to model AMPK activation ‘as a function of ADP binding’,  
since a multitude of other signals influence the amount of T172 which is phosphorylated in 
vivo, therefore a more sophisticated model of AMPK regulation  in the future may reveal 
more complexity than demonstrated here. Further information about the rates of the 
kinase/phosphatase activity, other regulatory signals and the mechanism through which 
T172 is protected against dephosphorylation is required in order for such a  
model to be produced.  
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 4.4.2.5 Ultrasensitivity 
In some cases biological systems are activated with a sensitivity of more, or less, than would 
be predicted by standard Michealis-Menten approximations. Ultrasensitivity is defined as a 
response where an increase from 10% to 90% of maximal requires a change in the initial 
signal of less than 81-fold (283). AMPK activation in INS-1 cells has been shown to be 
ultrasensitive in response to AICAR treatment (265).  
There are three ways, which may act in concert, that ultrasensitivity can be achieved;  
 1) Positive Cooperativity – where the binding of a ligand/activator increases the affinity of 
a second. There is no evidence for this in the AMPK system. 
 2) Multistep Ultrasensitivity – A single activator acts at multiple stages of a cascade, with 
rate constants of the effectors within a narrow range (284).  
 3) Zero-order Ultrasensitivity – One or more enzymes are operating under zero-order 
conditions, that is, the substrate concentration is significantly higher than the Km 
therefore the enzyme operates at Vmax. If a single enzyme in a futile cycle  
(e.g. a phosphorylation-dephosphorylation cycle) operates under zero-order and  
the second under first-order conditions a lag at the top or the bottom of the  
curve is observed (284). 
Previously the multistep activation of AMPK by AMP was considered as the source of 
ultrasensitivity (265), however it is likely that ADP binding is the key regulator of AMPK 
activity, as is demonstrated throughout this Chapter. Therefore multistep ultrasensitivity  
(by AMP) is no longer a viable explanation for the in vivo observation that AMPK is activated 
in an ultrasensitive manner (1, 177). Suggesting, perhaps, that AMPK activation operates 
mainly through zero-order effects. 
The equilibrium between phosphorylated and unphosphorylated AMPK is maintained 
through activity of the kinase and phosphatase. An increase in ADP shifts the equilibrium 
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from favouring the phosphatase reaction to the kinase reaction, which is both constitutively 
active and operating under zero-order conditions. This switch relies upon carefully balanced 
reaction rates, which are therefore sensitive to changes in ADP concentration over a narrow 
range and results in rapid activation/inactivation of AMPK.  
Whilst ultrasensitivity is not considered further in this thesis, it is an interesting mechanism 
through which high sensitivity may be introduced into the regulation of AMPK,  
and should be considered in the future modelling studies on the activation of AMPK in vivo. 
 
 4.5 Conclusion 
In this Chapter I demonstrated that a coupled spectrophotometric assay can be used to 
effectively monitor AMPK catalysis and a number of kinetic parameters were determined. 
Binding of AMP at Site-1 mediates allosteric activation in vitro and binding of AMP/ADP at 
Site-3 mediates protection of T172 against dephosphorylation by phosphatases (1).  
This was demonstrated experimentally through competition of NADH with these regulatory 
effects and through simulation of the in vitro assays.  
Simulation of AMPK binding site occupancies, given estimations of intracellular AXP 
concentrations, suggest that 1) allosteric activation by AMP may not be an important 
regulatory point in vivo, 2) ADP can effectively compete with Mg.ATP for binding at the 
regulatory binding site, and 3) this occupancy increases 4-fold when ‘stressed’ AXP 
concentrations are used.  
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 Chapter 5:  Structure of a truncated AMPK complex 
 
 5.1 Abstract 
In this Chapter X-ray crystallography was used to determine the structure of a truncated 
AMPK complex with C-ADP. The AMPK structure is compared to an unlabelled ADP-bound 
form. This study verified that C-ADP bound in a homologous fashion to ADP, specifically in 
the same exchangeable binding pockets, and revealed the additional contacts made 
between the fluorescent adduct and AMPK.  
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 5.2 Introduction – X-ray Crystallography 
 5.2.1 Overview 
X-ray crystallography, Nuclear Magnetic Resonance (NMR) and cryo-Electron Microscopy 
(EM) are the three most widely used techniques to investigate the macromolecular 
structure of proteins. Each has a number of benefits and limitations which make their use 
complementary in the study of different biological questions. NMR is often used as a 
solution state technique and provides information about the kinetics and dynamics of a 
protein; however its use in structure determination is generally limited to proteins with a 
molecular weight of under 50kDa (285). Single particle cryo-EM can produce low resolution 
(>5Å) structures of asymmetric protein complexes with molecular weight between  
0.1-0.5MDa (286). X-ray crystallography has no size limitations per se and it offers the 
highest atomic resolution, however it requires that the protein molecules are amenable  
to crystallisation. Over 80% of the protein structures present in the PDB were determined  
by X-ray crystallography. 
 
X-ray crystallography proceeds through four major steps: 1) protein purification;  
2) crystallisation; 3) data collection; 4) data processing. A fifth may be added if a 
homologous structure is not available for molecular replacement, in this case the ‘phase 
problem’ must be overcome. 
 
This introduction was compiled from a number of sources: 
Notes from the BCA Protein Crystallography Summer School 2010; ‘Protein Crystallography 
with Coffee’ - Airlie McCoy (287); ‘Crystals, X-rays and Proteins’ – D. Sherwood and J. Cooper 
(288); Personal Communications - Bing Xiao and Steven Gamblin (NIMR). 
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 5.2.2 Crystallography 
Crystal Packing and Symmetry 
A crystal is a solid in which the molecules are arranged in a lattice constructed of identical 
unit cells, described by three dimensions a, b and c, and three inter-axial angles ,  and  
Each unit cell has the same environment as every other one. The simplest lattice 
arrangement is termed primitive (P). The lattice may also be arranged as body centred  
(I centred), centred on all faces (F centred) or centred on a single face (A, B, or C centred).  
Crystal symmetry is defined as the set of operations, the application of which superimposes 
the asymmetric unit on itself. There are three types of crystallographic symmetry; rotation, 
reflection and inversion. Since proteins exist in a single chiral form the latter two symmetry 
types are not present in their crystals. 2-fold, 3-fold, 4-fold and 6-fold rotational symmetry 
are allowed in a protein crystal; their presence places restrictions on the unit cell 
parameters of the lattice. There are seven ‘crystal systems’ which conform to the definition 
of a unit cell and to the possible symmetry operations; triclinic, monoclinic, orthorhombic, 
tetragonal, trigonal, hexagonal and cubic. When combined with the possible centring 
operations they give rise to 14 distinct lattice types.  
Further lattice complexity is added by the presence of screw axes. Screw rotations are 
described as the order of the rotation (2, 3, 4 or 6) followed by a subscript indicating the 
fraction of the unit cell of the translation. There are 11 crystallographically allowed  
screw rotations. Combining all the point groups and lattice types gives a total of 65 unique 
space group symmetries possible for protein crystals. Some are particularly favourable for 
packing of globular molecules; over a quarter of the structures in the PDB belong to the  
space group P212121.  
The unit cell dimensions determine the spacing and arrangement of the reciprocal space 
lattice. The symmetry relationships between the intensities of reflections, and the patterns 
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of systematically absent reflections, arises from the crystallographic symmetry operators 
that apply to each crystal.  
The asymmetric unit is the smallest unit of structure that can generate the whole crystal 
after application of the crystal symmetry. There can be any number of molecules in the 
asymmetric unit, the occurrence of more than one copy gives rise to the phenomenon of 
non-crystallographic symmetry. Knowing the space group, the unit cell, and the contents of 
the asymmetric unit defines the positions of all atoms in the crystal.  
 
Braggs Law 
X-rays have a wavelength on the order of 0.1nm (1Å) which is comparable to the spacing 
between atoms in a protein. The crystal lattice acts as a diffraction grating allowing the 
underlying molecular transform to be sampled in a discrete fashion. When the diffracted 
waves constructively interfere an interference (or diffraction) pattern is produced.  
The arrangement of unit cells, according to the unit cell parameters and space group, 
determines the spacing and symmetry of the reciprocal lattice, whilst the arrangement of 
atoms within the asymmetric unit defines the underlying molecular transform and thus the 
intensity of each reflection.  
Diffraction is described by Braggs law, which relates the distance between the layers of 
atoms in the crystalline lattice (d), the wavelength of the X-rays (), the angle of incidence of 
the X-ray beam (θ) and the order of the reflection (n).  
2𝑑 𝑠𝑖𝑛(𝜃) = 𝑛𝜆 
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Reciprocal Space versus Real Space 
Within a crystal the position of atoms are described in terms of real space co-ordinates. 
Reflections arising from diffraction are described in terms of their position in reciprocal 
space (constructed based on 1/d). Thus, a large unit cell dimension results in reflections 
which are close together in reciprocal space.  
 
The axes in reciprocal space are termed a*, b* and c* (a* being perpendicular to b, c, b* to 
a, c, and c* to a, b), and the angles between them , , and .  
 
The miller indices describe the position of reflections within reciprocal space.  
Each reflection is assigned a Miller index, that is a set of the three integers (h, k, l).  
The spacing d in Bragg’s Law is given by the Miller indices, which denote the plane in the 
crystal for which Bragg’s Law is satisfied for that reflection.  
 
Friedals Law states that the intensity of any given reflection (h, k, l) is equal to the intensity 
of the reflection (-h, -k, -l), thus the diffraction pattern has a centre of symmetry.  
 
The intensities (F) of each reflections are determined by the position of atoms within the 
asymmetric unit. Every atom makes a contribution (positive, negative or zero) to the 
intensity of each reflection. 
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Structure factor (F) determination  
The structure factor equation relates how intensities (F) of reflections arises from the 
position of each atom, and follows the general form: 
F(hkl) =  fne
2πi(hxn+kyn+lzn)
N
n=1
 
But is perhaps expressed more helpfully as: 
A(hkl) =  fncos2π(hx + ky + lz)
N
n=1
 
B(hkl) =  fnsin2π(hx + ky + lz)
N
n=1
 
Where: A = Fcos∅ B = Fsin∅ and thus F =  A2 + B2          ∅ = tan
B
A
  
 
So structure factors can be calculated from a given model (Fcalc) but only structure 
amplitudes can be directly measured for a crystal (Fobs). Ultimately refinement aims to 
minimise the differences between these Fobs and Fcalc values. 
 
Electron density (ρ) determination  
A Fourier transform is used to convert a given set of amplitudes (F) and phases (φ) to an 
electron density map. Electron density at a given point in real space, is given by: 
ρ(x, y, z) =
1
V
   |F|(h, k, l)e −2πi(hx+ky+lz)+φ(h,k,l)lkh   
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Molecular replacement 
Full information about the phases of the diffracted waves cannot be extracted from protein 
crystal diffraction. ‘The phase problem’ can be solved directly, in the case of small 
molecules, or experimentally using isomorphous replacement or anomalous scattering 
methods. These techniques rely on changes in reflection intensities when a reference wave 
of known phase interferes with a diffracted wave of unknown phase. In the first  
the reference wave comes from heavy atoms and in the latter from,  
for example, selenomethionine.  
 
Another approach to phasing is molecular replacement, which takes initial estimates of the 
phases from a model and iteratively improves them. This relies on the existence of a 
structure with reasonable similarity (often associated with at least 20% sequence identity) 
to the target structure.  
The model and target structures must be computationally aligned; this is achieved 
traditionally through the use of Patterson functions. The Patterson function is a Fourier 
transform calculated from intensities alone; setting all the phase values to zero. It produces 
an interatomic vector map containing both intramolecular and intermolecular information. 
The Patterson functions calculated from the model and experimental data are compared; 
first the model structure data must be correctly rotated/orientated (based upon  
self-vectors) then translated to the correct position (based upon cross-vectors).  
Maximum-likelihood methods play an increasing role in the computation of rotation and 
translation operations used in molecular replacement. 
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Refinement and Model Building 
The electron density is displayed as a contour map with peaks at the atomic positions.  
Fo-Fc maps reveal positive and negative electron density arising from differences between 
the calculated and observed intensities. The amino-acid chain and ligands are modelled into 
the map. Manual and automated refinement of the structure aims to make the model fit the 
experimental data as closely as possible, minimising differences in the Fo-Fc map.  
The process is interactive and iterative. Higher resolution maps allow the model to be built 
more easily and often largely automatically. 
The crystallographic R-factor is monitored to follow the progress of refinement.  
Values of around 1/10th of the resolution limit are considered acceptable, thus reflecting the 
fact that high resolution refinement results in much more accurate coordinates.  
During the process of refining and building the model it is important to avoid over fitting of 
the data and model bias. This occurs because of the relatively low observation:parameter 
ratio. In order to avoid this problem a number of reflections are left out of the refinement, 
the Rfree is independent of the refinement process and should improve with the R-factor.  
 
A number of geometrical factors contribute to the model refinement process; the lengths of 
the bonds and angles between atoms, the conformations of secondary structure elements 
e.g. -helices and -sheets and restrictions on the conformation of the peptide backbone. 
Adding these parameters as restraints in refinement acts to improve the 
observation:parameter ratio. This is important because at about 2-5Å resolution most 
crystals only provide one observation (reflection) per refined parameter (4 per atom;  
x, y, z and B-factor).  
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 Rigid body refinement refines the position of protein domains, therefore the number of 
parameters being fitted is greatly decreased. Translation-libration-screw (TLS) refinement 
also treats groups of atoms as single units, refining the B-factors as a function of their 
translation and libration (oscillations). These ‘bulk’ corrections can thus be refined with a 
high observation:parameter ratio even with low resolution data. Non-crystallographic 
symmetry i.e. if you have more than one protein molecule in the asymmetric unit,  
can be used to improve the electron density maps by real space averaging, as can solvent 
flattening techniques. There are many methods employed in the process of model- building 
and refinement, only the key techniques have been touched upon.  
 
 5.2.3 Crystallography Work-flow 
Protein purification 
Generally, protein crystallisation is highly dependent on the homogenity and 
monodispersity of the sample. Generation of recombinant proteins in a stable, soluble  
and concentrated form for X-ray crystallography often proves to be a major  
bottleneck in the process (289). In many cases large numbers of constructs are screened 
before a protein sufficiently fulfils these criteria. Constructs can be designed to reduce the 
number of domains present and decrease flexible linkers or N/C terminal regions.  
Many constructs are designed around the products of limited proteolysis experiments.  
Protein solubility can be improved in a number of ways; attachment of solubilising fusion 
tags, mutations of surface hydrophobic residues or oligomerisation interfaces and use of 
orthologous proteins from alternative organisms (289).  
Protein stability can be improved through use of thermostable homologous proteins from 
bacterial species, co-expression of chaperones or binding partners, and expression in 
mammal cell lines to increase post-translational modifications.  
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The ability to achieve high levels of protein concentration can be improved through 
introduction of ligands, binding partners, mutation of oligomerisation interfaces and 
optimisation of salt concentrations and pH. 
 
Crystallisation 
The second bottleneck in the process is the production of protein crystals. Crystallisation has 
a reputation for being a ‘black art’ because of the difficulty in predicting the conditions 
which will lead to crystal formation. 
  
Crystallisation occurs when the concentration of the protein in solution is greater than its 
limit of solubility. In many cases the sample will precipitate, however, through screening of 
many buffer conditions (varying pH, salts, additives, organic solvents, polymers etc.) it is 
possible to produce protein crystals. The process of crystallisation proceeds through a 
number of stages, first the protein becomes supersaturated, next an energy barrier must be 
overcome in order for nuclei to form from which the crystal lattice grows. If the sample is 
impure contaminants are incorporated into the lattice blocking further growth. Ideally the 
buffer conditions result in a small number of nucleations that grow into crystals greater than 
100m in size. This process depends on both the starting precipitants concentrations and 
how they vary over time.  
Using vapour diffusion experiments the precipitant concentration can be altered over the 
early course of the crystallisation. Precipitant and protein are mixed in a small drop either 
suspended over a larger volume of precipitant (hanging drop) or sitting in a well surrounded 
by a precipitant reservoir (sitting drop), these sealed wells are generally incubated at a 
constant temperature (often 18oC). Through evaporation of water molecules and other 
volatile species the two liquids equilibrate over time. 
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The introduction of crystallisation robots has significantly increased the number of 
precipitant conditions which can be screened, and decreased the amount of protein 
required per condition as they can accurately pipette nanolitre sample volumes.  
Additionally the availability of commercial screening kits makes large numbers of buffers 
readily accessible.  
The resolution to which a crystal diffracts is a function of both its size and the order  
of the lattice: 
  Size is important because the number of unit cells in the crystal is proportional to its 
volume, and the strength of the X-ray scattering is proportional to the number of unit 
cells. Therefore a larger crystal, provided it is well ordered, will usually produce 
diffraction data with a better signal:noise ratio. 
  The crystalline order also affects the strength of the scattering; it is usually inversely 
correlated to solvent content (high solvent content correlating with looser packing – 
most crystals are 50-60% solvent).  
  Conformational heterogeneity of the sample can also contributes to disorder within the 
crystal lattice.  
  Crystal mosaicity is a function of the order of the microdomains within the crystals.  
The mosaicity associated with a given reflection relates to the ‘sharpness’ of the 
reflection with respect to the angular rotation range. Highly mosaic crystals (>0.75o) 
have a lower signal:noise than low mosaicity crystals (<0.5o) and thus diffract  
to lower resolution.  
 
Crystal handling 
During exposure to X-rays crystals suffer from radiation damage, resulting in a breakdown of 
crystalline order. In order to minimise this radiation damage diffraction data is collected at 
liquid N2 (temperature; ~100K). For the solvent within the crystal to produce amorphous, 
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rather than crystalline, ice most crystals require a cryo-protectent to be added to the 
mother liquid. Many crystallisation conditions require the addition of cryo-protectant,  
this subjects the crystal to changes in osmotic pressure which can result in cracking or 
 loss of order. If the solvent is not sufficiently cryo-protected ice crystals will form damaging 
the lattice and producing a strong diffraction pattern which interferes with the diffraction of 
the protein. Glycerol, 2-methyl-2,4-pentanediol (MPD) and low molecular weight 
polyethylene glycol (PEG) are often used as cryo-protectants.  
The process of ‘fishing’ for crystals, mounting them in a loop and flash freezing them can put 
a lot of physical stress on the crystal which may also result in cracking or a loss of order. 
 
Data collection 
There are two major X-ray sources commonly available to structural biologists;  
home sources which are typically Cu/W rotating anode generators and synchrotron sources. 
The latter offers high brightness, high intensity, higher energy, tuneable, monochromatic  
X-rays which often greatly improve the quality of the data and rate of data collection.  
Typically crystals mounted in cryo-loops are placed on a goniometer and maintained within 
a nitrogen cryo stream. The crystal is rotated around a fixed axis perpendicular to the beam 
path. Diffraction patterns are collected at regular oscillations (0.1-2o) such that a complete 
data set is acquired (i.e. have sampled the whole of reciprocal space). The unit cell and 
space group of the crystal are often determined prior to data collection so that an optimal 
collection strategy can be produced. For example, an orthorhombic space group requires 
only 90o of data to be collected for all the unique reflections to be measured.  
The diffracted X-ray’s are detected on a charge-coupled device (CCD), the distance of the 
detector from the crystal determines the maximum resolution of the data-set. 
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Auto-indexing, Integration and Scaling 
The basic problem encountered with the interpretation of diffraction patterns is the fact 
that they are a series of 2D planes sampling the 3D reciprocal lattice.  
The first step of data processing (autoindexing) determines the unit cell, lattice type, 
mosaicity and orientation of the unit cell with respect to the instrument.  
The data from each diffraction pattern is integrated and scaled into a single dataset, 
characterised by Miller indexes, intensities and associated errors for each reflection.  
The scaling together of diffraction images must be refined to account for fluctuations in the 
beam strength, radiation damage, the crystal volume in the beam path, and differences in 
the background signal across the detector. Ideally the dataset has high signal-noise,  
high redundancy and high completeness.  
 
Molecular replacement, Model Building, Refinement and Structure Validation 
The starting point is a set of coordinates for a model structure. Once this model can be 
positioned appropriately, model phases can be calculated for the new  
(experimental) structure. The process of improving an electron density maps through 
refinement of the atomic positions and temperature factors, and the process of building a 
model into the density, are increasingly combined into single automated programmes  
(as described in Section 5.2.2).  
Before a structure can be deposited in the PDB it must be validated in a number of ways. This 
is to ensure that at an atomic and secondary structure level it conforms to stereochemical and 
geometrical parameters, e.g. planarity, bond angles/lengths, hydrogen bonding distances, 
torsion angles etc. Robust validation helps to eliminate incorrect structures. 
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 5.3 Methods 
 5.3.1 Crystallisation of AMPK with C-ADP  
Crystals of AMPK, rat α1396-548
 
human β2187-272rat 11-330, were grown by vapour diffusion at 
18oC in sitting drop trays of 24 wells. The reservoir volume was 500μl. AMP was present at 
two times the protein concentration (9mg/ml). Drops were prepared by mixing  
equal volumes of AMPK-AMP with well solution (7% PEG-3350, 0.1mM  
2-(N-morpholino)ethanesulfonic acid (MES) pH 5.5) in a 2μl drop. Crystals appeared in two 
days and grew to a maximal size over 7 days. Crystals that reached at least 50μM in width 
were deemed suitable for soaking with C-ADP solution (starting concentration 2mM).  
Crystals were harvested with a loop and transferred into a drop of reservoir solution 
containing 10% ethylene glycol, and subsequently into a second drop containing  
25% ethylene glycol before being plunged into liquid nitrogen (100K). Frozen crystals were 
stored in liquid nitrogen until data collection.  
Crystals were screened for diffraction in-house on a MicroMax 007HF rotating anode 
coupled to a RaxisIV++
 
detector. Crystals were maintained at 100K and were exposed for  
2 minutes at 0.5o
 
oscillation at 1.54 in two orientations 90oC apart. For those crystals which 
diffracted during screening a full data set was collected by the oscillation method 
(0.5o/frame, 2 seconds/frame, 0.97) at the Diamond Synchrotron Light Source (UK).  
A single crystal was used to collect the data set, which was processed as described  
in Section 5.4.  
 
 5.3.2 Materials  
24-well plates from Hampton Research. MES, ethylene glycol and PEG 3350 from Sigma.  
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 5.4 Results and Discussion 
The truncated AMPK complex crystallised here (rat α1396-548human β2187-272rat γ11-330 -  
Figure 46) was designed from the results of limited proteolysis and sequence analysis. 
Recombinant protein was overexpressed in a BL21 E.coli cell line, following lysis protein was 
purified through Ni2+-affinity and gel filtration steps (described in Chapter 2). Purity was 
assessed by SDS-PAGE (Figure 47) and DLS.  
The AMPK truncate has previously been crystallised by members of the Gamblin laboratory in 
complex with AMP/ADP/ATP/mant-AXP/ZMP, some structures of which are described in  
Xiao at el (2007) (87). Use of similar crystallisation conditions (7% PEG-3350, 0.1mM MES  
pH 5.5) yielded a number of crystals which stained yellow (the colour of the coumarin 
chromophores) upon soaking with 0.5mM C-ADP. Crystals typically belong to the 
orthorhombic space group P212121.  
 
Diffraction data extending to 2.5Å Bragg spacing were measured and processed using Denzo 
and Scalepack (290). The structure was solved by molecular replacement with 2V8Q as a 
model using Phaser (291). All three nucleotides, as well as water molecules were omitted 
from the molecular replacement and initial phase calculations. Crystallographic refinement 
was carried out using the rigid body, simulated annealing and TLS protocol program package 
Phenix (292) and additionally Refmac5 (293). Models were manually adjusted and water 
molecules added using Coot (294). Figures were created with pymol 
(http://pymol.sourceforge.net/). Crystallographic statistics are shown in Table 15. 
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Figure 46: Domain schematic of AMPK crystallisation construct.  
The shaded areas are not present in the truncated crystal structure. Abbreviations:  
AID: autoinhibitory domain, GBD: glycogen binding domain (also referred to as the 
carbohydrate binding module), CBS: cystathionine β-synthase. 
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Figure 47: Purified recombinant rat α1396-548human β2187-272rat γ11-330. 
The purified protein was resolved on a 12-14% SDS-PAGE Novex gel and stained with 
InstantBlue. The molecular weight markers are indicated on the left (kDa) and the identity of 
the bands and their molecular weights on the right. 
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Table 15: Crystallographic statistics. 
 
  
205 
 
The overall structure of the crystallised construct has been discussed by Xiao et al (87) and is 
shown in Figure 48 and Figure 49. Each of the three nucleotides sit in a partially basic pocket 
formed at the interface between a pair of CBS motifs. In my maps electron density 
corresponding to the non-exchangeable AMP (Site-4) and two C-ADP molecules bound in 
the exchangeable -domain Sites 1 and 3 was observed (Figure 49, Figure 50 and Figure 51).  
 
Coumarin 
In Site-1 residues 119-126 adopt altered conformations in order to accommodate the 
coumarin adduct. Most significant is that of Tyr-120 which forms a hydrophobic interaction 
with the coumarin ring (Figure 52a). The terminal NH2
 
atoms of Lys-126 shift 8Å compared 
to their position in the ADP-bound structure and form a hydrogen bond with the coumarin 
group. Additionally the side chain of Asn-92 interacts with the coumarin moiety.  
 
In Site-3 the loop formed by residues 265-271 moves in order to accommodate the 
coumarin-adduct (Figure 52b). The non-fluorescent moiety of the nucleotide occupies the 
same volume of space as in the ADP-bound structure. The only interaction between the 
coumarin and the protein is a hydrophobic stacking of the coumarin ring with Phe-243,  
this residue moves 3.6Å from its position in the ADP-bound structure (Figure 52b).  
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Figure 48: The C-ADP/AMPK complex. 
Ribbons representation of the structure of the regulatory fragment of AMPK complexed 
with one AMP and two C-ADP molecules (AXP shown as white sticks and labelled).  
The subunits are indicated and coloured as follows ; pink, β; green, α; blue. PDB ID: 2YA3. 
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Figure 49: The -subunit from an orthogonal view to Figure 48. 
Cartoon representation of the -subunit in pink; the positions of the bound AMP/C-ADP are 
shown in stick representation and labelled. PDB ID: 2YA3. 
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Figure 50: Expanded views of the C-ADP binding sites. 
Electron density is from an Fo-Fc
 
omit map where the nucleotide have been removed from 
the coordinate model, contoured at 1.0σ. PDB ID: 2YA3. 
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A  
 
B  
 
Figure 51: C-ADP and ADP bound to the -subunit. 
Overlay of ADP (blue) and C-ADP (pink) bound structures at (A) Site-1, and (B) Site-3.  
The coumarin (labelled) fluorophore is conjugated to ribose and protrudes from the AXP 
binding site. PDB ID: 2YA3. 
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Figure 52: (A) Interactions of coumarin with Site-1.  
Overlay of ADP-bound (blue) and C-ADP bound (pink) structures. Nucleotides are shown in 
stick representation. Tyr-120 is shifted to accommodate the coumarin fluorophore and 
forms a hydrophobic interaction with it. The loop extending from residue 119-126 adopts an 
altered conformation in the C-ADP bound structure.  
(B) Interactions of coumarin with Site-3. 
Overlay of ADP-bound (blue) and C-ADP bound (pink) structures. Phe-243 is shifted to form 
a hydrophobic interaction with the coumarin moiety. The loop extending from residue  
265-272 is also labelled, and adopts an altered conformation in the C-ADP bound  
AMPK structure. 
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Adenine 
In both sites the amino group at the N6 position of the adenine moiety forms two hydrogen 
bonds with the carbonyl groups of main chain residues (Val-129 and Arg-151 in Site-1;  
and Ala-204 and Ala-226 in Site-3). The N1 group is involved in a single hydrogen bond with 
a main chain amino group (Figure 53a) (Val-129 and Leu-276 in Site-1 and  
Site-3 respectively). In Site-3 the N7 amino group of adenosine interacts with the side chain 
of Arg-298. Additional hydrophobic interactions, such as those of Met-83 and Leu-128 with 
the adenosine ring in Site-1 also contribute to binding.  
 
Ribose 
One of the key features of the nucleotide binding site is the hydrogen bonding between the 
two ribose hydroxyl groups with the side chain of an aspartate residue (Asp-89 in Site 1, 
Asp-244 in Site 3 and Asp-316 in Site-4). Since the coumarin adduct is linked to the ribose 
group a number of these interactions are lost, although the C-AXP still bind tighter than 
their unlabelled equivalents (Section 3.4.3.1). The C-ADP in Site-3 is bound in a somewhat 
different conformation to ADP. The 2’-hydroxyl group of the ribose ring is shifted 1.8Å 
compared with the ADP structure. This is a result of small shifts in the orientation of D244 
and its neighbours in order to accommodate changes in the main chain conformation 
following the movement of a nearby loop described earlier. In place of the hydrogen 
bonding between the 2’ OH and Asp-244 there is an interaction with a water molecule not 
normally present in the site. Normal interactions with Arg-268 are also lost in the C-ADP 
structure (Figure 53b).  
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Figure 53: (A) Interactions of C-ADP adenosine ring with Site-1 residues. 
A number of hydrogen bonds between the adenine ring and main chain carbonyl and amino 
groups are formed. Similar interactions are seen in all AXP:AMPK structures.  
(B) Interactions of C-ADP ribose with Site-3 residues. 
Asp-244 forms hydrogen bonds with the ADP (blue) ribose. In the C-ADP bound structure 
(pink), the nucleotide is shifted such that the 2’ OH group interacts with a water molecule 
(shown as a blue sphere) rather than Asp-244.   
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Figure 54: Interactions of C-ADP with Site-3. 
Although the ADP (blue) and C-ADP (pink) nucleotides occupy the same volume of space, 
the α and β phosphates adopt different conformations. 
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Phosphates 
The phosphate groups form a network of hydrogen bonds with the hydroxyl groups of a 
number of serine and threonine residues; Thr-86, Thr-88 with Site-1, and with the positively 
charged side-chains of a number of residues within the pocket; Arg-151, His-150 and Lys-242 
with Site-1. In Site-3 the phosphates are present in a somewhat different conformation than 
observed in other structures, the α-phosphate forms hydrogen bonds with His-297, Ser-241 
and Arg-298, whilst the β-phosphate interacts with Arg-69, Phe-243 and Arg-298 (Figure 54). 
However, despite this altered conformation the phosphates occupy the same volume of 
space within the binding pocket. 
 
Discussion 
The use of fluorescently-labelled nucleotides is undoubtedly a useful way to measure the 
binding of unlabelled AXP to proteins. However the presence of relatively large and 
hydrophobic fluorescent groups conjugated to the AXP may introduce additional,  
non-specific or non-competitive interactions between the ligand and the protein. This is not 
unprecedented particularly with large adducts such as julolidine derivatives of AXP (247). 
This can be controlled for in two ways; firstly by performing titrations in the presence of 
large concentrations of the native ligand and ensuring no signal change is observed, and 
secondly through crystallisation of the ligand:protein complex.  
 
I verified that the coumarin nucleotide derivatives bound to the same sites as the unlabelled 
species by determining the crystal structure of the regulatory fragment in complex with  
C-ADP for comparison with an ADP bound structure. The 2:1 stoichiometry conforms with 
the conclusions drawn from the C-AXP fluorescence titrations (Section 3.4.3.1). No density 
corresponding to non–specific binding was observed, although this doesn’t preclude weaker 
binding at sites blocked by crystal packing. 
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The structure presented here shows that the labelled ADP in Site-1 makes similar 
interactions as the unlabelled ADP. The C-ADP bound at Site-3 adopts a slightly different 
conformation to that in the ADP-bound structure; however the same volume of space is 
occupied and the stability of the protein is unaffected. In both sites additional contacts 
between the protein and the coumarin moiety were present: this is important because the 
coumarin group is attached to the ADP through the ribose group. Such contacts are 
necessary since they form the basis of the signal change upon C-AXP binding to the protein. 
It was long suspected that the fluorescence contribution of C-AXP’s bound at the two sites 
was not equal. The coumarin moiety of the C-ADP bound at Site-3 is non-planar likely 
resulting in decreased fluorescence emission from this site (295).  
Only two tryptophan residues are present in the -subunit. W116 is positioned close to the 
coumarin group of the ADP bound to Site-1 (the tighter site), it is likely FRET from this site is 
responsible for much of the signal observed in Section 3.4.3.4. 
 
 5.5 Conclusion 
X-ray crystallography is a powerful technique for structure determination and as a tool to 
validate protein:ligand interactions and stoichiometries. The availability of a readily 
purifiable and crystallisable protein within the Gamblin laboratory allowed me to validate a 
number of conclusions drawn from the fluorimetry work presented in Chapter 3.  
Here I showed that an AMPK truncate bound to C-ADP with a stoichiometry of 2:1 and at the 
same sites as unlabelled ADP. No non-specific binding was observed nor any significant 
changes to the proteins structure or stability.  
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 Chapter 6:  SNF1 Summary 
SNF1 is the S.cerevisiae AMPK ortholog, similar to AMPK it plays a role in managing cellular 
energy homeostasis (Appendix 1.1.2). SNF1 is a heterotrimer comprising -like (Snf1), -like 
(Gal 83, Sip1, and Sip2) and -like (Snf4) subunits (Appendix 1.1.3 and Figure 59).  
Unlike AMPK, SNF1 is not regulated by AMP but recently the Carling laboratory 
demonstrated ADP protection of T210 (equivalent to T172 in AMPK)  
from dephosphorylation by phosphatases (Appendix 1.1.4) (2).  
 
In parallel to the work studying AMPK, I characterised the binding of nucleotides to SNF1 
and the enzymes regulation by ADP using the techniques described in Chapters 3 and 4.  
Due to space constraints the major conclusions of this work are described here and 
summarised in Figure 55, while the methods and results are given in Appendix 1.2. 
 
Similar to AMPK, SNF1 binds two exchangeable nucleotides, however the yeast enzyme 
binds AXP much more weakly than AMPK (Appendix 1.2.2).  Kd values of around 80M and 
1150M (dependent on phosphorylation state of the sample) were determined for the 
tighter and weaker sites respectively (Table 17 and Table 18). The tighter site also binds 
NADH with an affinity of ~7M, a crystal structure of SNF1 confirms that this is Site-4 of the 
Snf4-subunit (Figure 65)(2).  
 
Unfortunately, the identity of the weaker site could not be determined via crystallography, 
likely due to the weak nature of the AXP:SNF1 interaction (2). Attempts to mutate AXP 
binding sites, with the aim of specifically ablating AXP binding at a single site and thus 
determining which is the second exchangeable site, were not successful (Appendix 1.2.2.1). 
217 
 
CD of wild-type and mutant proteins confirmed that the samples had similar secondary 
structure content (Appendix 1.2.3). It is thought that the inability to knock-out binding at 
each site is a homologous phenomenon to that described in relation to the AMPK mutants  
(see Section 1.2.2.1).  
 
In Chapter 3 weaker binding of Mg.ATP relative to Mg2+-free AXPs to AMPK was described.   
SNF1 was also found to bind Mg.ATP more weakly than AXPs (Appendix 1.2.2). In fact 
Mg.ATP probably binds SNF1 too weakly, particularly at the second site, for this to be 
physiologically relevant.  This raises the interesting possibility that SNF1 acts directly  
as an ADP sensor. 
 
Protection against T210 dephosphorylation by ADP was demonstrated using the NADH 
coupled spectrophotometric assay described in Section 4.2.4 (shown in Appendix 1.2.4).  
As NADH binds at the tighter site (Site-4) and does not compete with this regulatory effect, 
it seems that the weaker, but as yet unidentified, binding site mediates regulation of  
kinase activity (2).  
 
ADP occupancy of the regulatory site over the concentration range used in the in vitro 
coupled assay was modelled.  Occupancy of the weaker second site correlated with the 
dose-dependence of ADP protection against dephosphorylation, supporting the assignment 
of regulatory function to ADP binding at the weaker AXP site (Appendix 1.2.5). 
No extensive attempts to model regulatory site occupancy given S.cerevisiae intracellular 
nucleotide (mM) and Mg2+ concentrations were undertaken, some simulations were 
performed to demonstrate that SNF1, most probably, acts directly as an ADP sensor as the 
weaker site is never completely saturated by nucleotide (Appendix 1.2.5).  
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Figure 55: Summary of the AXP binding affinities and their regulatory roles in SNF1. 
Ribbons representation of the SNF1 Snf4 subunit with one bound ADP molecule  
(PDB ID: 3T4N). The four potential AXP binding sites are labelled. The average Kd values for 
AXP and Mg.ATP interaction at the tighter exchangeable Site-4 and the weaker second site  
(as determined by C-ADP displacement – Table 17), are indicated. The location of the 
weaker AXP binding site is unknown, but binding of ADP at this second site is thought to 
mediate protection against T210 dephosphorylation. 
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 Chapter 7: Discussion 
AMPK has emerged as an integral regulator of cellular and whole body metabolism.  
By reacting to multiple stimuli AMPK is an important point of signal integration;  
sensing changes in cellular metabolism and coordinating a plethora of downstream responses.  
Upon activation, AMPK acts to minimise energy expenditure (by inhibiting processes such as 
protein synthesis, cell proliferation, fatty acid and glycogen synthesis) and maximise energy 
production (through increasing the supply of, and consumption of, lipids and 
carbohydrates). Thus, AMPK activates enzymes involved in the uptake and oxidation of  
fatty acids and glucose.  
 
Regulation by ADP 
AMPK was named on the basis that AMP regulates the activity of the kinase.  
Subsequently, ATP was shown to inhibit this activation and it was therefore proposed that 
AMPK responds to increases in the AMP:ATP ratio during periods of cellular energetic stress. 
In 1995 Davies et al showed that in addition to allosterically activating AMPK, AMP also 
protected T172 (the residue critical in activation) against dephosphorylation  
by phosphatases (164).  
For a number of years the role of ADP in the regulation of AMPK was largely ignored. 
Recently, the Carling laboratory re-examined the role of ADP and consistent with previous 
studies found that ADP did not allosterically activate the enzyme. However, ADP was shown 
to protect AMPK T172 from dephosphorylation by phosphatases,  
in a manner similar to AMP. In parallel, they were also able to demonstrate that ADP 
protected the S.cerevisiae homologue of AMPK, SNF1, from dephosphorylation of T210 
(equivalent to T172 in AMPK).  
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ADP is present in the cell at a higher concentration (100-200M) than AMP but lower than 
ATP (3-8mM) (1, 275, 279-281). It has always been difficult to understand how low (1-5M) 
cellular concentrations of AMP could compete with ATP (3-8mM) for binding to the same 
sites on AMPK. Given that the cellular concentration ADP is around 102 greater than AMP,  
it is a more feasible candidate to compete with high concentrations of Mg.ATP.  
I argue that ADP is likely to be the key regulator of AMPK in vivo where modulation of the 
rate of dephosphorylation is critical in determining the fraction of AMPK which is activated 
(as the major upstream kinase, LKB1, is constitutively active). 
 
In order to complement the observation that ADP regulates both AMPK and SNF1,  
and to address the issue of ADP competition with ATP, this project aimed to characterise the 
interactions of AXPs with both enzymes; determining the stoichiometry of those 
interactions and the associated equilibrium dissociation constants. 
 
Through displacement of fluorescently labelled nucleotides, affinities for AXP (± Mg2+) were 
determined. Binding of C-ADP to Site-1 and Site-3 of a truncated AMPK complex was 
confirmed through crystallography (Chapter 5). For both AMPK and SNF1 it was found that 
C-AXPs and AXPs bind exchangeably at two sites but each with significantly different 
affinities. Mg.ATP binds more weakly than free ATP to both enzymes (as summarised in 
Figure 56 and Figure 55). This relatively low affinity for Mg.ATP is important in explaining the 
competitive binding of regulatory nucleotides in vivo where Mg.ATP concentrations are very 
much greater than those of AMP/ADP (Chapter 3).  
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Figure 56: Summary of the AXP binding affinities and their regulatory roles in AMPK. 
Ribbons representation of the mammalian -subunit with three bound AMP molecules  
(PDB ID: 2V8Q). The four potential AXP binding sites are labelled. The average Kd values for 
AXP and Mg.ATP interactions at the exchangeable sites (as determined by C-ATP 
displacement  -Table 7) and the proposed regulatory roles, are indicated. 
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In addition to the use of fluorescently labelled nucleotides, displacement of NADH was used 
to study AXP interactions with AMPK. NADH binds at the tighter nucleotide binding site, 
Site-1. This is thought to be in the tighter site because 1:1 molar equivalent soaks of AMPK 
crystals consistently produce electron density maps with occupancy of Site-1 and not Site-3.  
Using a coupled spectrophotometric assay NADH was shown to compete with the allosteric 
activation of AMPK by AMP, but not with AMP/ADP protection against T172 
dephosphorylation. My conclusion, therefore, is that binding of AMP at Site-1 mediates 
allosteric activation, whilst binding of AMP/ADP at Site-3 mediates protection of T172 
against dephosphorylation (indicated in Figure 56) (Chapter 4).  
 
Attempts were made to mutate Site-1 and Site-3 of AMPK (Chapter 3) in order to eliminate 
AXP binding at single sites and thus confirm assignment of distinct regulatory roles to the 
relevant sites. A number of point mutants were tested but in no case was specific AXP 
binding abolished. Significantly, mutants in which a conserved Asp residue, known to 
coordinate the ribose hydroxyls, was mutated to Ala, did not abolish AXP binding.  
The fact that these mutations do not eliminate binding in the expected manner, suggests 
that the aspartate:ribose interactions are not critical for AXP binding. In other studies these 
mutants have been assumed (without being tested) to specifically ‘knock-out’ binding at 
each site (177), an assumption which may not be valid. 
It is clear that residues from more than one CBS provide contacts to a single AXP.  I suggest 
that because the -subunit is a flat disc-shaped structure and that networks of residues within 
the ‘core’ interact with AXP bound at sites other than that to which they are nominally 
assigned, it is unsurprising that a particular mutant has effects beyond the site of mutation.  
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Recently, Chen et al described a number of -subunit point mutants which reduced allosteric 
activation of AMPK. Only mutants directed at Site-3 and Site-4 produced this phenotype, 
suggesting that it is not Site-1 which mediates allostery, as proposed in this thesis and 
elsewhere (1, 144). However, Chen et al (2012) described no measurement of the binding 
affinity or stoichiometry of nucleotide interactions, nor was the effect of mutation on 
protection against dephosphorylation reported. It is more than possible that mutation of 
Site-3 and Site-4 resulted in reduced nucleotide binding at Site-1; as demonstrated in 
Section 3.4.3.5, and described in the previous paragraph. It is difficult to design  
‘AXP site-specific’ mutants.  
 
A program was designed to model occupancy at the two exchangeable nucleotide sites 
based upon the Kd values determined experimentally. Firstly, aiming to simulate the in vitro 
activity assays and regulation by nucleotide, and secondly to demonstrate whether likely 
physiological concentrations of AMP and ADP would be capable of competing with Mg.ATP. 
 
First, the equilibrium dissociation constants determined in this study were used to calculate 
occupancy of AMPK binding sites under the conditions of the in vitro assays employed in 
studying allosteric activation and protection against dephosphorylation  
(where concentrations of the AXPs are, of course, known). Occupancy of AMPK Site-1 by 
AMP correlated with the concentration dependence of allosteric activation, whilst 
occupancy of Site-3 by AMP correlated with the dose dependence of protection of T172 
against dephosphorylation. Therefore, the modelling and experimentally determined Kd 
values support the assignment of the regulatory functions of the two AXP binding sites  
(Chapters 3 and 4).  
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Further modelling studies were performed in which site occupancy was determined from 
plausible estimates for intracellular nucleotide and magnesium concentrations (outlined in 
Chapter 4). Despite the relative increase in AMP concentration (1 to 5M) being greater 
than that of ADP (50 to 200M), it is the absolute concentrations that determines the 
occupancy of the binding sites. As such the potential occupancy of ADP is much greater  
than that of AMP. 
The occupancy of both Site-1 and Site-3 by AMP was minimal (less than 0.4%). This suggests 
that perhaps AMP regulation, is not an important mechanism of AMPK activation in a 
cellular setting. However, as both AMP and A-769662 allosterically activate and glycogen 
allosterically inhibits AMPK, this phenomenon is hardly likely to be an artefact;  
but the mechanisms by which it works remain, for the moment, obscure. 
 
Occupancy of Site-3 by ADP was found to be more significant (2.68%) despite competition 
for binding by Mg.ATP. Furthermore, ADP occupancy of this site was increased 4-fold when 
'stressed' AXP concentrations were used in the modelling (to 10.14%). This modelling, based 
upon the Kd values measured in Chapter 3, clearly demonstrates that ADP has the potential 
to bind to, and regulate, a proportion of cellular AMPK in response to changes in  
cellular nucleotide ratios.  
The mitochrondrial uncoupler, DNP in conjunction with sorbitol, rapidly alter the cellular 
ADP:ATP ratio and thus potently activate AMPK. Together these compounds activated AMPK 
12-fold relative to untreated cultured muscle cells. This suggests that roughly 8% of AMPK 
might be active under normal conditions. This figure is in the same range (2.5-10%) 
estimated in my studies.  
The modelling does, of course, have a number of limitations, not least the uncertainty 
surrounding the cellular AXP/Mg2+ concentrations which are cell-type dependent. It is also 
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unclear how to couple binding site occupancy to kinase activation, without first knowing the 
relative rates of phosphatase activity with respect to the ADP-bound and unbound 
AMPK(T172). Furthermore, for modelling of the system, it will be necessary to know what 
the basal level of cellular AMPK activity is and what increase in active AMPK is required for 
downstream responses to occur. And, of course, these values may differ in a tissue,  
stimulus and isoform dependent manner. 
 
 
In parallel to these studies, the Gamblin laboratory determined the structure of an active 
mammalian AMPK complex (12(GBD)1), which suggested a potential mechanism 
through which T172 could be protected against dephosphorylation (summarised in  
Figure 57). The phosphorylated T-loop, ordered in this structure, interacts with the  
-subunit and forms a number of contacts which stabilise the loop. In this conformation, 
access to the phosphorylated residue by phosphatases is blocked. The idea is that this 
protected state is promoted by AMP/ADP binding and results in protection against T172 
dephosphorylation. It is suggested that in the Mg.ATP bound form the T-loop is not 
stabilised through interaction with the -subunit and is therefore more accessible to 
phosphatases/inactivation.  
A second interesting feature of this crystal structure was the presence of a loop (known as 
the -hook), situated in the linker joining the N-terminal kinase domain with the C-terminal 
scaffold domain. The -hook interacts with the -subunit, forming a partial lid over the  
Site-3 AXP binding site. It is thought that the binding of regulatory AMP/ADP to Site-3 
facilitates binding of the -hook. Interaction of the -hook with the -subunit is thought to 
restrict the flexibility of the preceding -linker region and, in doing so, promote binding of 
the kinase domain to the regulatory subunit and therefore protect T172 from 
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dephosphorylation. Upon occupancy of Site-3 by Mg.ATP, the-hook is unable to bind to 
the -subunit owing to steric clashes between the -phosphate and the -hook.  
It is proposed that dissociation of the hook, increases flexibility of the -linker, destabilising 
the T-loop/-subunit interface and ultimately resulting in the kinase domain becoming 
flexibly tethered to the rest of the heterotrimer (summarised in Figure 57). It will be 
interesting in the future to determine the on/off rates which describe the interchange 
between the bound/unbound (active/inactive) state of the -kinase, and how they differ in 
the presence of regulatory nucleotides. It is probable that the variation in thermostability, 
tertiary structure and mobility observed via CD and MALLS were due to differences in the 
overall architecture of the bound/unbound kinase AMPK structures. 
 
It is unclear how the AID, crystallised in an isolated kinase structure but not featuring clearly 
in the 12(GBD)1 structure, fits into this model of AMPK regulation. Perhaps the 
autoinhibited kinase structure exists when the -kinase is flexibly tethered to the rest of the 
heterotrimer offering an extra level of AMPK regulation.  
 
An important question that remains from these studies is how AMPK is allosterically 
activated by AMP binding at Site-1 but not by ADP/ATP.  From an energetic consideration 
only a small change in the structure might be required to mediate this activatory effect, 
perhaps as little as the introduction of an additional hydrogen bond.  
 
SNF1 
Displacement of fluorescently labelled nucleotides (C-ATP) and NADH was also used to 
determine equilibrium dissociation constants for the interaction between SNF1 and AXP. 
SNF1 was found to bind two AXP’s exchangeably, with one site having significantly higher 
affinity than the other (Appendix 1).  
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NADH binds SNF1 at Site-4 (verified in a crystal structure (2)), the tighter of the two  
AXP binding sites. Similarly to AMPK, NADH does not compete with the protective effect of 
ADP against dephosphorylation, suggesting that it is the second, weaker, nucleotide binding 
site which mediates this effect in SNF1 (indicated in Figure 55) (Appendix 1). Probably owing 
to the very weak AXP binding at the second site (>1mM), crystallographic studies were 
unable to reveal its identity.  
The interaction between Mg.ATP and SNF1 at the weaker site could not be determined in 
these studies (>1mM), and is perhaps too weak to be physiologically relevant, given 
intracellular Mg.ATP concentrations in the millimolar range.  This suggests that SNF1 acts 
directly as an ADP sensor (Appendix 1).  
 
AMPK Regulation 
The present study was undertaken to determine the relationship between AMPK activity 
and regulation by nucleotides. However, in a cellular context the system is more complex. 
Glycogen, for example, is an allosteric inhibitor of AMPK activity perhaps acting by reducing 
access of substrates to the -kinase. It would be interesting to determine what affect, if any, 
glycogen and the other ligands have on nucleotide binding and on the bound/unbound 
conformation of the -kinase.  
 
Changes in Ca2+ concentration also influence AMPK regulation, independent of AXP 
concentrations, through regulation of its upstream kinase, CaMKK. Whilst some stimuli 
may only influence Ca2+ or nucleotide levels, most stresses, e.g. exercise, are likely to cause 
simultaneous activation of AMPK through both pathways. In many instances there is a close 
relationship between changes in Ca2+ and nucleotide levels, providing complementary 
pathways to activate AMPK.  
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Figure 57: Model of AMPK regulation. 
It is suggested that interactions of the -hook (dark blue) with Site-3 restricts the flexibility 
of the -linker (dark blue) promoting interaction of the -kinase (yellow) with the  
-subunit (green). In this bound conformation the T-loop (pink loop) is stabilised and T172 
protected from dephosphorylation. The T-loop is phosphorylated at T172 by upstream 
kinases and dephosphorylated by phosphatases, the rates of these reactions is as yet 
undetermined and depends on the bound/unbound conformation of the -kinase. 
Nucleotide binding to the -subunit affects the proportion of bound/unbound -hook, and 
therefore bound/unbound -kinase domain. 
Additionally the GBD is flexibly tethered to the rest of the heterotrimer, and interacts with the 
rest of the heterotrimer, an interface overlapping the -kinase:-subunit binding surface.  
The AID (yellow loop) is also thought to interact with and inhibit the -kinase domain.   
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In addition to the ligands which regulate AMPK there are several post translational 
modifications which may alter the enzyme’s activity. The role of these modifications is still 
relatively poorly understood. For example, in the case of autophosphorylation S108A 
mutants have altered AMP regulation and decreased basal activity. Although some 
differences between AXP affinities for phosphorylated versus unphosphorylated AMPK were 
observed in Chapter 3 (in general tighter binding to the unphosphorylated form), no binding 
studies were performed with specific autophosphorylation mutants. Myristoylation of the  
-subunit has been reported to cause AMP/ADP to promote phosphorylation of AMPK.  
It would be interesting to determine whether these effects are the result of weaker 
nucleotide binding to AMPK, and if so which site mediates these effects. Or, alternatively, 
due to disruption of the mechanism through which AMP binding is transduced to the  
-kinase via the -hook.  
It is probably the case that the complex interplay between acetylation, myristoylation, 
ubiquitination, and phosphorylation/dephosphorylation of AMPK modulates its activation state. 
 
The different characteristics of subunit isoforms, splice variants etc. also affect AMPK 
regulation. -subunit isoforms and splice variants are most likely to affect the affinity of the 
heterotrimer for AXPs, potentially shifting the point at which AMPK becomes significantly 
ADP-bound and therefore activated. There are studies which show key differences in the 
AMP regulation of these isoforms, e.g. allosteric activation of 2-containing complexes is 
around 3.7-fold compared to 1.7-fold in 1-containing complexes (138). Due to the poor 
expression of the 2 and 3 isoforms, the binding of AXP to these isoforms has not  
been examined. It would be interesting to undertake biophysical and structural studies on 
these isoforms to see if they reveal anything about the differences in nucleotide  
binding and regulation.  
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-subunit isoforms regulate the localisation of the heterotrimer be it to cellular membranes 
or to glycogen, and mediate regulation by sugars and myristoylation. The -subunit also 
plays an important role in mediating the activatory effect of A-769662 and perhaps other 
pharmaceutical agents. Therefore, the different-isoforms present an important 
opportunity for targeted drug design. 
The -subunit isoforms may perhaps have altered enzymatic properties and different 
preferences with regards to their upstream kinases and phosphatases; they also have varied 
substrate specificities and different regulatory mechanisms mediated through 
phosphorylation of their C-terminal tails. Interestingly, 2-containing complexes extracted 
from cells display higher fold allosteric activation compared to 1-containing heterotrimers, 
although they seem to have similar dose-response curves (138). In the future it would be 
interesting to examine 2-containing complexes to see if they display any differences in 
nucleotide binding affinities, and to determine if 1/2 containing heterotrimers are 
protected against dephosphorylation by AMP/ADP with similar concentration dependence. 
As the model in Figure 57 demonstrates, there could be a complex interplay between 
binding of AXP, interactions of the -hook/linker and the autoinhibited state,  
which determines the bound/unbound state of the -kinase. Isoform specific differences in 
the on/off rates which describe the interchange between these conformations may have a 
significant impact on the proportion of active/inactive (bound/unbound) AMPK.  
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AMPK Activation and Effects 
Owing to the complex nature of the regulation of AMPK heterotrimers the conditions under 
which the enzyme becomes activated are unlikely to be the same in different cell-types. 
Although zero-order ultrasensitivity models, discussed in Section 4.4.2.5, predict what is 
essentially step-like activation it seems probable that the AMPK response need not be  
'all or nothing'. It is possible that regulation operates along a concentration gradient;  
at low levels of AMPK activation certain targets are phosphorylated, and as activated AMPK 
levels rise other substrates become important. Such a process may be based upon diffusion, 
localisation or substrate availability.  
With so many downstream targets, affecting a wide range of fundamental cellular 
processes, it would seem important that small fluctuations in ATP concentrations are not 
'overreacted to’ by binary AMPK activation, and that those processes which can most 
quickly to restore ATP levels are prioritised over other options which may be used as  
a long-term effect.  
It seems paradoxical that AMPK appears to either activate or inhibit a particular process 
dependent on the cell-type being studied. This is evident in the case of apoptosis,  
where activation of AMPK can either promote or inhibit cell death. One can only speculate 
as to what may underpin these observations; is it a property of the AMPK heterotrimers 
present in different tissues (i.e. differences between the subunit isoforms)? Or perhaps it is 
due to some fundamental property of the different cell-types, such as 
expression/localisation of substrates, concentrations of regulators or exposure to stresses?  
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Concluding Remarks 
The two major conclusions drawn from this work, published in Xiao et al (2011)(1)  
and Mayer et al (2011)(2), and summarised in Figure 55 and Figure 56, are; 
1) In the mammalian AMPK system, AMP binding at Site-1 mediates allosteric activation and 
AMP/ADP binding at the weaker Site-3 mediates protection against T172 
dephosphorylation. In the yeast SNF1 system ADP binding at the weaker of the two sites 
mediates protection of T210 against dephosphorylation.  
2) The somewhat weaker binding of Mg.ATP compared to ADP in both AMPK and SNF1 
systems, allows ADP to compete effectively with the high intracellular concentrations of 
Mg.ATP, thus allowing ADP to regulate both enzymes in vivo.  
 
Despite being the subject of many years of intensive study there remains a great deal which 
is unknown about AMPK, its regulation, and its cellular role. ADP certainly appears to be an 
important regulator of AMPK, and is perhaps one of the few ‘universal’ signals which 
activate AMPK. 
 
Understanding the complex interplay between the regulators of AMPK and the downstream 
effects of activation (or inhibition) on cellular activity will ultimately require a much more 
sophisticated modelling study than that possible in this Thesis (Chapter 4). However,  
it seems probable that integration of the wealth of information available about AMPK, 
particularly its regulation and activation, into a single model will be important in 
understanding the threshold at which AMPK is activated in a cellular environment.  
Coupling such a model of AMPK regulation to modelling of stimulation/inhibition of the 
multiple downstream effectors will potentially reveal how crosstalk between  
AMPK-regulated pathways controls so many central cellular processes.  
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 Appendix 1: Nucleotide binding to SNF1 
 1.1 Introduction 
 1.1.1 Overview 
In 1981, SNF1 serine/threonine protein kinase was genetically identified in a screen of 
S.cerevisiae strains unable to utilise sucrose as a carbon source (snf, sucrose-
nonfermenting). Mutants had defects in the expression of the SUC2 gene which encodes the 
sucrose degrading enzyme, invertase (6). Although AMPK was named in 1988, its orthology 
to SNF1 was not apparent until cDNA encoding an AMPK  domain was cloned in 1994.  
The convergence of the yeast and mammalian studies marked the creation of the  
AMPK family (6). SNF1 is activated by phosphorylation of T210 and inactivated by 
dephosphorylation of this residue (summarised in Figure 58). 
 
 1.1.2 SNF1 cellular targets/activity  
SNF1 kinase activity focuses on adaption to glucose limitation and the response to  
cellular stresses. It also has roles in nutrient responsive developmental processes  
(e.g. meiosis and sporulation), ageing and haploid invasive growth (296). These actions are 
carried out through transcriptional regulation and direct activation of effector molecules.  
 
Yeast cells principally metabolise glucose and other sugars as their energy source.  
However they are capable of adapting to changes in the available carbon-sources in the 
environment. Nutrient-induced signalling networks allow rapid adaption to changes in 
conditions and derepression of these processes is crucial for adaption and survival.  
Glucose is known to repress genes involved in the metabolism of non-preferred carbon 
sources and to induce those involved with its usage, for example glycolytic enzymes.  
The SNF1 pathway is one of three glucose sensing systems, the others operating through 
Snf3/Rgt2 and cyclic AMP.  
The SNF1 heterotrimer is involved in the transcriptional activation of glucose-repressed and 
inhibition of glucose-induced gene sets, through the phosphorylation of transcriptional 
activators and repressors e.g. Sip4, Cat8 and Mig1, or by stimulating the transcriptional 
machinery directly. For example, in Snf1 mutants Mig1 remains in the nucleus rather than 
translocating to the cytoplasm upon glucose depletion, thereby the glucose-repressed state 
of numerous genes is maintained (297). Significant glucose repression is still observed in 
snf1 mig1 double knockout cell lines, demonstrating the functional redundancy of multiple 
pathways in glucose inhibition (298). 
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Additionally, SNF1 kinase regulates a number of metabolic pathways during nutrient 
limitation. Nutrient limitation leads to an increase in glycogen synthesis brought about 
through dephosphorylation and thereby activation of glycogen synthase (GS) (the enzyme 
responsible for 1 4 glycogen chain extension) by the GAC1/Glc7 phosphatase complex. 
SNF-mediated phosphorylation of this phosphatase is key in its activation. SNF1 also 
phosphorylates and inhibits GS kinase Pho8, an enzyme which inactivates GS (299).  
Both SNF1 and its substrates are localised to glycogen during nutrient limitation.  
SNF1 has also been shown to inhibit anabolic pathways such as lipid biosynthesis during 
periods of nutrient limitation, an activity which is homologous to the mammalian AMPK. 
SNF1 negatively regulates acetyl-coA carboxylase, the first enzyme of the fatty acid 
synthesis pathway (300). SNF1 is also responsible for upregulation of the INO1, the  
gene-product of which is required in a rate limiting step of inositol-containing phospholipid 
biosynthesis; as a consequence snf1Δ mutants are auxotrophs for inositol (301).  
 
In yeast cells stress factors influence a wide range of cellular functions in a ‘general  
stress response’. These stress factors regulate the co-ordinated induction of many stress 
genes through the presence of a conserved cis-element in their promoters, namely the 
Stress Response Element (STRE). Two factors, Msn2 and Msn4 regulate this element. 
Mutant cell lines deficient in negative regulators of SNF1 (e.g. reg1Δ) have abnormally active 
SNF1, and during periods of carbon starvation this activity inhibits the nuclear import of 
Msn2, reducing the cellular stress response. However osmotic and heat-shock induced Msn2 
import is not affected ,suggesting stress-dependent differences in the processes regulating 
Msn2 translocation (302).  
Snf1Δ mutants show severe growth defects when grown in the presence of 1.2M NaCl or 
0.3M LiCl, demonstrating a link between SNF1 activity and salt stress (299). It is thought that 
SNF1 is involved in the regulation of ENA1 expression, the gene-product of which is a P-type 
ATPase involved in the extrusion of Na+ from the cytosol (303).  
It is clear that the SNF1 enzyme has a central role in maintaining the viability of yeast cells, 
particularly in the response to changes in the extracellular environment, particularly 
nutrient availability. 
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 1.1.3 SNF1 subunits 
Similar to the mammalian AMPK enzyme, SNF1 is a complex formed of three subunits the 
equivalent of the AMPK  subunits, arranged with 1:1:1 stoichiometry (summarised in 
Figure 59). Formation of the heterotrimer is independent of glucose availability (304).  
All three subunits are required for activity (305).  
 
The  subunit 
The Snf1 () catalytic subunit is constitutively expressed from the SNF1 gene (Figure 59) 
(306). The N-terminal catalytic domain has a classic bi-lobal kinase fold as described 
elsewhere (Appendix 1.4.2) (129, 307). 
A C-terminal regulatory domain mediates interaction with the kinase domain, the Snf4 () 
and  subunits, and with the Glc7-Reg1 phosphatase complex. There is also a short 
unconserved sequence N-terminal to the kinase domain containing a stretch of 13 
histidines which do not appear to be essential for function (304). An AID has been 
defined through mutational analysis. This sequence lies between residues 381 to 414 in the 
central portion of the protein. Residues in this region have also been implicated in the  
reversible interaction, which is thought to regulate the kinase’s catalytic activity (308). 
Deletion of the AID increases kinase activity (308) and relieves the requirement for Snf4 to 
activate Snf1 (309). The extreme C-terminal region (515-633) of Snf1 is required for 
interaction with  subunits (308).  
Activation of the Snf1 kinase requires phosphorylation of T210 by upstream kinases, its 
mutation to alanine results in a phenotype similar to that of the SNF1 mutant (310). 
Furthermore, complex formation with the β and  subunits is essential for kinase activity 
even when T210 is phosphorylated (305). 
 
SNF1 has been shown to phosphorylate the SAMS peptide in vitro (300). SNF1 and AMPK are 
thought to have similar but distinguishable substrate recognition motifs. If anything SNF1 
has a more stringent substrate specificity than AMPK defined as n-X-R-X-X-S-X-X-X-n  
(n = hydrophobic residue, X = any residue). (267, 311). 
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The  subunits 
The S. cerevisiae genome encodes 3 -subunits; Sip1, Sip2 and Gal3 (Figure 59). The relative 
abundance of the -subunits is regulated by glucose availability with Gal83 being the major 
isoform, Sip2 expression increasing during growth on non-fermentable carbon sources,  
and Sip1 concentrations remaining comparatively low throughout (312).  
The isoforms have different preferences for phosphorylation by Sak1, Tos3 and Elm1 
upstream kinases (discussed in Appendix 1.1.4). The -subunit is key in the association of 
the heterotrimeric complex (305). In the absence of a -subunit, Snf4 is unable to associate 
with Snf1, although similarly in the absence of Snf4 only trace amounts of -subunit interact 
with Snf1 (305). 
 
SNF1 has been shown to localise to glycogen via its -subunit GBD motif and through 
association with Reg1, a regulatory subunit of the Glc7 phosphatase which is also localised 
to glycogen, and which is thought to dephosphorylate SNF1. The isoforms have different 
affinities for glycogen binding with Gal83 binding strongly in vitro and Sip2 very weakly 
(296). Mutations in the GBD result in disregulation of the kinase, relieving glucose inhibition 
of SNF1 and therefore upregulating SNF1 dependent processes such as glycogen 
accumulation and expression of GS and Sip4 activation (161, 313, 314). 
 
The N-terminal sequences are divergent and confer subcellular localisation patterns of the 
SNF1 heterotrimer. In glucose loaded systems all three isoforms are cytoplasmic,  
upon glucose depletion Sip1 localises to the vacuolar membrane (requiring N-terminal 
myristoylation), Gal83 to the nucleus and Sip2 remains cytoplasmic (312).  
Both Sip1 And Sip2 are thought to be N-terminally myristoylated (296). The -subunits are 
both also auto-phosphorylated by Snf1 and phosphorylated by other kinases (for example 
Casein Kinase II) although it remains unclear what role this plays in regulating the complex 
(315). Sip2 is also thought to be acetylated in an age-dependent manner (316). 
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The  subunit 
 Snf4 is homologous to the AMPK -domain. It is a constitutively expressed protein of 331 
residues that is capable of binding to the Snf1 and -subunits as previously discussed  
(Figure 59) (317). It is required for catalytic activity of the heterotrimeric kinase complex both 
in vivo and in vitro (300). Snf4 cells exhibit a similar phenotype to that of Snf1cells (318).  
 
 Snf4 consists of four CBS domains forming two Bateman domains, which are capable of 
adenine nucleotide binding (319). Both the S.cerevisiae and S.pombe Snf4 subunits have 
been crystallised and show extensive structural homology with the mammalian  subunit 
(described in Appendix 1.4.4)(2, 143, 188, 189). Similar to AMPK four presumptive 
nucleotide binding sites exist, however in Snf4 only two are thought to bind nucleotides. 
Binding of nucleotides at the weaker site regulates the kinase as described in Appendix 1.1.4. 
 
 1.1.4 Regulation of SNF1 
SNF1 is rapidly activated by phosphorylation of T210 on the activation loop of the Snf1 
kinase domain in response to glucose limitation (296). This activation is transient, that is, 
after adaptation minimal SNF1 activity is required for continued growth in the glucose 
limited environment (320). Phosphatase mediated dephosphorylation is responsible for 
inactivation of the kinase (summarised in Figure 58).  
The upstream kinases and phosphatases of SNF1 and AMPK retain cross-species activity 
indicating some structural and functional conservation between the mammalian and  
fungal pathways (321). 
 
Upstream kinases 
Three upstream kinases were identified through a combination of genetics screens and 
mass spectrometry of affinity purified protein complexes (147, 322, 323). Snf1 T210 is 
phosphorylated by three related upstream kinases; Snf1 activating kinase-1 (Sak1),  
Elm1 and Tos3 (296). These kinases are highly similar and functionally redundant; only triple 
mutant cell lines share a phenotype with Snf1. These enzymes are not thought to be 
glucose regulated but seem to be differentially active dependent on carbon-source 
availability. Sak1 is the major activating kinase, it forms a stable complex with the  
SNF1 kinase (324). Elm1 and Tos3 form more transient interactions with SNF1 (325).   
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Figure 58: SNF1 kinase cycle.  
Phosphorylation of SNF1 by upstream kinases results in a fully active kinase complex. 
Dephosphorylation by the relevant phosphatases returns the protein to an inactive state. 
ADP binding to Snf4 protects T210 from dephosphorylation by phosphatases. 
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Figure 59: Domain schematic of SNF1 subunits.  
Abbreviations: AID: autoinhibitory domain, GBD: Glycogen Binding Domain (also referred to 
as the carbohydrate binding module), CBS: Cystathionine β-synthase.   
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SNF1 Phosphatases 
Dephosphorylation of T210 is catalysed by the PP1 family phosphatase Glc7, complexed 
with a regulatory subunit; Reg1. Multiple regulatory subunits are known to bind Glc7 and 
mediate its roles in numerous pathways. T210 is dephosphorylated in glucose-rich 
conditions by Glc7 (326), and in Reg1 mutant cell lines this effect is lost (321).  
In fact in Reg1 and Glc7 cell lines SNF1 is constitutively active (327).  
A number of yeast two-hybrid and co-immunoprecipitation studies have shown 
phosphorylated T210 dependent binding between Reg1 and Snf1 (327, 328).  
Reg1 is cytoplasmically localised in both glucose-rich and glucose-limited conditions (329).  
In the original model it was suggested that the SNF1:Reg1 interaction targets the kinase to 
glycogen particles where the Glc7 phosphatase is localised. Upon SNF1 dephosphorylation 
Reg1 dissociates and inactive SNF1 is released to the cytosol (327). Reg1 is phosphorylated 
in a SNF1-dependent manner allowing dissociation of the Glc7:Reg1 complex and perhaps 
stimulating Glc7 phosphatase activity (330). More recent data suggests that the Reg1:SNF1 
and Reg1:Glc7 interactions require the same binding surface, and that the interactions 
between Reg1, Glc7 and SNF1 must be more dynamic than originally thought (331).  
 
There is substantial evidence that the Glc7:Reg1 complex dephosphorylates SNF1 in vivo, 
however recently a second phosphatase has been implicated in SNF1 regulation.  
Sit4, a PP2A-like phosphatase was more recently implicated in T210 dephosphorylation 
(332). SNF1 and Sit4 were shown to co-purify, and T210 phosphorylation increase in Sit4 
mutants. PP2A family members have previously been shown to inactivate AMPK and SNF1  
in vitro (300).  
 
Regulation by nucleotide 
Regulation of SNF1 by AMP, either allosteric or through protection against 
dephosphorylation, has not been reported previously even at high AMP concentrations  
(2, 179, 300). However SNF1 activity has been shown to correlate with the cellular AMP:ATP 
ratio and mutations throughout the CBS domains disrupt activity (161, 333). For many years 
it remained a mystery as to why there was an apparent lack of nucleotide regulation of 
SNF1. Recently, it was shown by members of the Gamblin/Carling laboratories that ADP binding 
to Snf4 activates the SNF1 kinase through protecting T210 from dephosphorylation (2).  
This nucleotide protects T210 against dephosphorylation by a wide-range of phosphatases 
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both in vitro and in vivo, although it remains unclear which nucleotide binding site is 
responsible for this regulation (2). A simple model for Snf4 regulation of Snf1 kinase would 
be that ADP binding prevents the AID binding to the kinase domain, a conformational 
change regulated in some way by glucose availability (328).  
 
Although no direct measurements of interactions between nucleotides and SNF1 have 
previously been reported crystal structures of the Snf4 subunit are bound by AXP’s (Table 2, 
Figure 60). The S.pombe Snf4 subunit binds to two nucleotides at Site-2 and 4.  
This work demonstrated that AMP and ATP competitively bind at the same site, and that 
whilst Snf4 does not bind GMP it does bind cAMP (142, 188). No biochemical information 
about the AXP regulation of this homolog is available; it is therefore unclear what the 
relevance of this binding is physiologically. In crystal structures the S.cerevisiae Snf4 subunit 
binds nucleotide at a single site, Site 4.  As both the mammalian and the S.pombe analogues 
are known to bind at least two nucleotides it is possible that the crystallisation conditions, 
truncated construct or low affinities precluded nucleotide occupancy of a second site.  
 
 1.2 Results and Discussion 
 1.2.1 Expression of recombinant SNF1 complexes 
A Snf1(50-633), Sip2(101-415)Snf4 construct was used throughout these studies. The Sip2 isoform 
was used in preference to Gal83 in order to complement the S. cerevisiae crystal structure 
determined within the Gamblin Laboratory (2).  
 
Expression of recombinant AMPK is a well characterised system. The SNF1 subunits were  
co-expressed as described in Chapter 2 and transformed into a competent E.coli cell line. 
Recombinant SNF1 protein was affinity purified via the N-Terminal Snf1 polyhis-tag and 
further purified by size-exclusion chromatography (see Chapter 2). Figure 61 shows the 
product of SNF1 expression, purification and phosphorylation resolved by SDS-PAGE. 
 
The complex was phosphorylated in vitro with CaMKKas described for mammalian AMPK 
in Section 2.2.4 Although this is the mammalian upstream kinase it has previously been 
demonstrated to effectively phosphorylate the critical T210 residue positioned on the 
kinase activation loop (179).  
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Figure 60: Overlay of S.cerevisiae and S.pombe Snf4 subunits from two angles.  
Cartoon representations of S.cerevisiae Snf4 (pink) complexed with ADP (yellow sticks) (PDB 
ID: 3T4N) and S.pombe SNF4 (blue sticks) complexed with ADP and ATP (orange)  
(PDB ID: 2QRD). Sites are as numbered. 
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Figure 61: Purified, phosphorylated recombinant SNF1 (Snf1(50-633), Sip2(101-415)Snf4). 
The purified protein was resolved on a 12-14% SDS-PAGE Novex gel and stained with 
InstantBlue. The molecular weight markers are indicated on the left (kDa) and the identity of 
the bands on the right.  
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 1.2.2 Binding of nucleotides to SNF1 
A similar approach to that described in Chapter 3 was taken to determine the binding 
constants of nucleotides interacting with the SNF1 heterotrimer. 
 
Similar to AMPK the Snf1 subunit has an Mg.ATP binding pocket within its kinase domain.  
C-AXP’s did not compete for binding with staurosporine to mammalian AMPK, and the 
literature suggests that ribose-modified nucleotides do not bind to kinase Mg.ATP-binding 
pockets. Therefore it was assumed that C-AXPs did not bind to the Snf1-subunit and no 
controls in the presence of staurosporine were performed.  
 
C-ADP and C-ATP were used as probes to monitor nucleotide binding (Figure 13d).  
Upon binding SNF1 C-ATP undergoes a larger fluorescence change compared to C-ADP 
(Figure 62). In fact C-ATP produced a larger fluorescence enhancement upon protein binding 
than C-ADP in all the experiments described in this thesis. 
 
It was possible to demonstrate a stoichiometry of at least 2:1 by performing titrations at low 
temperatures and in the absence of salt, 2 values improved between 10- and 25-fold when 
fitting to a two-site rather than a one-site model (Table 16). Binding of nucleotides to SNF1 
is much weaker than to AMPK in general and it is impossible to rule out the possibility that 
KdII represents the weak binding of nucleotide at more than one site. However due to the 
statistical improvement upon fitting to a two-site model, the predicted homology with 
S.pombe Snf4 and the AMPK -subunit which both bind two exchangeable nucleotides, and 
the regulatory data it was decided to assume nucleotide bound at two sites.  
Equilibrium dissociation constants at 20oC in the presence of 100mM salt were determined 
as described in Section 3.3.1 (Figure 63). Unphosphorylated SNF1 bound C-AXP tighter than 
the phosphorylated form (Table 16). Displacement titrations with C-ADP were performed to 
define equilibrium dissociation constants for AXP binding (Table 17). 
 
NADH also proved to be a useful reporter for AXP binding to SNF1. NADH binds to SNF1 with 
1:1 stoichiometry with equilibrium dissociation constants in the low micromolar range 
(Table 16). The binding of NADH to SNF1 is significantly stronger than to AMPK. 
Displacement titrations produced dissociation constants for AXPs which were consistent 
with the tighter C-ADP site (Figure 64 and Table 18). Crystallographic studies suggest that 
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NADH binds in Site-4, and therefore that this is the ‘tight’ nucleotide binding site  
(Figure 65)(2). It is unclear to which site the second ‘weak’ nucleotide binds. NADH does not 
compete with ADP regulation of SNF1, therefore nucleotide binding to the second weaker 
site must be responsible for mediating this effect (2). 
 
Under S.cerevisiae physiological conditions, most of the ATP, and some of the ADP, is 
complexed with magnesium. Therefore, the effects of magnesium on nucleotide binding 
were explored. Experiments with C-ADP and C-ATP binding to phosphorylated SNF1 
demonstrated that magnesium does weaken binding since it ‘flattens’ the binding curve 
(Figure 66). Analysis of the curves is difficult but estimates of Kd values were obtained  
(Table 19 and Figure 66). Binding of C-ATP at the ‘tight’ site (Site-4) was weakened around  
4-fold in the presence of 5mM MgCl2, whilst a robust binding constant for Mg.C-ATP at the 
second site was undeterminable but is greater than 500M (much weaker than free C-ATP).  
AXP binding to SNF1 is significantly weaker than for C-AXP’s; AXP’s bind SNF1 around  
8-10 fold weaker at the tight site (Site-4), and 25-40 fold weaker at the second site 
compared with the corresponding C-AXP. These data suggest that the binding constant for 
Mg.ATP at the second, regulatory, site is too weak to be physiologically relevant (discussed 
further in Appendix 1.2.5).  
 
Similar to the data presented here, in which S.cerevisiae binds Mg.AXP much weaker than 
free AXP, S.pombe Snf4 has previously been shown to bind AXP uncoordinated by cations 
preferentially. Townley et al (2007) demonstrated that S.pombe Snf4 crystals grown in the 
presence of Gd3+lanthanide had no bound ions. This ion is known to substitute for Mg2+ 
cations in ATP substructures and provides a large anomalous signal for crystallographic 
studies (188). This observation suggests that unbound AXP are preferentially bound by Snf4, 
since the phosphate charge balance can be provided by the side chains of arginine residues 
rather than by bound cations.  
 
 1.2.2.1 Snf4 mutants 
It is suggested that ADP binding at the second, weaker site is responsible for mediating 
protection of T210 against dephosphorylation for two reasons: 1) ADP protects SNF1 T210 
from dephosphorylation by phosphatases with a half maximal effect of 500M (2).   
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Figure 62: Emission spectra of SNF1/C-AXP complexes. 
5M C-ADP (red) and C-ATP (blue) in the presence of 21M phosphorylated SNF1. C-AXPs 
were excited at 470nm and emission spectra recorded from 450 to 550nm at 20oC in the 
presence of 25mM Tris, 1mM TCEP, and 100mM NaCl (pH 8.0).  
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Figure 63: Measurement of equilibrium dissociation constants for the binding of AXPs to 
phosphorylated SNF1.  
Displacement of C-ADP from the SNF1:(C-ADP)2 complex by ADP monitored using the 
change in fluorescence at 470nm (excitation at 430nm). The solid lines are the computed 
best fits with Kd,I and Kd,II for C-ADP binding fixed at 9 and 27μM respectively. Inset: Titration 
of C-ADP with SNF1 plotted as change in fluorescence intensity as a function of SNF1 
concentration. All measurements were carried out at 20°C in 50mM Tris, pH8, 100mM NaCl, 
1mM TCEP (pH 8.0). 
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Figure 64: Measurement of equilibrium dissociation constants for the binding of AXPs to 
phosphorylated SNF1.  
Displacement of NADH from the SNF1:NADH complex by AXPs monitored using the change 
in fluorescence at 435nm (excitation at 340nm). The solid lines are the computed best fits 
with the Kd for NADH fixed at 12.3μM Inset: Titration of NADH with SNF1 plotted as change 
in fluorescence intensity as a function of SNF1 concentration. All measurements were 
carried out at 20°C in 50mM Tris, pH8, 100mM NaCl, 1mM TCEP (pH 8.0). 
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Figure 65: NADH binding to Site-4 (SNF1). 
A) Overlay of the crystal structures of NADH (Pink, yellow sticks) and ADP (purple, blue 
sticks) bound to the S.cerevisiae Snf4 subunit. Both ligands bind at Site-4 (PDB ID: 3TE5, 
3T4N). B) NADH makes similar contacts with Snf4 side chains as AXP. There are a number of 
additional interactions with the ribose and nicotinamide groups. 
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Figure 66: Measurement of equilibrium dissociation constants for the binding of AXPs to 
phosphorylated SNF1. 
A) Titration of C-ADP with SNF1. (B) Titration of C-ATP with SNF1. All measurements were 
carried out at 20°C in 50mM Tris, pH8, 100mM NaCl, 1mM TCEP (pH 8.0) plus (blue) or 
minus (green) 5mM MgCl2. 
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  NADH C-ADP C-ATP 
SNF1 Temp, Salt Kd (M) KdI (M) KdII (M) KdI (M) KdII (M) 
Phosphorylated 7
o
C 
0mM NaCl 
0.42 (0.19) 3.6 (1.5) 14.5 (3.1) 5.7 (3.1) 15.5 (5.4) 
Unphosphorylated 0.65 (0.14) 2.6 (1.3) 9.9 (3.5) 1.9 (0.9) 12.3 (4.1) 
Phosphorylated 20
o
C 
100mM NaCl 
12.3 (3.4) 9.1 (3.1) 30.7 (7.3) 11.8 (5.3) 27.1 (9.3) 
Unphosphorylated 4.7 (1.5) 7.5 (3.4) 22.5 (8.5) 9.9 (4.3) 21.0 (7.3) 
 
 
Table 16: Equilibrium dissociation constants for the binding of NADH and C-AXPs (SNF1). 
Dissociation constants were determined at 7/20oC by fluorescence titrations of C-AXP with 
SNF1 in 25mM Tris, 1mM TCEP (pH 8.0), with or without NaCl. The Kd values are reported as 
the mean (± SD) determined from at least two independent measurements.  
 
 
 
 
 
 
 
 
 
Table 17: Equilibrium dissociation constants for the binding of AXPs to phosphorylated SNF1. 
Dissociation constants were determined at 20°C by competition against C-ADP. The Kd 
values shown are the mean (±SD) determined from at least two independent 
measurements. All measurements were carried out at 20°C in 50mM Tris, pH8, 100mM 
NaCl, 1mM TCEP (pH 8.0). 
 
 
  
Ligand KdI (M) KdII (M) 
 vs C-ADP 
AMP 65 (15) 1450 (350) 
ADP 91 (25) 760 (200) 
ATP 85 (22) 1200 (300) 
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Table 18: Equilibrium dissociation constants for the binding of AXPs to phosphorylated 
and unphosphorylated SNF1. 
Dissociation constants were determined at 20°C by competition against NADH. The Kd values 
shown are the mean (±SD) determined from at least 3 independent measurements.  
All measurements were carried out at 20°C in 50mM Tris, pH8, 100mM NaCl, 1mM  
TCEP (pH 8.0). 
 
 
 
 
 
 
 
Table 19: Equilibrium dissociation constants for the binding of Mg.C-AXPs (SNF1). 
Dissociation constants were determined at 20oC by fluorescence titrations of C-AXP with 
phosphorylated SNF1 in 25mM Tris, 1mM TCEP, 100mM NaCl, 5mM MgCl2 (pH 8.0).  
The Kd values are reported as the mean (± SD) determined from at least two independent 
measurements. nd: Not determined. 
  
 Phosphorylated Unphosphorylated 
 vs NADH 
Ligand Kd (M) Kd (M) 
AMP 55 (12) 13.2 (1.7) 
ADP 72 (14) 33.6 (1.7) 
ATP 120 (25) 38.3 (13.4) 
 KdI (M) KdII (M) 
Mg.C-ADP 45.1 (16.8) 95.9 (32.6) 
Mg.C-ATP 41.6 (3.6) nd 
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The ADP binding constant for the second site is similar to this value suggesting that it is 
binding of ADP at this site which is responsible for regulation of the complex. 2) NADH binds 
at the tighter Site-4 and does not compete with regulation by ADP. Unfortunately the 
identity of the second site was not determined via X-ray crystallography due to the weak 
binding of AXP. Attempts were made to specifically ablate AXP binding at each site and 
confirm the identity of the weaker binding site via mutagenesis. 
 
As described in Section 3.4.3.5 DA mutants have been widely used in the AMPK field to 
‘knock out’ binding and specific AXP binding sites, through interruption of the ribose 
interaction with the protein. This key aspartate residue is conserved in Site-1, 3 and 4 of 
SNF1, and these residues were mutated to alanine. Equilibrium dissociation constants of  
C-ADP and NADH binding to these mutants were determined (Table 20). Although effects on 
binding were observed, none of the mutants specifically or completely ablated binding of 
these ligands. For example, despite crystallographic evidence that NADH binds in Site-4 the 
D83A mutation in Site-1 weakens NADH binding around 4-fold whilst the Site-4 D312A 
mutation only has a 2.5-fold effect.  
 
In the typical AXP binding site a number of branched-chain residues, often valine,  
co-ordinate the adenine moiety. Several mutants were designed to disrupt these 
interactions and preclude AXP binding. Again, equilibrium dissociation constants of C-ADP 
and NADH binding were determined (Table 21). In all cases binding of C-ADP was weakened 
at both sites compared to wild-type SNF1. NADH binding was also weakened in all cases, 
except the S144W (Site-1) mutant which appeared to bind with a slightly tighter affinity. 
However none of the mutants completely abolished AXP binding, therefore the identity of 
the second site remains elusive. 
 
S.pombe SNF1 binds AXP at Site-2 and 4 which are situated on diagonally opposed sides of 
the Snf1 subunit (Figure 60). In fact Site-2 is thought to be an ADP specific binding site (142). 
Additionally mammalian AMPK exchangeably binds two AXP’s at sites in the same diagonal 
arrangement (87). In S.cerevisiae it is Site-2 which lies diagonally opposite the known tight 
Site-4, if we assume that this arrangement is conserved perhaps it would have been sensible 
to further explore the effect of mutations on AXP binding to Site-2. However homologous 
tryptophan mutations in Site-2 did not have any effect on ADP regulation, suggesting that 
the binding was unaffected (2).   
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Table 20: Equilibrium dissociation constants for binding of NADH and C-ADP to wild-type 
and mutant SNF1.  
The Kd values shown are the mean (±SD) from 3 (NADH) or 2 (C-ADP) independent 
experiments  All measurements were carried out using unphosphorylated truncated SNF1 
(Snf1398-633 Sip2154-415 Snf4) complexes at 20°C in 50mM Tris (pH 8.0), 150mM NaCl, 1mM 
TCEP (NADH) and 7°C in 50mM Tris, pH 8, 1mM TCEP (C-ADP). 
 
 
 
Table 21: Equilibrium dissociation constants for binding of NADH and C-ADP to wild-type 
and mutant SNF1.  
The Kd values shown are the mean (±SD) from 2 independent experiments.  
All measurements were carried out using phosphorylated full-length Snf1 Gal83154-415 Snf4 
complexes at 20°C in 50mM Tris, 150mM NaCl, 1mM TCEP (pH 8.0).  
 NADH C-ADP 
Snf4 protein Kd (M) Kd,I (M) Kd,II (M) 
Wild-type 18.7 (3.8) 4.2 (0.4) 14.7 (4.9) 
D83A (Site-1) 75.7 (29.9) 1.8 (0.7) 24.9 (4.9) 
D240A (Site-3) 14.3 (3.7) 2.6 (1) 45.3 (19) 
D312A (Site-4) 45 (4.2) 8.4 (4.1) 38.9 (5.6) 
 NADH C-ADP 
Snf4 protein Kd (M) Kd,I (M) Kd,II (M) 
Wild-type 12.3 (3.4) 3.6 (1.5) 14.5 (3.1) 
L78W (Site-1) 13.9 (3.6) 10.5 (2.1) 27 (11) 
S144W (Site-1) 7.8 (0.7) 8.1 (2.2) 36 (10.5) 
V220W (Site-4) 15.1 (4.1) 6.9 (1.8) 23.5 (6.9) 
V307W (Site-4) 12.2 (5.0) 8.7 (1.2) 35 (8.5) 
255 
 
 1.2.3 Circular Dichroism  
The use of far-UV CD for studying the secondary structure content of protein samples in 
solution was described in Section 3.3.2. Spectra of both phosphorylated and 
unphosphorylated SNF1 were collected at 20oC (Figure 67). Estimation of their secondary 
structure content highlighted no significant differences between the two AMPK  
species (Table 22). Thermal unfolding of the two protein samples suggested that neither was 
classically denatured, instead a drop in signal at ~55oC was observed indicating the 
formation of -fibrils (Figure 68). This is analogous of the denaturation of phosphorylated 
AMPK described earlier in Section 3.4.4.1. Far-UV spectra collected at 80oC and  
analysed for their secondary structure content confirm this increase in -content  
(Table 22 and Figure 67). 
Near-UV CD offers information about the tertiary structure of a protein, spectra of 
phosphorylated and unphosphorylated SNF1 were collected (Figure 69). The observed 
spectral bands are the sum of all absorptions, both positive and negative, for this reason the 
signals may be small despite the large numbers of tryptophan, phenylalanine and tyrosine 
residues present in SNF1. The spectra of both SNF1 species contain a negative tyrosine band 
with a maximum between 255-270nm, a positive tryptophan band at ~290nm and positive 
phenylalanine signal between 255-270nm. In both cases the phosphorylated sample 
produces higher intensity bands than unphosphorylated SNF1 suggesting some local 
differences in the environment of a number of aromatic amino acids in the two species.  
The binding of AXP to a number of Snf4 point mutants was described in Appendix 1.2.2.1. 
The far-UV CD spectra of these proteins were recorded and compared with the relevant 
wild-type SNF1 as indicated in the figure legends (Figure 70 and Figure 71). No significant 
differences between the secondary structure content of these mutants and wild-type SNf1 
were observed, suggesting that these point mutations have little effect on the overall 
heterotrimeric structure or stability (Table 23).   
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Figure 67: Far-UV CD spectra (SNF1). 
Phosphorylated (green) and unphosphorylated (red) SNF1 far-UV CD spectra were recorded 
at 20oC. Phosphorylated (pale green) and unphosphorylated (pink) SNF1 far-UV CD spectra 
were recorded at 80oC. Samples were diluted in water. 
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Table 22: Secondary structure content predictions (SNF1). 
Truncated (Snf4(1-322)Sip2(304-415)His-Snf1(457-633), phosphorylated and unphosphorylated 
(Snf1(50-633), Sip2(101-415)Snf4) SNF1 far-UV CD spectra were recorded at the indicated 
temperatures and secondary structure content predicted as described Chapter 3.  
 
 
  
 % 
SNF1   Turns Unordered 
Unphosphorylated (20
o
C) 25.2 21.5 19.7 33.5 
Phosphorylated (20
o
C) 23.7 22.2 19.9 34.6 
Unphosphorylated (80
o
C) 20.6 26.7 22.6 31.3 
Phosphorylated (80
o
C) 20.3 22.1 20.3 38.7 
Truncated wild-type 18.5 26.7 20.9 33.2 
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Figure 68: Thermal denaturation (SNF1). 
Phosphorylated (green) and unphosphorylated (red) SNF1. Protein samples diluted in water. 
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Figure 69: Near-UV CD spectra (SNF1). 
Phosphorylated (green) and unphosphorylated (red) SNF1. Protein samples diluted in water. 
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Figure 70: Far-UV CD spectra (SNF1). 
Wild-type truncated (Snf1398-633 Sip2154-415 Snf4) SNF1 (red), D312A mutant (blue) and D240A 
mutant (purple). Samples were diluted in water and recorded at 20oC. 
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Figure 71: Far-UV CD spectra (SNF1). 
Phosphorylated wild-type SNF1 (green), L78W (orange), V220W (blue), V307A (purple)  
and S144W (pink). Samples were diluted in water and recorded at 20oC. 
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 % 
Snf4 mutant   Turns Unordered 
D240A (Site-3) 20.4 25.4 21.2 32.6 
D312A (Site-4) 18.9 26.4 21.1 33.0 
Phosphorylated L78W (Site-1) 23.4 18.0 17.8 40.8 
Phosphorylated S144W (Site-1) 21.4 18.5 17.8 42.3 
Phosphorylated V220W (Site-4) 23.7 19.2 19.0 38.5 
Phosphorylated V307W (Site-4) 23.4 19.1 18.6 39.2 
 
 
 
Table 23: Secondary structure content predictions. 
Far-UV CD spectra of Snf4 point mutants were recorded and secondary structure content 
predicted as described in the Section 3.3.2. Truncated (Snf4(1-322)Sip2(304-415)His-Snf1(457-633)) 
and phosphorylated (Snf1, Gal83(101-415) Snf4) SNF1 backgrounds were used in  
these experiments. 
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 1.2.4 Kinetics 
The NADH-coupled spectrophotometric assay has not previously been used to study SNF1 
kinetics/activity. Initially I determined the Km values with respect to the SAMS peptide 
(18.8M, Figure 72b) and ATP (157.1M, Figure 72a). The Vmax values calculated as 
19.2nM/Sec and 17.0nM/Sec at saturating ATP and SAMS concentrations respectively.  
Although there are many examples of the classic SAMS peptide assay being used to monitor 
SNF1 activity, there are almost no reports of the Km/Vmax with respect to SNF1’s substrates 
(2, 147, 300). A single example suggested a Km of 108M with respect to SAMS. In their 
study SNF1 was purified from yeast cells, unlike the bacterially expressed recombinant SNF1 
used in this work, perhaps this explains the differences in the calculated and published  
Km value (267).  
 
It has previously been reported that SNF1 is neither allosterically activated nor protected 
from dephosphorylation by AMP. However, ADP was recently shown to protect T210 from 
dephosphorylation by phosphatases. The time course and concentration dependence of this 
effect were demonstrated using the NADH-coupled assay (Figure 73). The effect saturates at 
around 1.5mM ADP, with half maximal activation at around 500M, in line with the 
previous report of this regulation (2). 
The Snf1 kinase Mg.ATP binding pocket binds Mg.ADP (the product of the phosphorylation 
reaction). It must also be considered that high Mg.ADP concentrations may inhibit the 
kinase reaction in some way. This is unlikely for two reasons; 1) the affinity of ADP and ATP 
for the kinase is very low, for AMPK Mg.ATP binds with an affinity of greater than 0.5mM,  
2) although the incubation contains high concentrations of ADP the aliquot transferred to 
the kinase reaction is very low (~1M) and is immediately converted to ATP by the coupled 
assay enzymes. Only if the koff for Mg.ADP were very slow could this inhibit  
SNF1 phosphorylation.  
NADH binds in Site-4 (as observed in the crystal structure of a SNF1 truncate (2)) with a Kd of 
12.3M (Table 16). It was demonstrated in Mayer et al (2001) using the standard SAMS 
assay (Figure 29b) that when NADH is included in the incubation mix at increasing 
concentrations no competition with the protective effect of ADP is observed. Therefore,  
I can conclude that binding of ADP at Site-4 is not responsible for the protection against 
dephosphorylation (2).   
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A 
B 
Figure 72: Determination of Km values (SNF1). 
With respect to (A) ATP (SAMS = 130M) and (B) SAMS peptide (ATP = 500M). SNF1 was 
phosphorylated in vitro and its activity measured at a range of substrate concentrations. 
Activity of SNF1 is plotted as a function of substrate concentration. Solid lines depict the 
velocity of the reactions measured by the NADH coupled assay.  
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A   
 
B   
 
Figure 73: Phosphatase assays (SNF1).  
(A) 8.5M phosphorylated SNF1 was incubated in the presence of PP2C, with (blue) and 
without 1mM ADP (red). At a number of time points AMPK activity was measured.  
(B) Phosphorylated SNF1 was incubated in the presence of PP2C and increasing ADP 
concentrations. After 40 minutes, SNF1 activity was measured, results are displayed as 
percentage of phosphorylated T172 remaining. All phosphatase assays were performed at 
25oC. SAMS and ATP concentrations were 100M and 500M respectively.   
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 1.2.5 Modelling 
A modified version of the program outlined in Section 4.4.2.2 was produced to allow 
calculation of the occupancy of the two SNF1 nucleotide binding sites. The results presented 
in Mayer et al (2011) demonstrate, through competition with NADH, that binding of ADP at 
Site-4 cannot be responsible for the protection against dephosphorylation (2). The first aim 
of the modelling was therefore to demonstrate that the second weaker nucleotide binding 
site would become occupied by ADP over a concentration range which is consistent with the 
observed concentration dependence of the ADP protecting effect (Figure 73).  
The second more ambitious aim was to demonstrate that physiologically realistic variations 
in AXP concentrations could bring about significant increases in ADP-bound SNF1 species, 
and therefore active phosphorylated SNF1. Yeast cells are able to survive much greater 
decreases in ATP concentration and increases in AMP/ADP concentrations than mammalian 
cells. It is not therefore unreasonable that the protecting effect of ADP on 
dephosphorylation in SNF1 is seen over a higher concentration range than with AMPK.  
This would also be consistent with the observation that SNF1 has evolved to function with 
significantly weaker binding constants for AXPs.  
 
In vitro occupancy of Snf4 binding sites 
Modelling the occupancy of SNF1 nucleotide binding sites was more problematic than 
modelling the mammalian system, particularly because there are unavoidably large errors 
associated with some SNF1:AXP Kd values described in Appendix 1.2.2, especially those for 
the weaker of the two sites.  
 
Calculation of AXP species concentrations (H.AXP, Mg.AXP, Ca.AXP etc) was performed as 
described in Section 4.2.5 via the Cornish-Bowden method. The in vitro assays were all 
carried out using phosphorylated (active) SNF1. Equilibrium binding constants for AXP 
binding to Site-4 and the second site were taken from Table 17. 
 
Good estimates of Kd values for the binding of Mg.AXP species to SNF1 were not determined 
using the fluorescence techniques described in Appendix 1.2.2 owing to the weakness of the 
interactions. Kd values for Mg.C-ATP/Mg.C-ADP binding at Site 4 (the tighter, NADH binding 
site) and Mg.C-ADP binding to the second weaker site were compared to those for these 
nucleotides uncoordinated by Mg2+. The extent to which the presence of Mg2+ would reduce 
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the strength of the interaction with AXPs was assumed to be the same as for C-AXPs  
(Table 19) and binding constants estimated in this way are given in Table 24. There are,  
of course, very substantial errors associated with these estimations. For example, in the 
case of ADP binding at the weaker site (30.7 ± 7.3M for C-ADP 95.9 ± 32.6M for  
Mg.C-ADP, and 760 ± 200M for ADP) the fold reduction for C-ADP is 3.1 ±1.3M and the 
estimated Kd for Mg.ADP is then 2350 ±1150M. 
 
The concentration dependence of the protective effect of ADP on T210 dephosphorylation 
determined using the SAMS assay (Figure 17) is similar to that observed using different 
methods (2).  
  
The pre-incubated phosphatase reaction contained only 10mM Mg and ADP in addition to 
SNF1 and the phosphatase. Therefore the only nucleotide species present (and therefore 
able to occupy the sites) are Mg.ADP and ADP. The modelling (Figure 74) shows occupancy 
of the weak site as a function of the total ADP concentration. Although substantial 
occupancy of the regulatory site is seen over this ADP concentration range the shape of the 
curve is not precisely the same as that observed experimentally (Figure 73). There may,  
of course, be many reasons for this discrepancy: 
  The binding constant for Mg.ADP is very poorly defined (2350 ±1150M –  
see above) and Figure 74 shows the substantial effect of varying the Kd in this range. 
  The ADP is around 85% Mg2+-bound in the presence of 10mM magnesium over the 
range of ADP concentrations used. It is assumed that both species protect against 
dephosphorylation and this may not be the case.  
  The occupancy of Site-4 also varies over this ADP concentration range and it may be 
that occupancy of this site could modulate the effect of ADP/Mg.ADP bound in the 
regulatory site.  
  Since dissociation constants for the SNF1 system are poorly determined one cannot 
exclude the possibility that occupancy of Site-4 could have some cooperative effect 
on occupancy of the regulatory site (described in relation to AMPK  
in Section 3.4.3.2). 
 
If we assume that the SNF1 activation loop is protected in the same way as in the AMPK 
system (i.e. packing of the phosphorylated T210 residue against the regulatory domain) then 
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two species exist: kinase-bound and kinase-free. ADP binding to Snf4 is then assumed to 
shift the equilibrium from the free to the bound form. In terms of regulation the important, 
but unanswerable, question is to what extent does ADP binding shift this equilibrium.  
 
In vivo occupancy of Snf4 binding sites 
Any truly successful model of SNF1 requires one to answer (at least) the following questions; 
What are the nucleotide (AXP) levels in yeast and how much do they change under stress 
conditions? What is the intracellular free Mg2+ concentration? What is the concentration of 
phosphorylated SNF1 under ‘resting conditions’ and how much must it be elevated to 
generate the required response? What are the enzymatic characteristics (particularly the  
Km values) of the kinases and phosphatases that regulate the phosphorylation- 
dephosphorylation cycle in SNF1? How precisely does the protecting effect of ADP/Mg.ADP 
work and does it provide complete or only partial protection? What is the role of the AID? 
Most of these questions cannot be answered easily, but it is of interest to consider what the 
binding constants determined in this work, in concert with plausible estimates of AXP and 
Mg2+ concentrations, can tell us about regulation of SNF1 by ADP in vivo.  
 
A number of methods to monitor intracellular nucleotide concentrations have been 
developed, the primary methods are described in Section 4.2.6. Literature estimates of 
adenine nucleotide concentrations in S.cerevisiae are often highly variable, for example,  
ATP 2-8mM and ADP 1.1-4mM (273, 334, 335). It seems that yeast are more tolerant of 
large fluctuations in nucleotide levels than mammalian cells. 
Intracellular Mg2+ concentrations affect the percentage of ADP present as Mg.ADP  
(Figure 75), and therefore the extent to which the regulatory site is occupied (as Mg.ADP 
binds SNF1 more weakly than ADP). The free Mg2+ concentration is unknown but is thought 
to be between 0.1mM and 1mM in eukaryotic cells and is not thought to fluctuate with 
environmental Mg2+ concentrations (281). Given these concentrations the ratio of 
ADP:Mg.ADP would change from 1:0.15 at 0.1mM free Mg2+ to 1:1.5 at 1mM (Figure 75); 
this is therefore a very important factor in SNF1 regulation.  
Even total concentrations of adenine nucleotides in S.cerevisiae are not high enough to 
completely saturate the regulatory site. Mg.ATP (present at mM concentrations) binds SNF1 
very weakly (Kd >2.5mM) at the regulatory site and most (>95% for a free Mg
2+ 
concentration of 1mM) of the cellular ATP will be present as this species. As noted above, 
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the concentrations of ADP/Mg.ADP will depend on the free Mg2+ concentration but even at 
low [Mg2+] the ADP concentration (in which case most ADP is free and this form binds more 
tightly) would not be high enough to saturate the regulatory site.  
It therefore seems that SNF1 may simply act as a direct sensor of ADP/Mg.ADP 
concentrations, and that the binding of ATP is not physiologically relevant.  
 
In the majority of documented cases of ATP depletion the ADP concentrations actually 
fluctuate around a rather narrow range, and any increases are transient. Perhaps the 
sensitivity of SNF1 activation is such that these small ADP concentrations are sufficient to 
stimulate the relevant downstream pathways, microenvironmental ADP concentrations play 
a role or perhaps the methods used to determine cellular nucleotide concentrations are an 
inaccurate representation of the real cellular state. 
 
Nonetheless it is clear that ADP is a key activator of SNF1. Of course, SNF1 activation is 
mediated by numerous factors in addition to ADP increases, such as cellular localisation of 
SNF1, -subunit isoform, availability of substrates, and post-translational modifications 
(phosphorylation, myristoylation and acetylation). The kinetics of the upstream kinases and 
phosphatase(s), their localisation and concentration are also integral to controlling the 
extent of SNF1 activation.   
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Table 24: Estimation of Mg.AXP Kd values. 
Equilibrium binding constants were determined as described in Appendix 1.2.2 and 
displayed in Table 16 (row 2), Table 19 (row 3) and Table 17 (row 5). The fold decrease in 
affinity of C-AXP compared to Mg.C-AXP affinity and the estimated binding constants for 
Mg.AXP species are italicised.  
  
 KdI (M) KdII (M) KdI (M) 
C-AXP  9.1 (C-ADP) 30.7 (C-ADP)  11.8 (C-ATP) 
C-AXP 5mM MgCl2 45.1 (C-ADP) 95.9 (C-ADP) 41.6 (C-ATP) 
Ratio 5-fold 3-fold 3.5-fold 
AXP 91 (ADP) 760 (ADP) 85 (ATP) 
AXP (5mM MgCl2) 451 (ADP) 2374 (ADP) 299 (ATP) 
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Figure 74: % occupancy of SNF1 nucleotide binding sites.  
% occupancy of the second, weaker, site by Mg.ADP/ADP (red), calculated from Kd values in 
Table 24. ± experimentally determined error measurements (light red)  
(Table 16 and Table 17).  
Input: 0mM NADH, 0mM AMP, 0mM ATP, 0.00825mM SNF1, 10mM MgCl2, 0mM CaCl2, pH 
7.5.  
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Figure 75: ADP and Mg.ADP species. 
% free ADP (blue) and % Mg.ADP (red) species over the excepted eukaryotic range of free 
Mg2+ concentrations. Starting AXP values taken from (336), wild-type S.cerevisiae cells 
grown on Trehalose media (1.06mM AMP, 2.5mM ADP, 4mM ATP).  
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